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Abstract 
Rheumatic heart disease (RHD) is the leading cause of aortic valve disease in the world. Surgery to 
repair or replace the diseased valves is the only means to save a patient’s life once the disease 
becomes symptomatic. Transcatheter aortic valve replacement (TAVR) has revolutionised the 
treatment of age-related degenerative aortic valve disease, but is currently not suitable for the 
majority of RHD sufferers due to the rapid degeneration of flexible leaflet valves in younger patients, 
contraindications of commercial devices to regurgitant or non-calcific aortic valve disease, and also 
due to resource or funding limitations. The current research project aimed to develop and test novel 
compressible balloon-expandable stents suitable for patients with symptomatic rheumatic aortic 
valve disease, and which would allow for a percutaneous polymeric valve to be manufactured, be 
crimped onto balloon-based devices, and be expanded into a compliant or non-calcific native aortic 
valve.  
Several stent concepts were developed and evaluated using Finite Element Analysis (FEA) and two 
favoured concepts were selected for more complex FEA, in which the balloon was simulated using an 
Ogden material model, and rigorous testing. The stent material, a nickel-cobalt-chromium alloy, was 
modelled as an isotropic elasto-plastic material with isotropic hardening. The novel stent designs 
incorporated a native leaflet-mimicking crown shape for continuous leaflet attachment and 
mechanisms to anchor the stented valve within compliant aortic roots.  The first of the favoured 
designs provided tactile location during delivery and anchored using self-expanding arms on a balloon-
expandable frame of the same material (“self-locating stents”). The second design anchored using 
arms that protruded during deployment as a consequence of plastic deformation incurred during 
crimping (“expanding arm stents”). Prototypes were successfully manufactured through laser cutting 
and electropolishing and showed good surface quality. In vitro testing included determination of 
crimping and expansion behaviour and measurement of mechanical properties such as resistance to 
migration in the anatomy. Valve performance was evaluated through in vitro haemodynamics in a 
pulse duplicator and durability was tested in a high-cycle fatigue tester. Simulated use testing was 
performed using cadaveric animal hearts. Finally, valves were also implanted into the aortic valve 
position of pigs (in acute termination experiments) through a transapical approach in order to verify 
valve deployment behaviour and function in vivo, and determine the stent’s ability to anchor in the 
native anatomy.  
Stents could be crimped to diameters below 6mm and deployed using commercial balloons and 
proprietary non-occlusive deployment devices. FEA simulations of stent crimping and deployment 
matched experimental behaviour well and provide a tool to optimise stent performance. Peak Von 
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Mises stresses during deployment (1437 MPa and 1633 MPa for self-locating and expanding arm 
stents, respectively) were comparable to a “zig-zag” stent simulated for control purposes (1650 MPa). 
Radial strength, evaluated for expanding arm stents, was lower than the Control stent (116 N vs. 347 
N). This design, although predicted to be safe under fatigue loading, had a lower fatigue safety factor 
than the Control stent. Stents resisted migration to forces of at least 22 N, which is four times greater 
than physiological loading on the valves. Polymeric valves incorporating the stents were constructed 
and demonstrated good in vitro haemodynamic performance (Effective Orifice Areas ≥2.0cm2, ΔP<9 
mmHg, regurgitation <6%) and durability of over 400 million cycles. Designs functioned as intended in 
simulated use tests. Valves constructed using self-locating stents could be successfully deployed 
without rapid pacing in eight of nine pigs, and valve position was correct in seven of these. Valves of 
expanding arm stents remained anchored in six of eight attempted implants in pigs. This study has 
demonstrated proof of concept for a novel balloon-expandable stent for a polymeric transcatheter 
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Nomenclature/Abbreviations
Activated Clotting Time (ACT) Standardised test of blood clotting time 
Acute Rheumatic Fever (ARF) Inflammatory disease caused by auto-immune response to streptococcal throat 
infection 
American College of 
Cardiology (ACC) 
American Heart Association 
(AHA) 
Antigen mimicry Auto-immune responses based on similarity between the body and a foreign 
microorganism 
Aortic annulus/ virtual 
annulus/ virtual ring/ basal 
ring/ surgical annulus 
Fibrous area at the base of the aortic valve, defined by various terms; Surgical 
annulus is crown-shaped while others are used to describe a ring at base of the 
leaflets 
Aortic Stenosis (AS) Aortic valve narrowing 
Aortic Regurgitation (AR) Aortic valve disease causing leakage 
Atrium (pl. atria) Thin-walled upper chamber of the heart 
Atrioventricular (AV) node Specialised group of heart muscle cells in centre of heart that help regulate 
conduction of electricity in the heart 
Bézier curve Parametric curves used to generate smooth shapes based on a finite number of 
parameters 
Biological heart valve (BHV) Heart valve constructed using animal (including human) tissue 
Bundle of His Part of the heart’s electrical conduction system that conducts electrical signals 
from the AV node to the tip (apex) of the heart 
Calcification Deposition of calcium in body tissue, causing hardening 
Central fibrous body Strongest fibrous area of the heart at areas where valves meet 
Central Venous Pressure 
(CVP) 
Blood pressure in the venae cavae, just before blood returns to the heart 
Coaptation Area of contact between surfaces of valve leaflets 
Commissure Area where leaflets join 
Commissurotomy Surgical separation of joined leaflets 
Compliance Amount by which a dimension (esp. valve diameter) changes with load (esp. 
pressure) 
Computed Tomography (CT) X-ray imaging system capable of producing cross-sectional images
Computer-aided Design (CAD) Use of computers to design 
Computer Numerical Control 
(CNC) 
Automated computer control of manufacturing 
Contrast angiography Medical imaging technique that uses a radiopaque substance to visualise body 
cavities, particularly in the heart  
Coronary arteries Arteries that supply the blood to the heart 
Cusp/ Leaflet/Lunula Flexible flaps that open and close in a heart valve 





The use of ultrasound waves to study the heart, with probes either on the chest 
(transthoracic) or down the gullet (transoesophageal) 
Effective Orifice Area (EOA) Area of the blood stream where diameter is the smallest, after passing through a 
narrowing such the aortic valve.   
Elastic limit The stress beyond which permanent deformation occurs 
Elastic modulus Measure of stiffness of a material defined as the slope of the stress-strain curve in 
the elastic region (recoverable deformation) 
Electrospinning Technique that uses electricity to draw polymer fibres into a fabric 
Embolus/ Embolisation An object carried in the blood stream to block a cavity/ the process by which the 
object detaches 
xiv
Endothelial cells Thin layer of cells lining the inside of a blood vessel 
Endurance limit The cyclic stress at which a material can resist fatigue failre indefinitely 
Engineering stress/strain Stress calculated as applied load divided by the original cross-sectional area/ strain 
calculated as deformation divided by the original length of the material 
Fatigue strength See endurance limit 
Fatigue safety factor Ratio of a particular stress state at a point and the point of intersection with the 
“Goodman” line (see Goodman diagram below).  
Fibrosa Fibrous layer on the aortic side of the aortic valve leaflets 
Fibrosis Excessive fibrous tissue formation 
Fibrous trigones Thickened ends of fibrous continuity between aortic and mitral valves 
Finite Element Analysis (FEA) Numerical technique to solve physical problems based on dividing the problem 
into simpler parts  
Fluid Structure Interaction 
(FSI) 
In modelling, a method of coupling computational fluid modelling to solid 
structural modelling 
Fluoroscopy Continuous X-ray imaging 
Food and Drug Administration 
(FDA) 
United States federal agency governing food and healthcare, including medical 
devices 
Foreshortening Percentage change in length (esp. a stent) from compressed to final conditions 
Goodman diagram Graph of mean versus alternating stress; infinite life is assumed if stress state 
(mean and alternating) are below a line constructed from the UTS and endurance 
limits of the material (the Goodman line).   
Hollomon Power Law Stress/strain relationship such that stress is a power function of strain 
Hoop force Force in circumferential direction 
Hourglassing An error in numerical analysis caused by zero energy degrees of freedom. 
Intellectual Property (IP) Creations (typically inventions) frequently legally protected through patents. 
Inter-commissural distance 
(ICD) 
Distance between the commissures of a valve 
International Standards 
Organisation (ISO) 
International non-governmental organisation that creates standards 
Ischaemia Lack of oxygen supply to tissues due to insufficient blood flow 
Isotropic Having the same properties in all directions 
Left bundle branch (LBB) Branch of the Bundle of His that travels down the left side of the intraventricular 
septum, the wall separating the two ventricles 
Left Ventricular Outflow Tract 
(LVOT) 
Part of the left ventricle through which blood passes out the ventricle 
Lumen The space inside a tube-like structure such as an artery 
Mechanical heart valves 
(MHV) 
Synthetic replacement valve with rigid parts; the majority have a tilting disc or two 
hinged rigid leaflets 
Membranous septum Thin part of the ventricular septum close to the aortic valve 
Mesh In FEA, the subdivision of a structure or problem  into smaller regions known as 
elements, for which equations may be solved  
Multi-detector row Computed 
Tomography (MDCT)/ Multi-
slice CT (MSCT) 
CT system equipped with multiple rows of detectors to create images of multiple 
sections. 
Nadir Lowest point of a structure such as a crown or leaflet 
Nodulus of Arantius Thickening in the middle of the free edge of a leaflet 
Ogden material model Non-linear hyper-elastic model to describe the behaviour of materials like rubber 
Percutaneous coronary 
intervention (PCI) 
Catheter-based method of opening a blocked coronary artery 
Radial force Force directed towards or away from the centre of a curve such as a stent 
Rayleigh damping Viscous damping of a material proportional to mass and/or stiffness 
Recoil The percentage that a stent moves backwards once a force or displacement is 
removed; used particularly to refer to the spring back following expansion 
Rheumatic Heart Disease 
(RHD) 
Damage to the heart valves as a complication of rheumatic fever 
Shear locking An error in FEA that makes elements appear to be stiffer than they are in bending 
xv
Sinotubular Junction (STJ) Area between the Sinus of Valsalva and the ascending aorta 
Sinus of Valsalva (SoV) Widenings of the wall of the aorta at the level of the aortic valve 
Spongiosa Gel-like central layer of a heart valve leaflet 
ST elevation Raised portion of the electrocardiogram (ECG) known as the ST segment, which 
corresponds to the depolarisation phase of the heart cycle; an indicator of 
ischaemia. 
Stent/ Stent graft A support frame or structure/ a covered stent 
Strain / Peak Plastic 
Equivalent Strain (PEEQ) 
Deformation associated with a stress / amount of permanent strain in a material 
Stress (Von Mises, Maximum 
Principle) 
Forces acting on a particular area in a material. Von Mises stress (based on 
distortion energy) is considered to be the best stress value to describe yielding 
(onset of permanent plastic deformation) in ductile (malleable) materials. 
Maximum Principle Stress is the highest value of tensile (pulling) stress (or the 
least compressive stress) in the material; although best for brittle materials, it is 
used in the study of fatigue of ductile materials 
Structural valve dysfunction 
(SVD) 
Inability of a heart valve to function due to changes in its physical structure, such 
as through calcification of leaflets 
Surgical Aortic Valve 
Replacement (SAVR) 
Removal and replacement of a heart valve through direct surgery 
Systole Part of the heart cycle where the muscle contracts and blood is ejected 
Total Regurgitant Fraction Total percentage of blood that flows backwards during systole, including closing 
flow and leakage through the valve  
Transcatheter Aortic Valve 
Implantation/ Replacement 
(TAVI/TAVR) 
Catheter-based method of implanting/replacing a diseased heart valve; the terms 
are typically used interchangeably 
Triangle of Koch A triangle (used as a landmark for the AV node) on the inside surface of the right 
atrium defined by three anatomical structures  
True stress/ strain Stress calculated as the applied load divided by the instantaneous cross-sectional 
area/ strain calculated as the instantaneous change in the instantaneous length 
Ultimate Tensile Strength 
(UTS) 
Highest stress determined in a tensile test 
Valvuloplasty Widening of a narrowed valve, typically using a balloon 
Ventricle/ Ventricular Septum Main muscular chambers of the heart/ wall separating the two ventricles 
Ventricularis Elastic layer on the ventricular side of the aortic valve leaflets 
Ventriculo-aortic junction 
(VAJ) 
Region between the left ventricular muscle (myocardium) and the fibrous aortic 
wall 
Yield Stress See elastic limit 
Young’s Modulus See elastic modulus 
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1 Introduction
1.1 Background and Motivation
Rheumatic heart disease (RHD) is the leading cause of aortic valve disease in the world and is 
responsible for over 1 million deaths per year. It is estimated that up to 78 million people are living 
with RHD, the majority of whom live in the developing world (Paar et al., 2010; Sliwa & Zilla, 2012; 
Zühlke et al., 2015). Surgery to repair or replace the diseased valves is frequently the only means to 
save a patient’s life once the disease becomes symptomatic (Cannon, Roberts, Milne, & Carapetis, 
2017; Carapetis, 2007; Sliwa & Zilla, 2012; Zühlke, Engel, Remenyi, Wyber, & Carapetis, 2013; Zühlke, 
Mirabel, & Marijon, 2013). 
Transcatheter aortic valve replacement (TAVR) is a minimally-invasive procedure that has 
revolutionised the treatment of aortic heart valve disease over the last decade (Taramasso et al., 
2014). Most of these procedures are carried out within developed countries, on elderly patients who 
suffer from age-related calcific degenerative aortic stenosis (AS). A comparatively recent intervention, 
TAVR (with commercially available replacement devices such as the Edwards Sapien™) was originally 
used to treat patients who have unacceptable or high risk for open-heart surgical valve replacement. 
It is increasingly being used to treat patients at moderate risk (Reardon et al., 2017) but there is 
currently insufficient clinical evidence to support the use of the devices in low risk patients 
(Panayiotides & Nikolaides, 2014; Rosato et al., 2016). Although surgical valve replacement for low-
to-moderate risk patients, and TAVR for high risk and inoperable patients are considered the standard-
of-care in the developed world, these devices are unsuitable for the majority of the developing world, 
where there are relatively few cardiac surgery centres, catheterisation laboratories or the 
sophisticated hybrid laboratories (with associated advanced X-ray imaging equipment) required for 
transcatheter delivery of commercial TAVR devices. Furthermore, TAVR devices are too expensive to 
be affordable in developing economies (Neyt, Van Brabandt, Devriese, & Van De Sande, 2012). There 
is therefore a great need for lower cost TAVR devices and procedures suitable for developing countries 
(Remenyi, ElGuindy, Smith, Yacoub, & Holmes, 2016; Zilla, Brink, Human, & Bezuidenhout, 2008). 
Researchers within the Cardiovascular Research Unit (CVRU) at the University of Cape Town have 
recognised the need for a TAVR procedure that can be simplified to make it possible to perform heart 
valve replacements and repairs at regional hospitals. Transcatheter valve deployment devices are 
therefore being developed that do not occlude blood flow during deployment, and allow valves to be 
placed using tactile information about location within the heart instead of relying on advanced 
imaging. The devices incorporate balloons that can deploy a replacement valve in the affected 
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anatomy. An example of a device currently in development is shown in Figure 1-1. In parallel with the 
development of the deployment devices, replacement aortic valves are also being developed. While 
commercial TAVR valves are hand-sewn using animal tissue leaflets, the ability to mass-produce valves 
with polymer leaflets would make these valves far more accessible to hospitals in developing 
countries.  
The current thesis project aims to develop and test a novel balloon-expandable stent for a polymeric 
TAVR. It forms part of the broader programme to develop a low cost and durable balloon-expandable 
replacement heart valve suitable for patients with symptomatic rheumatic aortic valve disease. The 
valve is intended to be delivered to the site of implantation and deployed by the devices discussed 
above. 
Figure 1-1. Non-occlusive deployment device, rendering and sketch of deployment
1.2 Aim
This thesis project involves the development of a new technology. Specifically it aims to develop and 
test a balloon-expandable stent suitable for use in RHD, suitable for the manufacture of polymer 
valves and able to be crimped onto deployment devices. 
1.3 Thesis Outline
Chapter 2 provides a literature review of heart and aortic valve anatomy, as well as presenting details 
of the effect of rheumatic heart disease on the aortic valve. It also presents a summary of commercially 
available transcatheter aortic valves or valves in development, and describes published work on stent 
and valve design and simulation. Finally it presents concluding comments on the literature review and 
defines the specific objectives of the thesis. 
Chapter 3 presents the user needs and design requirements identified for the valve (and describes 
how this is translated to the engineering requirements for the stent) and presents methodology 
related to design and material selection. 
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Chapters 4 and 5 describe the numerical and experimental methods. Specifically Chapter 4 presents 
the theory and methods related to computational modelling of stent performance; Chapter 5 presents 
the methods used to manufacture stents, and the methods used to test stent and valve performance 
using in vitro bench tests and in vivo studies in large animals. 
The results of design and testing are presented in Chapters 6 and 7. Specifically Chapter 6 describes 
the generation and selection of stent concepts to satisfy user needs; Chapter 7 presents the results of 
simulation, prototyping and test activities performed on favoured design concepts selected from 
Chapter 6. 
Chapter 8 provides a discussion of the results in the context of prior work in the field and compares 
the solution to the engineering requirements. 
Chapter 9 concludes the report, discusses limitations and provides recommendations for further 
research and development, including recommendations for design alternatives. 
The thesis layout is presented as a flowchart in Figure 1-2. 
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2.1 Anatomy and Physiology of the Heart
The human heart is a four-chambered muscular pump that circulates blood around the body (Fuster, 
O'Rourke, & Walsh, 2007).  Referring to Figure 2-1, deoxygenated blood (blue arrows) from the venous 
system returns to the right atrium of the heart, where it is pumped through the tricuspid valve into 
the right ventricle. The blood is then ejected by the right ventricle through the pulmonary valve and 
then through the lungs, where oxygen is absorbed and carbon dioxide is released. The newly 
oxygenated blood (red arrows) travels to the left atrium, where it is pumped into the left ventricle 
through the mitral valve. The blood is then ejected, by the contraction of the left ventricle, through 
the aortic valve to provide the body with oxygenated blood. The purpose of the four heart valves is to 
control the direction of blood flow, allowing forward flow and preventing backward flow (Yoganathan, 
Lemmon, & Ellis, 2000). 
Figure 2-1. Sectional anatomy of the heart1 
Immediately prior to contraction of the left ventricle, the mitral valve is open and the aortic valve is 
closed; the blood pressure in the left atrium and the left ventricle are therefore similar. As the left 
ventricle begins to contract, the pressure in the left ventricle rises rapidly and the mitral valve begins 
1 "Blausen 0457 Heart Sectional Anatomy" by Blausen Medical Communications, Inc. - Donated via OTRS, see ticket for details. Licensed 
under CC BY 3.0 via Wikimedia Commons - http://commons.wikimedia.org/wiki/ File:Blausen_0457_Heart_ Sectional Anatomy.png 
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to close. When the pressure in the left ventricle reaches the aortic pressure, the aortic valve opens. 
The aortic and ventricular pressures continue to rise together as the rate at which blood is ejected 
from the ventricle is greater than the rate at which the blood is delivered to the arterial branches. 
Towards the end of the ventricular contraction phase, aortic and ventricular pressures drop gradually, 
and the aortic valve leaflets begin to close just before ventricular relaxation. After the aortic valve 
closes, the ventricular pressure drops rapidly until the pressure in the ventricle is lower than the 
pressure in the left atrium and the mitral valve opens, allowing the ventricle to fill with oxygenated 
blood from the atrium. Near the end of ventricular systole, the pressure in the atrium and ventricle 
rise briefly due to atrial contraction, and the cardiac cycle repeats (Katz, 2010).   
2.2 Functional Anatomy of the Aortic Root
The anatomy of aortic valve and associated structures has been described for centuries, originating 
during the Renaissance, with sketches and descriptions by Leonardo da Vinci, and interest was 
renewed during the development of surgical aortic valve replacement (SAVR). Recently, interest in the 
anatomy of the aortic valve has been stimulated by the development of TAVR and the required 
understanding of anatomic factors relevant to the performance of these devices (Anderson, Becker, 
& Piazza, 2009; Piazza et al., 2008; Schubert & Ghanta, 2016). Knowledge of the anatomy is important 
in the development of replacement valves that must be positioned within the anatomy.  
The aortic root, illustrated in Figure 2-2, starts as a continuation of the left ventricular outflow tract 
(LVOT), at the base of the leaflets, ends at the sinotubular junction (STJ), and incorporates the three 
aortic valve leaflets and the sinus of Valsalva (SoV) (Piazza et al., 2008). The bulbous SoV creates 
vortices to aid in valve closure, prevents the valve leaflets from contacting the aortic wall and reduces 
leaflet stresses by allowing smooth leaflet closure (Katayama, Umetani, Sugiura, & Hisada, 2008). The 
coronary arteries usually arise from the two anterior SoV. The plane through the base of each leaflet 
attachment site (the basal ring) is typically referred to as the aortic annulus. The aortic annulus, 
however, rather than being a circular ring, is crown-shaped (Anderson, 1991), as can be seen in Figure 
2-2. Similarly, the intersection of the tubular aorta and the bulbous SoV means that the STJ is also
scallop-shaped rather than circular. Significantly for TAVR design, at the level of the basal ring, two-
thirds of the circumference of the aortic root is muscular (part of the ventricular septum) while the
remaining third is the fibrous continuity between the aortic valve and the mitral valve, as shown in
Figure 2-4.
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Figure 2-2. Schematic of aortic root, adapted from Sutton, Ho, and Anderson (1995) 
Figure 2-3. Image of the aortic root opened from the left ventricle (left) showing fibrous continuities between interleaflet 
triangles, the fibrous trigones, and the membranous septum, and a schematic (right) showing the relations of the 
atrioventricular conduction system with respect to the aortic valve leaflets, from Piazza et al. (2008) 
The basal attachment sites of the leaflets to the wall are below the level of the ventriculo-aortic 
junction (VAJ), the termination of the ventricular myocardium and the start of the aorta (Anderson, 
2000; Piazza et al., 2008) . De Kerchove et al. (2015) examined the anatomy of 58 fresh human aortic 
roots and identified that the VAJ is above the basal ring in the area around the right coronary cusp, 
from the nadir of the left coronary cusp to the nadir of the non-coronary cusp. Specifically the VAJ was 
4.6 ± 1.4 mm above the basal ring at the left coronary/right coronary commissure and 2.5 ± 1.6 mm 
above the basal ring at the right coronary/non-coronary commissure, as shown in Figure 2-5. 
Commissure










Lunula (free edge) of 
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ring and junction 
Crown-shaped 








Figure 2-4. Opened-out mitral and aortic valves, from Du Plessis and Marchand (1964).  
(A.L. – Anterior Mitral Leaflet; I.V.S – Intervalvular Space; L.F.T. – Left Fibrous Trigone; R.F.T. – Right Fibrous Trigone; P.L. – 
Posterior Mitral Leaflet).
Figure 2-5. View of an aortic root opened longitudinally, showing the basal ring (white line) and the VAJ (black dashed line), 
from De Kerchove et al. (2015). (L – Left coronary cusp; R – Right coronary cusp; N – Non-coronary cusp) 
Aortic root thickness was measured at the level of the basal ring and found to vary from 1 ± 0 mm at 
the left coronary/non-coronary commissure to 6.2 ± 1.2 mm at the right coronary cusp. The fact that 
the bases of the leaflets lie below the level of the VAJ is also demonstrated clearly in histological 
sections through the aortic valvar complex, as shown in Figure 2-6 (Piazza et al., 2008). The leaflets 
have a three-layered fibrous core (the layers are the collagenous Fibrosa, the gel-like Spongiosa and 
the elastic Ventricularis) and are lined with endothelial cells. The aortic valve therefore does not have 
a true structural annulus. It is useful at various times to refer the basal ring or virtual ring/annulus (the 
plane through the nadirs of the leaflet hinges), surgical annulus (the leaflet attachment margin) and 
the VAJ. The functional anatomy of the aortic valve cannot be understood in isolation, as the aortic 
valve is the centrepiece of a fibrous scaffold known as the cardiac skeleton, and is positioned between 
the mitral, tricuspid and pulmonary valves  (Bateman, Quill, Hill, & Iaizzo, 2013). 
L R N
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Figure 2-6. Histology of the aortic valvar complex (Piazza et al., 2008) 
. 
Unlike the right ventricle, which has a tubular muscular outflow tract (infundibulum) and therefore 
has a muscular boundary between the pulmonary and tricuspid valves known as the ventriculo-
infundibular fold (S. Y. Ho & Nihoyannopoulos, 2006), the aortic valve and mitral valve are intimately 
involved and are both essentially part of a single aorto-mitral orifice. Fibrous tissue extends between 
the aortic and mitral valves to form the aorto-mitral curtain (see Figure 2-4). The extremities of the 
fibrous curtain are thickened to form the left and right fibrous trigones, which support the curtain 
within the base of the left ventricle. The right fibrous trigone is continuous with the membranous 
septum and together they form part of the central fibrous body, the strongest part of the cardiac 
skeleton.  
Various authors have tried to quantify aortic valve compliance. Swanson and Clark (1974) determined 
the response of the aortic root to pressure by filling cadaveric human aortic roots with silicone rubber 
and allowing to cure while under pressure. They found that the valve diameter increased by a mean 
of approximately 10% over a pressure change of 100 mmHg, but there was very large variation 
between specimens. One of the specimens had 18% compliance over a 60 mmHg pressure change. 
Such cadaveric studies are limited by the fact that samples are not tested fresh, and the aortic root is 
excised from the heart, meaning that the influence of other structures in the heart is not considered. 
A better determination of valve diameter may be obtained using modern imaging techniques, as true 
in situ measurements can be made. Multi-detector Computed Tomography (MDCT) has the best 
agreement with surgical measurements compared to echocardiography and contrast angiography 
(Litmanovich et al., 2014; Tsuneyoshi, Komiya, & Shimamoto, 2016; Yano et al., 2012), and is 
considered the gold standard.  
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Changes in diameter between systole and diastole (i.e. compliance) were evaluated using MDCT by de 
Heer et al. (2011), who found that the mean diameter of the basal ring was 27.1mm and 27.4mm in 
diastole and systole, respectively (1% increase, not statistically significant), with a mean difference 
between the maximum and minimum diameters of 6.0 ± 2.6 mm in diastole and 4.6 ± 2.5 mm in 
systole. This demonstrates that the basal ring is oval over the entire heart cycle but becomes more 
circular during systole. The mean diameter of the STJ changed from 30.5mm in diastole to 31.2mm in 
systole. It is worth noting that the unpressurised “surgical” STJ has a diameter approximately 90% of 
the virtual annulus (Kunzelman, Grande, David, Cochran, & Verrier, 1994). Hamdan et al. (2012) also 
found using MDCT that perimeter increased by the small but significant (p=0.01) amount of 2.2% in 
normal patients despite a cross-sectional area increase of 11.2 ± 5.4%. They conclude that the increase 
in aortic valve area is almost entirely due to changes in annular shape rather than stretch. This finding 
is in sharp contrast to the reports of Blanke et al. (2012), who measured a change in perimeter-derived 
diameter of 7.3 ± 2.1% even though all patients had severe aortic stenosis. The authors speculate that 
the differences in measurement are a result of a two-fold improvement in both temporal resolution 
and sampling rate of the CT protocol, and the fact that the maximum perimeter does not necessarily 
occur at the same instant as maximum area. Differences between diameter measurements across CT 
studies may also be due to poor standardisation and different smoothing functions across MDCT 
systems (Tsuneyoshi et al., 2016). Due to the changing shape of the aortic annulus, traditional 2D 
echocardiography using a standard long-axis parasternal view does not lead to accurate annulus sizing. 
Table 2-1. Aortic root measurements of normal patients from 3D TOE, from Calleja et al. (2013), in mm 
Leaflet
Left Non Right
Leaflet ICD 21.3±1.7 22.8±1.7 21.8±2.1 
Leaflet Free Edge Length 30.6±2.4 32.2±2.3 31.6±2.7 
Leaflet height 14.9±1.2 15.8±1.3 14.4±1.6 
Annulus-leaflet-ostia
Left Right
Annulus-commissure 17.2±1.5 18.6±1.5 
Annulus-ostia 13.3±1.8 14.8±1.9 
Leaflet-ostia 11.3±2.1 11.6±2.4 
Annulus-STJ-SoV
Annulus STJ SoV
Diameters 24.2±1.9 25.3±2.0 30.2±2.7 
The normal aortic root is slightly asymmetrical, with the left cusp being the smallest.  Some 
discrepancies exist between measurements from surgery and from imaging.  Berdajs, Lajos, and Turina 
(2002) found using surgical measurements that inter-commissural distance (ICD) was largest for the 
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right coronary cusp, intermediate for the non-coronary cusp and smallest for the left coronary cusp 
(ratio of 1.08:1:0.87). Similarly the right sinus height was the largest, followed by the non- and left 
coronary sinus (ratio: 1.10:1:0.99). Calleja et al. (2013) however measured ICD from 3D 
Transoesophageal Echocardiography (TOE) to be largest for the non-coronary cusp (relative ratio 
0.96:1.0:0.93 for right:non:left). The dynamic behaviour of the valve is also asymmetric, and this 
asymmetry is considered to have an important haemodynamic role by decreasing the tilt angle of the 
aortic root during ventricular ejection (Loukas et al., 2014). Several key measurements of the aortic 
root from Calleja et al. (2013) are shown in Table 2-1. 
The conduction system of the heart is also closely associated with the aortic valve (Anderson, Yanni, 
Boyett, Chandler, & Dobrzynski, 2009). The atrioventricular (AV) node is situated in the triangle of 
Koch within the right atrium and is positioned close to the membranous septum on the ventricular 
part of the interleaflet triangle between the right coronary and the non-coronary leaflets, as shown in 
Figure 2-3. The bundle of His conducts electrical impulses from the AV node to the apex of the heart 
through left and right bundle branches, which run within the ventricular septum. The left bundle 
branch (LBB) runs superficially along the left ventricular septum from just below the membranous 
septum. The His bundle is positioned approximately 6 mm below the basal plane, while the LBB may 
be found 12mm below the valve (Atkinson, Kharche, Bateman, Iaizzo, & Dobrzynski, 2016). This has 
important implications for TAVR valves that have ventricular components because the lower the 
replacement valve is implanted in the LVOT the more likely damage will occur to the conductive 
tissues, which may cause heart block or rhythm abnormalities.  
The mean heights of the coronary arteries above the basal plane are approximately 13-15mm and 15-
17mm for the left and right coronary arteries, respectively (Calleja et al., 2013; Knight et al., 2009; 
Tops et al., 2008). Coronary height can vary dramatically; Knight et al. (2009) measured a range of 
9.8mm to 29.3mm for the left coronary ostium and 10.4mm to 28.5mm for the right coronary ostium. 
The behaviour of the aortic root is complex, with parts of the root dilating and tilting over the cardiac 
cycle (Loukas et al., 2014). Functionally, healthy aortic valve leaflets open rapidly during ventricular 
ejection, and are viewed as thin parallel lines in a long-axis transthoracic echocardiography (TTE) view, 
close to the wall of the aorta (Tilea et al., 2013). As the aortic root dilates during the ventricular filling 
part of systole, the commissures are pulled outwards, straightening the free edges of the leaflets and 
creating an orifice that is triangular rather than circular, as illustrated in Figure 2-7. The leaflets begin 
to close at the end of systole due to vortices created behind the leaflets within the SoV, and close fully 
during diastole (completion of ventricular filling). When the valve is closed, the leaflets are concave 
and the free edges of the leaflets, or lunulae, overlap to form a region of coaptation that prevents 
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aortic regurgitation. A fibrous thickening of the free edge at the midpoint, known as the Nodulus of 
Arantius aids in the prevention of regurgitation. 
Figure 2-7. Relative cross-sectional schematic of the aortic root: (A) End diastole; (B) During ejection, at maximum dilation. 
Adapted from Lansac et al. (2002) 
The ascending aorta is tilted with respect to the left ventricle. Buzzatti et al. (2013) found using MDCT 
that the long axes of the aortic root and the LVOT are at an angle of 22.3 ± 10.3° to each other. The 
plane of the STJ lies at an angle of 5 to 11° to the aortic valve basal plane due to the different sizes of 
the sinuses (of Valsalva) (Berdajs et al., 2002; Siew Yen Ho, 2009; Labrosse, Beller, Robicsek, & 
Thubrikar, 2006). 
Aortic valve diameter increases steadily with age. In combined autopsy studies involving 965 normal 
hearts, Kitzman, Scholz, Hagen, Ilstrup, and Edwards (1988) and Scholz, Kitzman, Hagen, Ilstrup, and 
Edwards (1988) found that mean aortic valve circumference increases from birth until death. Aortic 
valve circumference increases exponentially from 24 mm at 1 year of age to 52 mm at age 20 
(corresponds to equivalent circle diameters of 8 mm and 17 mm, respectively), and from 57/60mm 
(women/men) in the third decade of life to 79/85mm (women/men) in the tenth decade (equivalent 
diameters of 18/19mm and 25/27mm, respectively). In contrast the three other heart valves increase 
initially and decrease in the fifth to seventh decades of life, but this apparent decrease in size 
disappears when valve circumference is indexed for body surface area.  During valve closure, the aortic 
valve experiences a transvalvular pressure gradient of 80mmHg to 120mmHg, which acts normal to 
the leaflet surface and results in leaflet stretch and a large area of coaptation. During valve opening 
the valve experiences fluid shear stresses, and over the complete heart cycle the leaflets experience 
a complete curvature reversal, resulting in the development of bending stresses (Balachandran, 









2.3 Rheumatic Heart Disease
RHD is a valvular heart disease caused by one or more attacks of acute rheumatic fever (ARF). The 
bacterium responsible for the infection is Streptococcus pyogenes. The pathophysiology of ARF 
involves a combination of three factors, namely a rheumatogenic streptococcal strain, an individual 
with a genetic predisposition to the disorder and an abnormal immune response to the infection 
(Marijon, Mirabel, Celermajer, & Jouven, 2012). Central to the abnormal immune response is similarity 
between proteins on the surface of the bacterium and various cardiac proteins (antigen mimicry). An 
autoimmune reaction ensues in the heart, where antibodies generated as part of the immunological 
response to the pathogen cross-react with the cardiac proteins (Root-Bernstein, 2014). ARF typically 
occurs approximately three weeks after infection, which is usually pharyngitis, and can affect the skin, 
the large joints, the heart and the brain. When ARF leads to persistent heart valve damage, it is known 
as RHD. Serious complications of RHD include atrial fibrillation, infective endocarditis, stroke, 
pregnancy-related problems and heart failure (Remenyi et al., 2016). The first attack of ARF usually 
occurs in children between the ages of 5 and 15, while RHD is most prevalent amongst 25-45 year 
olds. RHD is firstly a disease of the mitral valve, and the occurrence of clinically isolated rheumatic 
aortic valve disease is rare (Nkoke et al., 2016). It has been reported that the aortic valve is never 
affected anatomically in RHD without also affecting the mitral valve anatomically (William C. Roberts, 
1970; William Clifford Roberts & Ko, 2008).2 The first two to three decades of life are primarily 
associated with mitral disease (first pure regurgitation, then mixed mitral disease and subsequently 
mitral stenosis). The involvement of other valves (in particular the aortic valve) increases with age 
(Remenyi et al., 2016). 
A recent global study of RHD, the REMEDY study (Zühlke et al., 2015), has demonstrated that RHD is a 
seriously neglected disorder in the developing world. Although a thorough prevention program 
requires education and surveillance programs, primary medical prevention of RHD involves preventing 
the first attack of ARF, and is achieved through treatment of suspected streptococcal sore throat using 
penicillin or other appropriate antibiotics (Gerber et al., 2009).  Secondary prevention (which aims to 
prevent recurrent bouts of ARF in patients who have documented RHD or who have had a previous 
attack of ARF) is achieved through continuous administration of prophylactic antibiotics (WHO, 2004). 
There is however no proven medical therapy that can alter the course of severe rheumatic aortic valve 
disease, and cardiac surgery is a life-saving intervention (Remenyi et al., 2016).  
2 The mitral valve may however function normally or the disease may not be clinically significant while the aortic valve is significantly 
affected. In this way a patient may present with aortic stenosis in the absence of mitral valve problems. 
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2.4 The Aortic Valve in Disease
Aortic valve disease falls into three major categories: degenerative, congenital or rheumatic. 
Congenital heart valve disease is usually related to the presence of a bicuspid valve. Figure 2-8 shows 
images of normal, bicuspid AS, tricuspid AS and rheumatic aortic valves. Although bicuspid valves are 
present in only 1-2% of the population, it is the most frequent indication for aortic valve replacement 
in individuals under 70 years of age in the developed world (Anderson, Becker, et al., 2009).  
Calcific degenerative aortic valve disease is associated with age and risk factor-related calcification of 
the heart valve leaflets and the annulus. In contrast, rheumatic valves are characterised by fibrosis, 
fusion of the leaflets at the commissures and along the zone of coaptation, and leaflet thickening. A 
loss of height of the cusps and commissures occurs in the early phases of the disease, but as the 
disease progresses scarring occurs together with cusp retraction (Matsumura et al., 2002; Waller et 
al., 1991).  
In the case of rheumatic aortic regurgitation (AR), the leaflet retraction and stiffening associated with 
leaflet thickening causes central regurgitation because leaflets are prevented from closing fully during 
diastole. Although calcification is frequently present in the leaflets of patients with rheumatic AR, 
calcification may be absent (Myers et al., 2010). Figure 2-9 shows an image of excised calcific tricuspid 
and bicuspid aortic valves and a tricuspid rheumatic aortic valve, which clearly show the penetration 
of calcium deposits through leaflet thickness, while in rheumatic valves the commissural fusion can be 
pronounced with much less calcium deposition. 
In rheumatic AS, commissural fusion and calcification cause a central triangular or “fish-mouth” 
narrowing. Since commissural fusion and leaflet thickening can affect valve area during systole and 
prevent tight valve closure during diastole, mixed AS and AR are common in RHD. For degenerative 
calcific AS, calcification starts at the regions of maximum flexion, the base of the leaflets, and 
progresses into the Sinus of Valsalva (Anderson, Becker, et al., 2009). In  rheumatic AS, however, 
calcium localisation tends to be more diffuse (Wallby, Steffensen, Jonasson, & Broqvist, 2013).  
The aortic root remodels longitudinally in patients with calcific aortic stenosis. Akhtar et al. (2009) 
showed that the heights of the left and right coronary arteries were 2.2mm and 1.6mm lower, 
respectively, in patients with calcific aortic stenosis compared to age-matched controls, and similarly 
the height of the sinotubular junction above the virtual annulus was lower in calcific stenosis than in 
controls (16.7 ± 2.0mm vs. 21.0 ± 2.3 mm). Free edge length of the leaflets was reduced by 
approximately 4mm in AS, while the effective height of the leaflets, defined as the distance from the 
annulus to the leaflet tip, was increased in AS patients by approximately 2mm. Annulus diameter did 
not differ significantly between AS and normal groups. These findings are in agreement with a more 
14
recent study by Calleja et al. (2013), who also found that the distance from the annulus to the 
commissures was 1.5 to 1.8 mm smaller in AS than controls. STJ and SoV diameters were not 
statistically different between AS and normal patients. 
Figure 2-8. A) Normal trileaflet aortic valve, B) Stenotic calcified bicuspid aortic valve, C) Calcified (degenerative) trileaflet 
aortic valve, D) Thickened leaflets and commissural fusion associated with Rheumatic aortic valve disease, from Anderson, 
Becker, et al. (2009) 
Figure 2-9. Excised diseased valves. A) Calcified (degenerative) trileaflet aortic valve, B) Calcified bileaflet aortic valve and 
C) Rheumatic aortic valve, from http://www.cthsurgery.com/aetiology-of-aortic-valve-stenosis.html.
As with normal patients, patients with AS have oval annuli (Tops et al., 2008). Buellesfeld et al. (2013) 
also found that the ovality was significantly more pronounced in the LVOT than in the annulus. They 
also showed that perimeter-derived diameters of the annulus, LVOT and SoV, as well as coronary ostia 
heights, were greater in men than in women, while ascending aorta diameter was similar between the 
sexes. In contrast to patients with AS, Calleja et al. (2013) found a significant increase in annulus 
diameter for patients with dilated aortic roots (for those with AR the average annulus diameter was 
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31.3 ± 3.8 mm vs. 24.2 ± 1.9 mm for controls). In the patients, ICD, leaflet length and leaflet height 
were higher in all leaflets compared to controls.  
Compliance is reduced in calcified valves. Hamdan et al. (2012) found that calcified valves experience 
a change in cross-sectional area of 6.2 ± 4.8% from diastole to systole, but in these patients there was 
a negligible change in perimeter (0.56 ± 0.85%). Several authors have evaluated valve compliance from 
pre-TAVR CT scans. Jilaihawi et al. (2012) found that perimeter-derived diameter increased from 23.8 
± 2.4 mm to 24.7 ± 2.5 mm (3.8%, p<0.001) and mean diameter increased from 23.3 ± 2.3 mm to 24.2 
± 2.6 mm over the heart cycle (3.9%, p<0.001). Figini et al. (2015) similarly reported an increase in 
perimeter-derived diameter of 2.7%, from 23.9 ± 1.83 mm to 24.5 ± 1.85 mm, p<0.001. Shibayama et 
al. (2014) reported comparable compliance of 1.9% for tricuspid aortic valves using TOE. Blanke et al. 
(2012) found an increase in perimeter of 7.3 ± 2.1% from CT scans, and they attribute these higher 
values to a higher resolution and sampling rate of their scans. von Aspern et al. (2015), however, 
reported only 0.9% change in perimeter-derived diameter (24.5 ± 3 to 24.7 ± 3) in pre-TAVR CT scans 
despite also using dual-source 128-row MSCT; in fact all patients showed less than 2mm difference 
between diastolic and systolic measurements.  
No published literature could be found relating to the compliance behaviour of aortic valves in 
patients with non-calcific aortic valve disease or RHD. Since rheumatic aortic disease is not associated 
with focal calcium in the annulus or sinus of Valsalva, the rheumatic aortic root may be more compliant 
than the degenerative calcific aortic root, although no literature has yet been found to verify this. 
Furthermore, as rheumatic aortic valves are associated with cusp fusion, they may be more suited to 
balloon-expandable valve implantation due to the ability for the balloon to perform a 
commissurotomy during implantation (Remenyi et al., 2016), as mitral valves with commissural fusion 
have been shown to benefit from balloon commissurotomy (Bouleti et al., 2012) 
2.5 Heart Valve Replacement
2.5.1 Surgical Valve Replacement
Since the first successful mitral valve replacement was performed in 1960, surgical heart valve 
replacement has become a routine procedure, with more than 300 000 procedures performed 
globally every year (Mohammadi & Mequanint, 2011). Two different types of surgical heart valves are 
currently implanted, namely mechanical heart valves (MHVs) and biological heart valves (BHVs), 
examples of which are shown in Figure 2-10 and Figure 2-11, respectively. MHVs are constructed 
entirely from synthetic materials, and although many different designs have been attempted, the 
most frequently implanted types are tilting-disc and bileaflet valves. MHVs are very robust and 
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durable, but require lifelong anti-coagulation (Abu-Omar & Ratnatunga, 2007). An inexpensive tilting-
disc valve called the Chitra valve has been produced and is widely implanted in India (P. Kumar et al., 
2004). BHVs incorporate material of biological origin and are either stentless or stented. Stented 
valves, usually constructed from porcine roots or bovine pericardium, incorporate a support frame 
and sewing ring, and animal tissues that are chemically treated to reduce antigenicity and calcification. 
Stentless valves do not have a rigid sewing ring or support frame and include hetero-grafts (from non-
human animal), homografts (from another human) or autografts (from the same patient). BHVs have 
a limited lifespan but do not require lifelong anticoagulation (G. Hoffmann, Lutter, & Cremer, 2008); 
BHVs are therefore typically chosen if anticoagulation is contraindicated in the patient, if 
anticoagulation is unavailable, if the patient is unlikely to be compliant on anticoagulation or in 
patients with life expectancy shorter than the expected durability of the valve (Abu-Omar & 
Ratnatunga, 2007).   
Figure 2-10. Medtronic Hall™ Tilting disc valve, Edwards MIRA™ bileaflet valve (Abu-Omar & Ratnatunga, 2007), and TTK 
Chitra™ valve (Walters, 2015) (left to right) 
Figure 2-11. Carpentier-Edwards Perimount™ pericardial valve and Edwards Prima Plus™ stentless bioprosthesis (Abu-
Omar & Ratnatunga, 2007)
2.5.2 Transcatheter Aortic Valve Replacement (TAVR)
TAVR represents the culmination of many developments in cardiac surgery, catheter-based 
intervention techniques and equipment design from the first surgical aortic valve dilation in 1912 to 
the first human TAVR in 2002. The history of significant events leading to the first human TAVR is 
presented in Table 2-2.  Andersen, Knudsen, and Hasenkam (1992) were the first to describe the 
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percutaneous implantation of an aortic valve as a closed-chest minimally-invasive alternative to 
surgical valve replacement. The first percutaneous implantation of a replacement valve in humans was 
performed by Bonhoeffer et al. (2000), who implanted pulmonary valves in children. The first human 
TAVR was performed by Alain  Cribier et al. (2002) in an inoperable patient with severe AS.  TAVR 
valves are compressed to a low profile for catheter-based insertion into the patient’s native aortic 
valve position using antegrade or retrograde approaches, and are deployed (or allowed to deploy) to 
their operating shape within the diseased native valve, forcing the diseased native cusps (leaflets) 
against the aortic wall. Figure 2-12 shows an image of a transcatheter aortic heart valve inflated on a 
balloon and an illustration of the same valve being deployed inside the native aortic valve using an 
antegrade transapical technique. 
Table 2-2. History of significant developments leading up to percutaneous aortic valve implantation 
Year Event
1912 Tuffier performs first aortic valve dilation by invaginating the aortic wall using his forefinger and pushing 
the wall through the diseased valve (Dhaval, 2010).  
1923 Cutler performs first successful surgical mitral valve repair (Bland, 1952) 
1941 Cournand and Richards perform the first diagnostic cardiac catheterisation (Mueller & Sanborn, 1995). 
1948 Bailey performs the first mitral commissurotomy, using a knife with a curved blade (C. P. Bailey, 1949) 
1950 First aortic commissurotomy, with a dilator instrument (C. P. Bailey, Bolton, Jamison, & Nichols, 1954) 
1952 Gibbon performs first successful open heart surgery using a cardiopulmonary bypass machine (Cohn, 2003) 
1952 Hufnagel implants first mechanical valve in the descending aorta (Butany et al., 2002) 
1953 First transaortic approach to commissurotomy (C. P. Bailey et al., 1954). 
1953 Seldinger technique developed for percutaneous interventional procedures (Seldinger, 1953) 
1960 Braunwald performs first mitral valve replacement, using a polyurethane valve with Teflon chordae 
tendinae (Braunwald, 1989) 
1960 Harken et al. (1960) perform the first successful surgical aortic valve replacement, with a mechanical valve. 
1960 Rohman, Goetz and team perform the first successful coronary artery bypass surgery (Dee, 2003) 
1962 Ross (1962) performs first aortic homograft valve replacement 
1964 Duran performs first porcine aortic valve replacement (Shumacker, 1992) 
1965 Davies (1965) describes the first use of a catheter-mounted, polymeric, valve 
1967 First transfemoral coronary angiography performed using special catheters (Judkins, 1967) 
1971 Ionescu performs the first implantation of a stented chemically treated bovine pericardial valve (Ionescu, 
Pakrashi, Holden, Mary, & Wooler, 1972) 
1985 Cribier performs the first adult balloon aortic valvuloplasty in adults (Alain Cribier, 2012) 
1989 First balloon-expandable aortic valve implanted into pigs by Andersen et al. (1992) 
2000 First percutaneous implantation of replacement valves in humans by Bonhoeffer et al. (2000); a bovine 
jugular vein was attached to a platinum-iridium stent and implanted into the right ventricle to  pulmonary 
artery conduits of children 
2002 First human implantation of a percutaneous aortic valve by Alain  Cribier et al. (2002) 
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Figure 2-12. Edwards Lifesciences Sapien THV™, deployed on balloon and illustrated antegrade implantation through the 
left ventricular apex (Chiam & Chao, 2013) 
The first commercially available TAVR devices, both of which received European certification in 2007, 
were the Edwards Sapien THV™, consisting of a tri-leaflet bovine pericardial valve mounted on a 
balloon-expandable stainless steel stent, and the Medtronic CoreValve™, consisting of a tri-leaflet 
porcine pericardial valve mounted on a self-expanding Nitinol frame. Today many devices have 
received the CE mark and many more are in development (Weiss et al., 2015). A list of CE-marked 
valves is shown in Table 2-3. Non-CE marked balloon-expandable valves are listed in Table 2-4. A list 
of polymeric transcatheter valves (historical and in development) is provided in Table 2-5. A 
comprehensive list of all valves known to the author is provided in Appendix A. 
There are also isolated reports of devices being used to treat aortic insufficiency (Cholteesupachai, 
Franzen, & Sondergaard, 2014; Dumonteil, Marcheix, Lairez, & Laborde, 2013; Franzone et al., 2016; 
Hildebrandt, Erbel, & Kahlert, 2013; Wei et al., 2015), including rheumatic aortic insufficiency 
(Ducrocq, Himbert, Hvass, & Vahanian, 2010), and the devices have been used for rheumatic AS 
(Akujuo, Dellis, Britton, & Bennett, 2015; Bilge, Saatci Yasar, Alemdar, & Ali, 2014; Daly et al., 2015), 
but these are off-label uses for most devices. It is interesting to note that during early animal trials of 
the Cribier-Edwards™ valve that more than 30% of valves migrated in the non-calcific aortic annulus 
(Dewey et al., 2006). Subsequent animal models required a modified Cosgrove™ annuloplasty ring to 
be stitched into the aortic root to eliminate stent migration (Edwards, 2015). 
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Table 2-3. CE Marked TAVR devices (Bourantas & Serruys, 2014; Rozeik, Wheatley, & Gourlay, 2014; Taramasso et al., 
2014; Weiss et al., 2015; Wiegerinck, Van Kesteren, Van Mourik, Vis, & Baan, 2016)
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Table 2-4. Non-CE-marked balloon-expandable TAVR (Ismail, Hon, Chan, & Leo, 2012; Jamieson, Zhang, & Quijano, 2006; 
Jilaihawi et al., 2010; Kemp et al., 2013; Leon, 2013; Pontes et al., 2013)
Table 2-5. Polymer TAVR (historical and active) (Bezuidenhout, Williams, & Zilla, 2015) 
2.5.3 Sutureless and Hybrid Valves
A number of different technologies have been developed to make surgical valve replacement easier 
and faster, and improve clinical outcomes. Sutureless valves such as the Perceval™ S (Sorin Group, 
Saluggia) eliminate the need for sutures and therefore reduce the duration of cardiopulmonary bypass 
and cross-clamping of the aorta. The valves simplify minimally invasive surgical procedures and are 
particularly appreciated in complex procedures (Phan et al., 2015). 













































































Two-part valves have been developed (by ValveXchange, Inc., Colorado) that comprise a permanent 
docking station and a replaceable set of leaflets that may be placed and exchanged using minimally 
invasive techniques (Vesely, 2010). Initially the docking stations were designed to be surgically 
implantable, but subsequent designs include transapical and transfemoral versions. 
2.5.4 Valve Longevity
Mechanical valves are more durable than bioprosthetic valves, with mechanical valves lasting 20-30 
years compared to 10-15 years for bioprosthetic valves (Vongpatanasin, Hillis, & Lange, 1996). 
Bioprosthetic valves are susceptible to calcification, pannus formation or leaflet tearing, and 
bioprosthetic valve design can dramatically affect long-term valve performance (Vesely, 2003). A 
landmark randomised trial by Hammermeister et al. (2000) found that all-cause mortality after surgical 
aortic valve replacement was significantly lower for mechanical valves than bioprosthetic valves (66% 
versus 79%). This was primarily due to the fact that primary valve failure rates were much higher for 
bioprosthetic valves; in patients younger than 65 years, 26% of bioprosthetic valves failed while in 
mechanical valves valve failure was completely absent.  
Age is a well-known predictor of bioprosthetic valve failure. As shown in Figure 2-13, freedom from 
explant for structural valve dysfunction (SVD) is almost 100% in 85 year-old patients, but is only 30% 
for 25 year old patients (Banbury et al., 2001). Current AHA/ACC guidelines (Nishimura et al., 2014) 
recommend that bioprosthetic valves should be considered in patients >70 years of age, mechanical 
valves should be considered in patients <60 years of age, and either valve may be considered in 
patients between 60 and 70 years of age (Class IIa recommendation). A recent propensity-matched 
multicentre cohort analysis showed, however, that there was no difference in 15 year mortality for 
patients between 50 and 69 years receiving mechanical and bioprosthetic valves, although re-
operation was more likely in the bioprosthetic device group and major bleeding was more likely in the 
mechanical device group (Chiang et al., 2014). The choice of valves for middle-aged patients remains 
controversial.  
Some investigators have noted that the valve guidelines are inappropriate for developing countries, 
where lower life expectancy, device and resource availability, the younger age of patients receiving 
valve replacements (see Figure 2-14), socio-economic status and other factors influence device 
selection (Choudhary, Talwar, & Airan, 2016; Zilla et al., 2008). Long-term durability of TAVR valves is 
not yet known since the devices have been CE marked for fewer than 10 years, and little attention 
was given to the issue as the first patients receiving the valves were elderly patients with limited life 
expectancy.  
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Figure 2-13. Fifteen-year freedom from structural valve dysfunction versus age at implant (Banbury et al., 2001) 
TAVR durability is becoming more important as valves are increasingly being used in intermediate risk 
and low-risk patients. Although the current data available beyond 5 years suggest that durability is 
similar for transcatheter and surgical valves, there are differences that may result in reduced reliability 
in the longer term. These include: the increased risks of worsening paravalvular leak; increased leaflet 
stresses due to potentially non-circular expansion, less flexible frames and the presence of the 
calcified native leaflets; the potential for leaflet weakening from crimping; and the risk of late 
dislocation (Arsalan & Walther, 2016).  
Figure 2-14. Age distribution for patients receiving replacement heart valves in a developing 
country and in the developed world (Zilla et al., 2008)
23
In the event of transcatheter valve failure, repeat TAVR (valve-in-valve procedure) is possible and has 
been shown to be safe, with good acute and medium term clinical outcomes (Barbanti et al., 2016). 
Although polymer valves have demonstrated in vitro durability of up to one billion cycles (equivalent 
of 25 years), no polymer aortic valve has ever demonstrated durability in humans beyond five years 
(Bezuidenhout et al., 2015). Despite the fact that bioprosthetic valves may be expected to last up to 
15 years (approximately 600 million heart cycles) in appropriately selected patients, international 
standards only require that valves be shown to remain functional for 200 million cycles in vitro and 
that the stent frame itself should remain functional for twice this duration (ISO-5840-3, 2013). 
2.6 Design and Simulation of Stents
Over the last two decades a large body of literature has been generated regarding the design and 
simulation of stents for percutaneous coronary intervention (PCI), peripheral vascular interventions 
and for vascular stent grafts, particularly with regards to understanding mechanical properties such 
as radial strength, compliance, resistance to embolization and fatigue life (Harewood, Thornton, & 
Sharp, 2011; Keevy, 2004; Marrey, Burgermeister, Grishaber, & Ritchie, 2006; Van der Merwe, Reddy, 
Zilla, Bezuidenhout, & Franz, 2008). This experience has provided a base for investigators to design 
and model stents for TAVR. The sections below present literature relating to stent design and 
modelling, respectively, with a focus on the modelling of stents used for transcatheter valves. 
2.6.1 Structural Design of a Stent
Several groups have proposed and compared structural members for use in stents (for coronary and 
peripheral arteries and for structural heart applications). Examples of typical and novel structural 
members are shown in Figure 2-15.  
The vast majority of stents are constructed of variations of zig-zag, “chicken-mesh” or diamond 
geometry (Sangiorgi et al., 2007; Stoeckel, Bonsignore, & Duda, 2002; Vaizasatya, 2013), and several 
authors have presented strategies for optimisation of such stents (Amirjani, Yousefi, & Cheshmaroo, 
2014; Hsiao, Wu, Yin, Lin, & Chen, 2014). Stent designs are frequently proposed to compare or improve 
particular mechanical properties, such as with Douglas, Phani, and Gagnon (2014), who compared the 
effect of different idealised stent geometries (chevrons, diamonds, auxetics and hybrid designs) on 
stent foreshortening, and Kumar et al. (G. V. P. Kumar & Mathew, 2008; Perme et al., 2009), who have 
proposed several stent designs to improve anchorage and paravalvular leak in transcatheter valves. 
Auxetic structures exhibit a “negative Poisson’s ratio” effect and are therefore useful for minimisation 
of stent foreshortening (Ali, Amin, Ansari, Minhas, & Shahid, 2015). 
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Figure 2-15. Examples of stent structures proposed in the literature. 
A) Diamond, auxetic and hybrid structures (Douglas et al., 2014; Karnessis & Burriesci, 2013), B) Several shapes to optimise 
stent performance (Vaizasatya, 2013), C) Flared designs for reduced leakage and improved anchoring, one of many
alternatives by the authors, including barbs (G. V. P. Kumar et al., 2013; G. V. P. Kumar & Mathew, 2009), D) Barrel-shaped 
stent (Atwood, Bougie, Carneiro, Pico, & Wnek, 2007), E) Double-layer (Basquin et al., 2010), F) Stent with locating 
members for behind cusps (Rudolph & Baldus, 2013), G) protruding members for anchorage (M. Young et al., 2012), H) 
Stent with multiple anchoring strategies (Marchand, Heim, & Durand, 2010a), I) a bi-stable stent structure (James & 
Waisman, 2016), J) Lattice shapes to reduce fatigue (Abad, Pasini, & Cecere, 2012) K) Negative Poisson’s ratio stent (Ali et 
al., 2015), L) Detaching “growth” stent (Ewert et al., 2004).  
Stents constructed from nitinol can be formed into a shape desired by the designer using heat 
treatment processes, including flared (G. V. P. Kumar et al., 2013), bulbous (Atwood et al., 2007), 
double-layered (Basquin et al., 2010) and complex winged shapes (Marchand et al., 2010a; Rudolph & 
Baldus, 2013). 
A particularly novel stent design has been described by M. Young et al. (2012). The authors developed 
an anti-migration nitinol valve stent that contains wing elements to anchor about the mitral valve 
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annulus. When crimped, the wings are flush with the rest of the stent, but when the stent is expanded 
the wings protrude first, as a result of “recessed indentations” on the wings. This expansion occurs 
not because of plastic strain within the stent but because of the unique wing design. James and 
Waisman (2016) describe a novel design that overcomes a limitation of nitinol stent designs, namely 
that a sheath is required to maintain the stent in its crimped condition. The authors developed a “bi-
stable” stent with stable configurations in both the crimped and expanded conditions, requiring only 
a small force to cause “snap-through” to the other stable condition. Ewert et al. (2004) describe a 
stent that overcomes another limitation of most stents, namely an inability to grow with the patient. 
The authors sutured two halves of a stent together with degradable sutures, which provides sufficient 
strength for the initial scaffolding of the vessel, after which the sutures eventually disappear and the 
vessel may grow. 
Stoeckel et al. (2002) have categorised stent designs according to geometry, form, material and 
method of fabrication. This initial categorisation was amended based on the stent structures described 
here and the valves described in Section 2.5.2 and Appendix A, and is presented in Appendix Figure 
B-1.
2.6.2 Leaflet Design
The design of the leaflet belly and free edge of the leaflet fall beyond the scope of this thesis. The 
stent and leaflet, however, share the shape of the leaflet attachment site. Although bileaflet and 
quadri-leaflet replacement valves have been developed and tested successfully, the majority of aortic 
valves described in the literature have trileaflet designs. A number of different shapes and 
mathematical expressions for surfaces have been used to describe natural valve geometry or to design 
replacement valves, including spherical, cylindrical, conical, paraboloid, alpharabolic, hyperboloid, 
ellipto-hyperbolic, domed, semi-domed, triangular and flat; analytically optimised shapes, including 
those based on Bézier curves, have also been described (Bezuidenhout et al., 2015).  
Several authors have observed that the leaflet attachment site is formed by the intersection of a flat 
plane with the conical or cylindrical aortic root (Labrosse et al., 2006; Mercer, Benedicty, & Bahnson, 
1973; Swanson & Clark, 1974), which means that the attachment site is necessarily elliptical, parabolic 
or hyperbolic. Labrosse et al. (2006) established a functional model of leaflet behaviour, where the 
three leaflets are identical in size, and the nadirs and commissures of the leaflets lie on the base and 
frustum of a cone, respectively. The area below the coaptation zone, namely the “load-bearing 
surface”, is nearly cylindrical when fully closed or fully open, and the attachment zone is defined as 
the intersection between the cone and a plane such that the “load-bearing surface” of the closed and 
open leaflets are mirrored about the plane. The attachment zone is therefore a combination of a 
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parabola for the load surface and straight lines for the coaptation area. This is illustrated in Figure 
2-16.
Figure 2-16. Schematic showing leaflet design as per Labrosse et al. (2006)
2.6.3 Computational Simulation of Stent Performance
The first FEA models of stents for percutaneous heart valves were performed by collaborating 
investigators at University College London (UCL) and the Politecnico di Milano in order to understand 
fatigue fracture in percutaneous pulmonary valves, firstly using free stent deployment (Schievano et 
al., 2007) and subsequently using post-intervention patient-specific models that included fatigue 
analysis based on a Goodman approach (Schievano et al., 2010).  
Many articles have been published on patient-specific FEA, with the goal of improving surgical 
planning. The most active academic groups in this area have included UCL (Bosi, Capelli, 
Khambadkone, Taylor, & Schievano, 2015; Capelli, Biglino, et al., 2012; Capelli, Bosi, et al., 2012; 
Capelli, Taylor, Migliavacca, Bonhoeffer, & Schievano, 2010; Spranger, Capelli, Bosi, Schievano, & 
Ventikos, 2015), University of Pavia (Auricchio, Conti, & Morganti, 2014; Auricchio, Conti, Morganti, & 
Reali, 2014; Morganti et al., 2015; Morganti et al., 2014), and University of Leuven (Bosmans, Famaey, 
Verhoelst, Bosmans, & Vander Sloten, 2016; de Jaegere et al., 2016; Schultz et al., 2016), although 
others are active.  
Wu et al. (2016) reported on the crimping, expansion and Fluid Structure Interaction (FSI) analysis of 
a valve constructed using a nitinol stent frame, meshed with reduced integration hexahedral 
elements. The valve was partially crimped with twelve plates, with leaflets already attached, before 
releasing into a patient-specific aortic root. Cyclic loading provided by FSI allowed strain-based fatigue 
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analysis to be done. Most studies omit leaflets from crimping and deployment analyses; the inclusion 
of leaflets was shown by J. Bailey, Curzen, and Bressloff (2015) to have little effect on stent shape. In 
order to determine the effect of physiological loading on stent leaflets, leaflets may be positioned 
within the stent frame after deployment, and then pressure may be applied to the leaflet and stent 
surfaces (Auricchio, Conti, Morganti, et al., 2014; Gunning, Vaughan, & McNamara, 2014). The 
inclusion of the native leaflets and calcium deposits has however been shown to improve the accuracy 
of patient-specific models (Ovcharenko et al., 2016; Russ et al., 2013). Starting position has also been 
shown to affect stent shift and final implant position (Russ et al., 2014). 
Imaging performed during and after valve implantation has been used to generate post-intervention 
patient-specific FEA models. Investigators at ETH Zurich have used linear-elastic beam elements to 
calculate interaction forces between the stent and aortic root based on the deformed stent state 
reconstructed from CT scans of patients who had received the CoreValve (Gessat et al., 2014; Hopf, 
Gessat, Falk, & Mazza, 2012; Hopf, Sundermann, et al., 2017). The use of linear elastic beam elements 
allows computation time to be dramatically reduced (Hopf, Gessat, et al., 2017). Schievano and 
colleagues reconstructed models of valve stents from biplane fluoroscopic images in three states 
(deployed condition, at systole and at diastole) as a tool to predict fatigue fracture. The measured 
displacements of the struts from the crimped condition to each of the three analysed conditions were 
used as boundary conditions for an FEA model. In particular, Cosentino et al. (2014) used logistical 
regression analysis to predict failure in Melody valves, and Schievano, Capelli, Cosentino, Bosi, and 
Taylor (2012) used Goodman and Sines-based fatigue analysis to predict fatigue failure in valves. 
Several authors have modelled the deployment of stents in simple geometry or in idealised or generic 
aortic anatomy (Dimasi et al., 2015; Ovcharenko, Klyshnikov, Savrasov, Nyshtaev, & Kudryavtseva, 
2015; Sturla et al., 2016; Tzamtzis, Viquerat, Yap, Mullen, & Burriesci, 2013). Ovcharenko et al. (2016) 
compared the use of patient-specific models to models based on simplified generic geometric data 
from multiple patients. Tzamtzis et al. (2013) calculated the hoop force of a 26mm Edwards Sapien™ 
valve implanted in 22mm tubes (of various stiffnesses) to be up to approximately 14N, which 
corresponds to a radial force of 88N. 
Free stent crimping, deployment and/or crushing (i.e. in the absence of an aortic root) have been 
performed to compare or optimise stent designs (G. V. P. Kumar et al., 2014; Ovcharenko, Klyshnikov, 
Savrasov, Nyshtaev, & Glushkova, 2014; M. Young et al., 2012), evaluate alternative materials (G. V. 
P. Kumar, Jafary-Zadeh, Tavakoli, & Cui, 2016), and study fatigue behaviour (Esterhuyse et al., 2012;
G. V. P. Kumar et al., 2013). Full patient-specific simulations (particularly those that incorporate the
native leaflets and calcium deposits) clearly result in the most accurate predictions of stent stresses,
strains and deployed shape, but the stent stresses vary from patient to patient, and a large sample of
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patients may be required to satisfactorily determine the likelihood of fatigue fracture in a general 
patient population. Free stent deformation is a useful and effective tool to compare stent designs in 
preparation for more comprehensive analyses.  
Stents have been meshed with a variety of element types, including beam elements (Bosmans et al., 
2016; Gessat et al., 2014), full integration hexahedral elements (Ovcharenko et al., 2016) , 
incompatible mode hexahedral elements (Wang, Sirois, & Sun, 2012), and reduced integration 
hexahedral elements, which are the most commonly used (Auricchio, Conti, Morganti, et al., 2014; 
Gunning et al., 2014; Wu et al., 2016). A comparison of several element types for stent modelling is 
provided by Hall and Kasper (2006).  
Contact between the stent and crimping/expansion tools typically include friction (Auricchio, Conti, 
Morganti, et al., 2014; Gunning et al., 2014) but may also be frictionless if stent movement is 
constrained in the axial direction (Morganti et al., 2014). Although self-expanding stents do not 
require deployment, most balloon-expandable stent expansion is modelled using an expanding rigid 
cylinder (Vy et al., 2015). Realistic balloons are however being used more frequently to deploy stents 
(Auricchio, Conti, Morganti, et al., 2014; Bosi et al., 2015; Wang, Kodali, Primiano, & Sun, 2015) since 
stent deployment behaviour is more realistic when balloons are modelled (De Beule et al., 2008).      
2.7 Concluding Remarks from Literature Review and Statement of Objective
The aortic valve is a nearly-symmetrical tricuspid valve situated at the centre of a fibrous skeleton and 
is in close proximity to all the other heart valves and to the conduction system of the heart. The 
literature review has highlighted a number of anatomical factors that are particularly relevant for 
TAVR design: 
 No true anatomical aortic annulus exists. At the level of the basal plane, one third of the 
circumference is made up of the fibrous continuity between the aortic and mitral valves.  
 The annulus is best thought of as a crown-shaped structure that follows the leaflet attachment 
lines. A cylindrical valve expanded into the root will contact the root along this crown shaped 
region. The VAJ, which represents the junction between the muscular myocardium and the 
fibrous aorta, extends above the basal plane, and is also not a true ring as frequently 
represented. Therefore some of this crown region is muscular above the virtual annulus. 
 The virtual aortic annulus is elliptical in shape, and valve area increases from diastole to systole 
primarily due to changes in eccentricity, rather than to tissue stretch. Valve sizing is therefore 
most appropriately performed using diameters derived from perimeters. Compliance (change is 
diameter over the heart cycle) is typically reported to be less than 4%.  
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 The aortic root dilates such that during ventricular ejection the leaflets form a triangular rather 
than circular orifice. 
 The height of the coronary ostia above the basal plane varies greatly among patients, with mean 
heights between 13 and 17mm. 
 The LBB is approximately 12mm below the virtual annulus 
 The aortic root is slightly asymmetric (typically approximately 10% difference from mean 
measurements for ICD and SoV height) and tilts slightly with respect to the left ventricle. 
 The diameter of the aortic valve increases with age 
 In contrast to degenerative bicuspid and tricuspid aortic valve disease, where calcium is 
deposited extensively in the leaflets and annulus, rheumatic aortic valve disease is fibrotic and 
characterised by thickening of the leaflets and fusion of the leaflets along the zone of coaptation 
 In calcific AS, the aortic root shortens, but annulus, STJ and SoV diameters are similar between AS 
and healthy aortic roots. Calcified valves are less compliant than healthy vessels. 
In developing countries, valve replacements are implanted into younger patients, in whom the failure 
rates of bioprosthetic surgical valves are high. Many of these patients have RHD, which is recognised 
as a seriously neglected disease in the developing world.  
A wide range of surgical, minimally invasive and transcatheter valves have been developed for the 
treatment of aortic valve disease. Several TAVR systems have CE Mark approval and are commercially 
available. Although the majority of TAVR are self-expanding, a number of balloon-expandable valves 
have been developed. All commercial transcatheter valves are bioprosthetic, but several groups have 
developed polymer valves. Medium term data suggests that transcatheter valves have similar 
durability to surgical bioprosthetic valves but long term data is not yet available. Four important points 
may be derived from examination of these transcatheter valves: 
 The majority of valves are constructed from Nitinol because they may be made retrievable and/or 
repositionable, and because Nitinol valves also have the advantage of being able to be heat set for 
shape fixation in their deployed condition, allowing complex shapes to be formed;  
 All commercial balloon-expandable valves have a uniformly cylindrical shape with repeating zigzag 
geometry around the circumference, related to the fact that the valves must be crimped and then 
deployed to their required size and shape using balloons; repeating patterns make this task 
simpler.  
 The majority of valves rely on a crown-shaped leaflet attachment to a skirt material, rather than 
on a continuous attachment to the frame. A notable exception to this is the Triskele valve from 
UCL. 
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 None of the balloon-expandable valves and few of the self-expanding valves are indicated for use 
in non-calcific AR, with none specifically indicated for rheumatic aortic valve disease. Valves 
without dedicated anchoring mechanisms are at risk of migration in the absence of leaflet 
calcification. As Remenyi et al. (2016) have stated, “development of newer generations of 
transcutaneous aortic valves that do not need the presence of cusp calcification for proper 
anchorage might offer an alternative to future surgical valve replacement”. 
Many stent designs have been proposed in the literature, and various simple and sophisticated 
approaches to the computationally modelling of their behaviour have been presented. No balloon-
expandable stent design has been reported that facilitates attachment of a polymeric valve and is able 
to anchor within a non-calcific aortic valve. We have therefore recognised an opportunity to develop 
a novel balloon-expandable stent that allows for continuous leaflet attachment and anchors 
effectively in the native aorta, even in the absence of calcification.  
This thesis therefore has the following specific research objectives: 
 Objective 1: Design a novel compressible and balloon-expandable stent for a transcatheter aortic
valve to which polymeric heart valve leaflets may be attached.
 Objective 2: Perform Finite Element Analysis (FEA) on stent designs to characterise deformed
geometry, quantify stresses and estimate fatigue risk.
 Objective 3: Manufacture stent and valve prototypes and confirm adherence to dimensional
specifications.
 Objective 4: Verify satisfactory performance of the stent against specifications using in vitro
laboratory tests and acute termination experiments in a large animal model.
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3 Design Inputs and Methods
3.1 Design Requirements
3.1.1 Valve Requirements
According to Pibarot and Dumesnil (2009) an ideal valve should be easy and practical to implant and 
should mimic the native valve, should not obstruct blood flow, should be non-thrombogenic, should 
have excellent haemodynamics and should be very durable. Vesely (2010) expands on this list from 
the surgical valve era, where the ideal valve was haemocompatible (did not create emboli, was inert 
chemically and did not damage blood elements), had excellent haemodynamics (offered no resistance 
to blood flow, closed rapidly, remained closed during the diastolic phase and was inserted at a 
physiological site), was practical to implant, durable and able to be fixed permanently, and did not 
annoy the patient. He observed, however, that some of these requirements are being re-evaluated or 
disregarded in the era of transcatheter valves. It is clear, however, that percutaneous valves need to 
strive for many of these same biocompatibility, haemodynamic, durability and implantability goals 
while being able to be compressed to a low profile and expanded to a functional size. 
Specific user needs for the valve were determined through interpretation of the literature, interviews 
with several cardiac surgeons, experience gained on device manufacturability from early experience, 
examination of current devices and observation of TAVR procedures at Groote Schuur Hospital, Cape 
Town. Those needs were then examined with regards to their relevance to stent design and recorded. 
These are listed in the first column of Table 3-1. 
3.1.2 Stent Requirements
The main purposes of a valve stent are to provide a frame onto which functioning leaflets may be 
attached and to support the leaflets within the anatomy. 
The relevant valve needs, which are primarily described qualitatively, were then translated into 
engineering requirements, quantified where possible and reasonable, and divided into the following 
categories: operational requirements (relate to the stent’s ability to satisfy its primary purpose); safety 
requirements (to ensure patient safety); performance requirements (to ensure good performance 
beyond the “standard” and to differentiate from other devices); preferred requirements (desirable 
but not mandatory); and manufacturing requirements (related to ease of manufacture and cost). A 
summary of the translation from user/customer needs to engineering requirements is presented in 
Table 3-1. 
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Table 3-1. Key current design requirements 
User  Needs Relevant to Stent Design Translational Engineering Requirements for Stent Design Method of verification
Operational Needs
 The implant must be able to operate in a
human heart and circulatory system at the full
range of native aortic valves sizes, body
temperatures, heart rates, cardiac outputs
and blood pressures expected in patients
affected by heart valve disease, including
young adult patients affected by RHD.
 The stent must have an outer diameter when expanded of 23mm (valve sizes of 20mm, 23mm, 26mm
and 29mm will be designed later to cover aortic annulus sizes of 18mm to 28mm). For this project, a
23mm valve will be designed to fit in a native aortic annulus size of 18 to 22mm. When fully expanded,
the stent must have an inner diameter of 23mm to hold leaflets designed for this geometry.
 The design must be able to be scaled to other sizes.




 The valve must be compatible with and must
be able to be deployed in the correct position
using a balloon-based or mechanical non-
occlusive deployment device
 The stent must be balloon-expandable
 The stent must not foreshorten in such a way as to interfere with good positioning (foreshortening may 
be ≤20%), and the sites of commissure attachments should not shorten at all.
 Stent crimped length should be <35mm
Attribute 
In vitro testing, numerical modelling 
In vitro testing, numerical modelling 
 The valve must be able to be used in aortic
valve stenosis, in pure regurgitant aortic
valves and in mixed aortic valve disease,
including fused commissures
 The stent should be able to hold the native leaflets away from the replacement leaflets
 Stent radial strength must be similar to or greater than 88N at 15% diameter reduction (Tzamtzis et al., 
2013).
 The stent must limit metal to artery ratio below 25% where possible to limit foreign-body response. 
 The stent must not suffer acute fracture even if over-deployed by 10% in diameter.
Ex vivo testing, In vivo testing 
Numerical modelling 
Attribute 
In vitro testing 
 The implant must be able to function at
physiological pressures and heart rates
associated with the intended patients for the
equivalent of 5 years at normal heart rates.
 Stent accommodate 14mm high leaflets (for 23mm valve)
 The stent should be constructed from a material with excellent strength and elongation properties.
 Stent function must not alter over 400 million cycles of loading from leaflet (haemodynamic) forces and 
from forces from the heart during extreme physiological conditions (this will not be demonstrated in this
project due to time limitations but will be included in design intent). The role of the stiffness of the
commissure posts should be considered.
 The stent must incorporate continuous attachment.
 The stent must not degrade over time
Attribute 
Attribute 
N/A. Not verified in this thesis. 
Attribute 
Attribute 
 The implant shall be suitable for single use.  The stent must be able to be crimped to its collapsed condition and expanded to its operating condition
without acute fracture and achieve the intended leaflet attachment shape at the expanded diameter.
In vitro testing, numerical modelling 
 The device must be compatible with all
accessories involved in the procedures.
 When crimped the valve must not protrude in a manner that is traumatic or will interfere with standard 
sheaths
In vitro testing, numerical modelling 
Safety Needs
 All materials used in the valve should be
biocompatible (in particular non-
thrombogenic and non-haemolytic) for
permanent implantation, and rapidly
incorporated and tolerated by the patient’s
tissues.
 The stent shall be constructed from a material with a known history as a blood-compatible implant
material.
 The stent must be electropolished to ensure that it presents a biocompatible surface with no burrs,
rough edges or protrusions visible under X50 magnification. Breakdown potential and corrosion should
be considered for manufacturing processes.
 The stent must resist damaging the replacement leaflets
Attribute 
Surface inspected. Corrosion and 




 The implant must remain in the deployed
position and resist early and late embolization.
 The stent must be able to anchor in an aortic annulus with compliance of up to 10%, assuming that valve 
location can be established through the deployment device or from fluoroscopic positioning.  Valve should 
not migrate under back pressures of 100mmHg; 23mm stent should therefore not migrate under 5.4N. In
animals, valve must not embolise.
 Stent recoil should be less than 5% to allow the 23mm stent to be implanted into a 22mm annulus (as
measured during systole) without separation from the annulus, and also to reduce the risk of annular
rupture and pressure on the mitral valve due to over-expansion.
Ex vivo testing, in vivo testing 
In vitro testing, numerical modelling 
 The implant shall not embolise during delivery
and deployment
 The stent should resist forces that tend to shift the valve on the deployment devices of at least 2N. N/A. Not tested in this thesis. 
 The implant must have a low risk of
atrioventricular block.
 The stent shall protrude no deeper into the left ventricle than 12mm, particularly at the position of the 
right coronary cusp and membranous septum.
Attribute 
 The implant must not significantly disrupt
mitral valve function.
 The stent shall not interfere with the function of the anterior mitral leaflet and shall have no sharp
edges that may damage mitral leaflet. 
Attribute, in vivo testing 
 The device must not block blood flow to the
coronary ostia significantly.
 Stent shall not block flow to the coronary arteries or jail with more than one strut or hairpin. In vivo testing 
Performance Needs
 The valve should be novel  The stent should have a novel design Attribute, patent review 
 The device and implant must be able to be
delivered to the site of implantation through 
either an antegrade or retrograde approach.
 Stent must be able to be positioned for antegrade or retrograde implantation Attribute 
 The device must be compatible with an access 
port or sheath
 Stent should allow sheathing but should ideally not require sheathing In vitro testing 
 The implant must contain radiopaque or
echogenic markers or signatures to allow
precise positioning within the native anatomy.
 Stent should be visible under fluoroscopy, with identifiable features to facilitate precise positioning. In vivo testing 
 The device must have a large orifice area and
present low resistance to forward blood flow.
 Without sacrificing radial strength, the wall thickness should be <0.5mm to maximise internal diameter,
encourage endothelialisation and reduce metal volume.
Attribute 
 Implant creates a minimal degree of flow
separation and stasis and should not induce
regions of high shear stress
 The angles of the struts should preferable not exceed 60 degrees from the axial direction on opening to
reduce blood wall shear stress. 
Attribute 
 The device and implant shall have a shelf life
of at least one year when first supplied.
 The stent properties must not alter over a period of 1 year in storage N/A. Not verified in this thesis. 
 The implant must minimize paravalvular leaks.  The stent must allow a skirt to be attached for sealing.
 The stent shall have sufficient scaffolding (ideally a minimum of 18 struts around the circumference) to
minimise paravalvular leaks.
In vitro testing 
Attribute 
 The valve should have a low crimped profile  The stent should be able to be crimped to an outer diameter of 6mm. In vitro testing, numerical modelling 
Preferred but Non-Essential Needs
 The device should be visually appealing to
clinicians.
 The stent should be attractive to surgeons N/A. Not verified in this thesis 
 The implant should be removable.  The stent should be removable N/A. Not verified in this thesis 
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Manufacturing Needs
 The valve is required to be provided in a fully
deployed condition, or in a condition that
allows it to be opened to a fully deployed
condition without fracture, and must be able
to be crimped down to a suitable diameter for
crimping onto a delivery and deployment
device.
 Stent should ideally be manufactured close to operating diameter for precise manufacture.
 The stent must be easily crimpable with standard techniques and equipment.
Attribute 
In vitro testing 
 The valve must be able to be manufactured
cost-effectively, including standard 
techniques where possible and using a spray-
coating process on a mandrel.
 The stent must be able to be easily expandable to an internal diameter of 23mm for valve manufacture.
 The stent shall be manufactured using established techniques for stents
 The stent must have a relatively open structure for spray to travel between struts to valve leaflets.
 Stents dimensional tolerance must be ± 20 µm (based on standard deviation).
In vitro testing 
Attribute 
Attribute 
In vitro testing 
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3.2 Stent Design, Drafting and Material Selection
3.2.1 Development Methodology
Stents were designed using a hybrid approach, combining design techniques favoured by the FDA in 
the United States and more current agile techniques. The FDA (through 21 CFR 820.30) and the 
International Standards Organisation (through ISO 13485 Clause 7.3) provide requirements relating to 
the control of medical device design processes as part of a quality management system. Both the FDA 
and ISO regulations describe, but do not strictly mandate, a traditional waterfall type development 
process (FDA, 1997). The process is iterative and subject to design reviews at the end of each phase. 
The waterfall model relies on the fact that the user needs are well understood at the beginning of the 
design, which is not always the case, and was not the case in this project. Furthermore, working 
devices are typically only ready late in the development. Another disadvantage is that it does not 
specifically allow for iterative design-test-redesign cycles in the design process. Recently the FDA 
launched its “Innovation Initiative” to facilitate innovation in medical devices (FDA, 2011). This 
pathway is similar to stage-gate or phase-based development processes considered best practices for 
medical device manufacturers (Pietzsch, Shluzas, Pate-́Cornell, Yock, & Linehan, 2009). The process 
makes clear the design-test-redesign cycles frequently used in medical device development. 
Additional “Scoping” and “Business case” are sometimes added to phase-based development for more 
complex projects. 
Figure 3-1. Project design and development model 
The current project concerns itself with the first three phases, namely ideation, invention and 
prototyping, and preclinical testing; a schematic of the approach is shown in Figure 3-1. The figure 





Develop Validate Design 
Bench test Redesign 
Customer Requirements 
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prototypes are tested, and illustrates the design-test-redesign loops that were used. This meant that 
concepts could be evaluated rapidly though simulation or bench testing, discarded early if unsuitable 
and tested further if promising. The methods for ideation and invention, including concept design and 
design refinement are discussed in Chapter 7. Prototyping and test methods are described in Chapter 
6.  
3.2.2 Drafting
Stent designs were rendered in computer-aided design (CAD) software (SolidWorks 2014, Dassault 
Systèmes SolidWorks Corp., Waltham, Massachusetts, USA) in one of two ways. For three-dimensional 
models and for the creation of Standard ACIS Text (.sat) files for detailed FEA, a wrap feature was used 
to emboss the stent onto the inside of a tube that was subsequently cut away. Angular symmetry 
allowed sketches to be drawn as a one-sixth sector of a cylindrical tube, and the stents were 
completed using “mirror” and “combine” features. These steps are illustrated in Figure 3-2 and Figure 
3-3.
Figure 3-2. Computer-aided drawing of 3D stent model. 
A) One-sixth geometry constructed as an embossed wrap on the inside of a tube of arbitrary wall thickness, B) The tube is
cut away, leaving one-sixth geometry, C) One-third sector constructed using a merged mirror feature. 
For stent manufacture (laser cutting), drawings were converted to Drawing Exchange Format (.dxf) 
files. Initially stents were drawn as single large sketches, but these became unwieldy due to large 
graphics memory requirements. Stents were subsequently modelled as short extrusions; as with the 
3D models, stents were drawn as one-sixth portion of the stent circumference, mirrored and 
combined to form the full stent circumference.  A new sketch was created from the extrusion using 
the “convert entities” feature, and finally the sketch was converted from a drawing of the stent 
geometry to the closed contours of the negative spaces that define the laser beam path. This 
geometry is illustrated in Figure 3-4. 
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Figure 3-3. Full stent geometry completed using “mirror” and “combine” features 
Figure 3-4. Computer-aided drawing of stents for manufacture 
3.2.3 Material Selection
Based on the requirements set out in Section 3.1.2, the ideal material for a balloon-expandable stent 
will have the following characteristics (estimated quantitative limits are indicated in parentheses): 
 High Ultimate Tensile Strength (UTS) for high radial strength; high strength in turn allows
thinner struts to be used, which will allow for lower crimped profiles (>600MPa)
 High strain to failure, to withstand high strut opening angles (>25%)
 High elastic modulus to reduce recoil (>100GPa)
 Relatively low yield strength to allow for easy crimping and to limit spring-back off the
balloon (Yield Stress < 600MPa)
 Excellent resistance to fatigue (Endurance limit > 100MPa, KIc > 10MPa.m1/2)
 Biocompatible (use in implants, good biocompatibility or corrosion potential > 500mV)
 Radiopaque (Density > 5g.cm-3)
Using the materials selection charts provided by Ashby (2005), an analysis of fatigue strength (KIc) 
versus elastic limit (σf) based on the above criteria produced a subset of materials that included most 
metals, and some composites, but notably excluded all ceramics and polymers. The modulus (E) versus 
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elastic limit (σf) chart further excluded traditional composites in general, and specifically excluded 
certain metal alloys, including the alloys of aluminium, magnesium and zinc, most of which also have 
low radiopacity and poor biocompatibility. Precious metals were also excluded for low strength. Alloys 
of iron were excluded due to their degradability. Most refractory metals and their alloys are unsuitable 
due to lower UTS (hafnium, tantalum and niobium), low elongation (rhenium) or high yield stress 
(tungsten, molybdenum). Copper alloys and carbon steels have poor biocompatibility. Although 
titanium alloys are popular in medical implants, commercially pure titanium has low UTS, and alloys 
of titanium have low elongation and relatively low modulus (Poncin & Proft, 2003).  
It is recognised that tantalum, niobium, platinum-iridium and various polymers have been used in 
balloon-expandable stent applications before (O'Brien & Carroll, 2009; Stoeckel et al., 2002), but they 
are relatively weak and therefore do not provide optimum properties for a contemporary balloon-
expandable valve stent. Based on good mechanical properties and biocompatibility, the list of 
potentially suitable materials was narrowed down to stainless steels (316LVM, ASTM F1586, ASTM 
F1314, nickel-free stainless steels, “platinum-chromium”), cobalt alloys (L605, MP35N, Elgiloy), nickel-
chromium-molybdenum alloys (Inconel) and martensitic nitinol. Martensitic nitinol has been used in 
balloon-expandable stents (Sangiorgi et al., 2007), but the low modulus and high elastic range would 
result in large amounts of elastic recoil. In general the cobalt alloys had superior properties to the 
stainless steel alloys. Although no evidence could be found that stents have been manufactured from 
Inconel, it is believed the alloys would produce stents with good properties, but still inferior to the 
cobalt alloys.  
MP35N was chosen as the desired stent material for the balloon-expandable valve due to its high 
Young’s modulus, large work hardening ability (stress difference between UTS and yield stress was 
large), high radiopacity and high elongation. L605 has greater strength and radiopacity, has proved 
effective in coronary stent design (Suttorp et al., 2015) and may be a superior stent material. MP35N 
was however more readily available commercially and has history as a valve stent material (it is used 
in the newer generation of Edwards Sapien™ valves (J. Bailey et al., 2015)), which is anticipated to 
have regulatory advantages.  
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4 Numerical methods
FEA was used to simulate crimping and expansion in order to determine deformed crimped and 
deployed geometries, to calculate maximum stresses and strains, and estimate stent fatigue 
resistance. FEA for stent modelling is also recommended by ASTM International (“Finite element 
analysis is a valuable method for evaluating the performance of metallic stents and in quantifying 
quantities such as internal stresses, internal strains, and deformation patterns due to applied external 
loads and boundary conditions”) (ASTM, 2014). Stress analysis for fatigue life is recommended by the 
FDA (“We recommend that you identify the critical locations of stress or strain on the stent using finite 
element analysis”; “[We recommend] that you use the mean and alternating stresses/strains obtained 
from the stress/strain analysis as input for the fatigue life determination”) (FDA, 2010). This chapter 
describes the pertinent FEA theory and details each step in the simulation procedure.  
4.1 Theoretical framework
FEA is a numerical technique for the approximation of continuous systems. Solutions to finite element 
problems may be approximated by replacing equilibrium equations with an equivalent weaker form, 
which is expressed as an integral equation. Abaqus uses the principle of virtual work, which states that 
for any set of small virtual displacements imposed on a body in equilibrium, the total external virtual 
work is equal to the total internal virtual work. Given a domain volume   and domain boundary 
surface  , the virtual work principle may be expressed as follows (Dassault-Systèmes, 2014; 
Zienkiewicz & Taylor, 2000): 




Equation 4-1 Principle of Virtual Work
where   ,   ,   and   are the virtual strain rate, virtual displacement, stress and boundary 
traction, respectively. 
Either implicit or explicit integration techniques may be used for the analysis of stents. Since the 
crimping and deployment of the stents in this thesis involves large displacements, large rotations, 
large strain, non-linear stress-strain data and non-linear boundary conditions (through complex 
contact), quasi-static Abaqus/Explicit analysis was considered the most appropriate method to model 
the stent behaviour.  
The governing equation for nonlinear dynamic analysis may be expressed as follows: 
  ( ) +    ( ) +    ( ) =  ( ) Equation 4-2 Governing equation 
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where    and    are the inertial and damping forces, respectively,     refers to the nodal point 
forces corresponding to the element stresses, and   is the external load vector; all loads are 
time dependent. 
The governing equation may be expressed in terms of the element mass, damping and stiffness 
matrices,  ,   and  , respectively as 
   +    +    =  ( ) Equation 4-3 Dynamic equilibrium
where  ,   and   are the nodal acceleration, velocity and displacement vectors. 
The dynamic equilibrium equation simplifies to 
   =  ( )  ( ) Equation 4-4 Simplified dynamic equilibrium
where   is the internal force vector. 
Explicit dynamic procedures are based upon the implementation of the central difference rule 
together with the use of diagonal element mass matrices. The central difference method may be 




) =   (  
 
 








Equation 4-5 Central difference method






 refer to the 
mid-increment values. 
The diagonal nature of the element mass matrix allows the accelerations at the beginning of the 
increments to be calculated by inverting the mass matrix in Equation 4-4 as follows: 
 ( ) =     ( ( )  ( )) Equation 4-6 Acceleration
Unlike implicit integration procedures, which are unconditionally stable, the explicit central difference 
method is conditionally stable, and therefore the time increment   must be less than a stable time 
increment: 
t ≤  
2
    
  1 +        Equation 4-7 Stability limit
where      is the highest eigenvalue and   is the critical damping fraction in the highest mode. 
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4.2 Modelling overview
Since the stent simulation aims to model quasi-static processes, time steps of 1 to 10 seconds were 
used, mass scaling was employed and the application of loads and moving boundary conditions were 
smoothed. To verify that the model was truly quasi-static, the ratio of kinetic energy to internal energy 
was checked to ensure that it remained below 5%. Due to the large number of increments required 
for complex stent modelling, double-precision floating-point format was used for all analyses. Two 
different types of analyses were performed. In order to more rapidly compare concepts, such as those 
described in Chapter 6, stents were crimped using rigid plates and deployed using an expanding 
cylinder; this allowed stent symmetry to be exploited and led to fast modelling times. This method will 
be referred to as the “simple” FEA method. In order to accurately model stent performance on the 
balloon (for preferred concepts described in Chapter 7), a more sophisticated method was utilised. 
This “complex” method simulated crimping the full stent geometry onto a folded balloon. Stent 
deployment was then performed by inflating the balloon with an internal pressure, after which the 
balloon was deflated and loads were applied to the stent to simulate physiological conditions.  A 
comparison between the simple and complex methods is shown in Table 4-1. 
Table 4-1. Comparison of simple and complex FEA methods used for stent modelling 
Step/Description Simple Complex
Stents Concept selection – 8 stents Favoured concepts – 2 stents 
Initial One-sixth stent Full stent 
Crimp Flat plates 30° apart, no balloon 
inside stent 
Flat plates 30° apart, folded balloon 
inside stent 
Relaxation after crimp Withdraw plates Withdraw plates 
Expansion Cylindrical shell Pressurised balloon 
Relaxation after expansion Withdraw cylinder Deflate balloon 
Loading None Radial pressure and leaflet loads 
Fatigue analysis None Goodman analysis 
4.2.1 Stent model creation
Three-dimensional stent geometry was exported from SolidWorks as a *.sat file as described before. 
A cylindrical coordinate system was calculated from the original Cartesian coordinates, with the origin 
of the system placed on the central axis of the stent. The stent was then manually partitioned and 
meshed using Abaqus version 6.14 (Simulia, Dassault Systems). The stent was modelled using an 
isotropic elasto-plastic material with isotropic hardening, a Young’s Modulus of 236GPa (Altman, 
Meagher, Walsh, & Hoffmann, 1998) and a Poisson’s Ratio of 0.40 (Matweb, 2016).  
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Engineering stress-strain data were determined from tensile testing, converted into True Stress and 
True Strain, and the plastic region of the curve was defined by discrete points along the True Stress-
Strain curve from initial yield stress. A Hollomon power law was used to define stress-strain behaviour 
after necking (described in Section 5.2). In order to eliminate stent vibrations that occur in the quasi-
static analysis during unloading (relaxation) steps, the material definition was edited to include 
Rayleigh damping with a mass-proportional damping constant   of 5, following confirmation that 
damping did not alter predicted peak stresses and strains. 
Points on the outside surface of the stent were constrained in the axial direction to prevent free body 
motion of the stent through all steps (one point for simple analyses and three for complex). These 
points were placed in areas of the stent anticipated to be positioned at the basal plane of the aortic 
cusps, or at the commissure posts. Any erroneous stress concentrations at these constraint points 
were removed during post-processing. For comparison purposes, Control stents were created based 
on Edwards Sapien 3™ stents. 
Since stents experience predominantly bending loads, stents were modelled using reduced integration 
8-noded brick elements (C3D8R) with hourglass control  (Hall & Kasper, 2006), and were monitored
for instability.3 Mesh sensitivity studies were performed to determine the effect of element selection
and mesh density on maximum von Mises stress and maximum displacement and this was compared
to computational cost. Although incompatible mode elements are frequently favoured for stent
analysis, modelling of stents with relatively large changes in geometry and large strains showed the
development of spurious modes that provided erroneous stress values even with a fine mesh. Similar
spurious modes in incompatible elements have been identified by Sussman and Bathe (2014). As a
result, the mesh refinement study describes only refinement using C3D8R elements. Details may be
found in Appendix C.
Certain stent concepts incorporated the use of cold-drawn MP35N wire welded to the stent frame. In 
these cases, the cold-worked material was assigned a yield stress of 1600 MPa, UTS of 2000 MPa and 
3 Standard fully integrated first order elements are not suitable for bending dominated problems due to their susceptibility to shear locking. 
Reduced integration elements are computationally inexpensive but are susceptible to hourglassing because strains can’t be detected at the 
central integration point. For this reason a minimum of four elements were used through the thickness. Even with four elements through 
the thickness, maximum stresses may be underestimated if they lie at the surface due to the fact that the central integration point is not 
near the surface. Incompatible mode elements are not susceptible to either shear locking (because of the incompatible deformation modes) 
or to hourglassing (because they are fully integrated elements). Despite being computationally more expensive than reduced integration 
elements, they can be used with a coarser mesh than with reduced integration elements because they model bending accurately. A major 
difficulty with incompatible mode elements is that they perform less accurately if they are not close to being perfectly cubic.
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elongation to failure of 3.4% (Prasad, Reiterer, & Kumar, 2014; Sorensen, Li, Gerberich, & Mkhoyan, 
2014). This data was converted to True Stress-True Strain as for the stent tubing. 
4.2.2 Balloon model creation
The balloon was drawn as a surface in SolidWorks in a folded condition, with four folds, as shown in 
Figure 4-3, and exported as a *.sat file. Only the 40mm cylindrical barrel portion of the balloon was 
drawn, i.e. the cones on the ends of the balloons were neglected. The circumference of the balloon in 
the zero-pressure condition was obtained from the measurement of a used 23mm commercial 
valvuloplasty balloon catheter.  
Balloon properties were obtained by cutting 10mm wide specimens from the balloon, in both 
longitudinal and circumferential directions, and performing uniaxial tensile tests on the samples in an 
Instron electromechanical tester, using a gauge length of 10mm. The stress-strain curves for the 
balloon material are shown in Figure 4-1. Two circumferential specimens and one longitudinal 
specimen provided usable data. The curves are similar for both directions over the first 10% strain, so 
the material was assumed to be isotropic. The specimen with the largest strain-to-failure, 
“Circumferential 1”, was used to generate material data for Abaqus. 
A third-order hyper-elastic Ogden material model was used to model balloon performance, based on 
the experimental data. The Ogden model is frequently used to describe the non-linear behaviour of 
polymers and rubbers.   
In Abaqus the strain energy potential is formulated as follows (Shahzad, Kamran, Siddiqui, & Farhan, 
2015): 















   Equation 4-8 Ogden
where λ   is the deviatoric principal stress,     is the elastic volume ratio, and   ,     and    
are material properties shown in Table 4-2. 
The Ogden model provided a reasonable approximation of the experimental data, as shown in Figure 
4-2.
Table 4-2. Ogden material parameters 
             
1 -12910 2 9.935E-4 
2 6914 4 0 
3 6427 -2 0 
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Figure 4-1. Stress-strain curves for balloon material 
Figure 4-2. Comparison between test data and Ogden material model 




A Poisson’s ratio of 0.4 and a balloon wall thickness of 0.045mm were used. The circumference of the 
balloon was measured to be 66.29mm. The mass density of the balloon material was artificially 
increased by a factor of 1000 and set to 1.04 x 10-6 tonnes/mm3 to decrease run times. Following 
partitioning, the balloon was meshed with 25,440 three-node triangular membrane elements (see 
Figure 4-3). The edges of the balloon at both ends were constrained in the axial direction. 
4.2.3 Crimping and relaxation
The crimping simulation was designed to replicate the crimping action of a 12-plate crimping device 
such as those offered by Machine Solutions Inc., Flagstaff, AZ, USA and by Edwards Lifesciences, Irvine, 
CA, USA. As per the Edwards crimper, the model plates move radially inwards, with no twisting. The 
moving plates were modelled as discrete rigid geometry. Since self-contact was anticipated across the 
symmetry planes used in simple models, analytical rigid surfaces were placed at symmetry planes. 
“Hard” frictionless general contact is used to model contact between the stent and the crimping 
plates. Stent plates moved from a diameter beyond the stent outer diameter to an inscribed diameter 
of 6mm. For complex models, the balloon was placed inside the stent prior to crimping. Hard 
frictionless general contact was also used to model stent-balloon contact. After expansion, plates were 
withdrawn in a relaxation step to a position just past the point at which the plates leave the stent 
surface. This point was established through coarsely meshed models. This was done to ensure that 
the velocity of the moving plates was reduced using the smooth load function, to reduce stent 
vibrations. 
4.2.4 Expansion and relaxation
Stent expansion for simple models was performed using a cylindrical tube that expanded to a final 
diameter of 23mm. Following stent expansion, the cylindrical tube was withdrawn to a position just 
past the point at which the cylinder leaves the stent surface, using a smooth step amplitude curve. 
Stent expansion for complex stent deployment was performed by applying a pressure of 4 atm to the 
inside surface of the balloon. The balloon was then deflated by applying a negative pressure to the 
inside surface of the balloon. 
4.2.5 Valve loading
To simulate the physiological loads on the stent in complex models only, deformed stent geometry 
and final stress conditions were imported into a new model. Since Perlman et al. (2013) showed that 
many patients experience a rise in blood pressure following TAVR, with an associated increase in pulse 
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pressure, a uniform pressure of 90 mmHg was applied to the outside surface of the cylindrical portions 
of stent. In addition, simple leaflets such as those described in section 6.1 were attached to the 
expanded stent using tie constraints and a conservative pressure of 100 mmHg was applied to the 
aortic surface of the leaflet to simulate the closing pressure during diastole. 
4.2.6 Radial crushing
Radial crushing of stents was modelled by importing deformed geometry (following crimping, 
relaxation, deployment and recoil stages described above under complex modelling) into a new 
Abaqus/Explicit model and importing the final complex model stress state as a predefined field. As for 
the crimping step, 12 discrete rigid plates were moved radially inwards from beyond the stent to an 
inscribed diameter of 8mm, using hard frictionless contact. Step time was 5s and low mass scaling was 
used to ensure that kinetic energy was less than 1% of internal energy. 
4.3 Model validation
Finite element models were validated for dimensional accuracy through comparison of recoil and 
foreshortening predictions and actual measurement of these parameters on physical prototypes. For 
validation of structural accuracy, the Control stent and each of the two favoured stent concepts 
underwent simulated crimping to 8 mm as for the simple model previously described, although the 
expansion cylinder was removed. The sum of radial reaction forces on the moving plates was then 
reported against diameter change. The simulated models were then compared to physical radial 
crushing tests performed as described in Section 5.3.3 A). 
4.4 Parameters for evaluation
4.4.1 Stent static behaviour
Geometry before crimping and geometry after expansion and relaxation were compared to each 
other. The magnitudes and locations of peak Von Mises Stress, peak Maximum Principal Stress and 
Peak Plastic Equivalent Strain was reported at the end of each step. The amount of recoil and 
foreshortening (see definitions in Section 5.3.3 B) were calculated and reported. 
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4.4.2 Stent radial strength
Radial force was calculated as the sum of radial reaction forces on the twelve moving plates and 
reported against diameter change. Radial strength was defined as the force required to compress the 
23mm stent by 15%, namely to 19.55mm. 
4.4.3 Stent fatigue
Stent fatigue analysis was performed using a traditional Stress/Life (S-N) or “modified-Goodman” 
approach (Marrey et al., 2006). In this method the mean stress    and stress amplitude    are 
calculated based on the Maximum Principle Stresses at beginning and end of the pressure loading 
step. Reported endurance limits for MP35N vary widely in the literature from 340 MPa to 620 MPa 
(Altman et al., 1998; Piehler, 2005; Pilliar, 2009), depending on the cold work present in the material, 
but the endurance limit     was conservatively taken to be 340 MPa (Pilliar, 2009). The true stress 
related to the UTS    was calculated from experimental data (see Section 7.2.1). The fatigue safety 
factor  , which determines how close the mean stress and stress amplitude are to the modified 
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Equation 4-9 Fatigue safety factor
where      and      are the maximum and minimum values of the maximum principle stress 
over the cycle. 
Calculation of the inverse of the fatigue safety factor allows the areas most at risk of fatigue fracture 




Stents were prototyped through laser cutting, acid descaling and electro-polishing. Following laser 
cutting, stents were descaled using corrosive acid solutions to remove oxides, and then stents were 
electropolished to achieve smooth surfaces and correct final dimensions. Certain prototypes required 
additional steps, including grinding and welding to achieve the desired functionality. 
5.1.1 Stent Cutting
Drawings obtained from CAD were imported into Computer Numerical Control (CNC) programming 
software (CAGILA, CAM-Service GmbH, Hannover, Germany) and converted into machine code that 
could be used by the laser cutter. Stents were laser cut from 23 mm MP35N tubing (wall thickness 
0.50mm), sourced in an annealed condition (Minitubes, Grenoble, France), using a StarCut Tube 
(Rofin-Baasel Lasertech, Starnberg, Germany) with a StarFiber FC fibre laser and 2-axis CNC motion 
control system. Stents were cut using oxygen as the assist gas and the following parameters: peak 
power was 200 W; pulse width was 35 µs; frequency was 4500 Hz; oxygen gas pressure was 10 bar. It 
was found that stents could be cut using a wide range of parameters, but the chosen parameters were 
determined empirically over several stent cutting attempts and produced reliable cutting, with 
relatively low reject rates and relatively low levels of oxide formation. Accurate cutting was achieved 
through rigorous optimisation of laser focus position and centrality and minimisation of tube rotation 
eccentricity (see Appendix D), and was verified through measurement of calibration disks.  
Cut stent strut dimensions were made larger than targeted final dimensions by applying an offset in 
CAGILA that compensated for the kerf width. The kerf width was estimated to be approximately 50 
µm based on discussions with the machine manufacturer (actual measurement of kerf width is 
described below). Since this means that the laser beam would cut 25 µm on either side of the laser 
path, an offset of 40 µm was applied to the cutting path. This was therefore expected to provide cut 
stent dimensions 30 µm larger than final desired geometry (for subsequent reduction during 
electropolishing). 
5.1.2 Descaling
Since laser cutting uses oxygen as an assist gas, an adherent black oxide layer forms on the surface of 
the stent. In addition to this oxide layer, some or all of the waste tube material remains between the 
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structural elements of the stent, and some dross and burrs remain where the assist gas has not blown 
the molten material out completely. Waste material and dross were removed mechanically from the 
laser cut stents, after which stents were immersed in an acidic solution in 50ml centrifuge vials placed 
in a heated ultrasonic cleaner (Labotec, 2.5L, 50W) for removal of oxides (known as pickling or 
descaling). A mixture of sulphuric acid, nitric acid, ammonium bifluoride and deionised water was used 
for pickling, following a period of research and experimentation described in Appendix D. This solution 
proved to be effective at removing oxides without aggressive base metal attack. Stents were soaked 
for up to three hours at 70±5°C and were sonicated for five minutes at 100% power every half hour 
during the soak, until no oxide material was visible on the stent surface. After pickling, stents were 
sonicated in deionised water for 10 minutes to clean stents and reduce carry-over of pickling solution 
to the electrolyte, and were then dried in air. 
5.1.3 Electropolishing
Electropolishing is an electrochemical machining process routinely used in the production of stents. 
The process creates a smooth, rounded, low-injury and biocompatible surface. It removes surface 
imperfections that may result in fatigue crack initiation and growth. It further removes the outer layers 
of material, thereby removing the heat affected zone and residual surface thermal stresses caused by 
the heat generated during laser cutting. Electropolishing was performed using the apparatus shown 
in Figure 5-1. 
Figure 5-1. Electropolishing apparatus 
Stents were electropolished in a glass beaker placed on a heated magnetic stirrer and the electrolyte 
was stirred using a PTFE-covered magnet stirrer bar. A stainless steel wire was connected as the anode 
(together with the stent). A cylinder with many holes was used as the cathode; the holes allowed the 
electrolyte to flow around the stent. Both anode and cathode were positioned horizontally to avoid 
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bubble tracks on the stent surface. A power supply unit capable of providing 3 A was used. The 
electropolishing process is dependent on a number of factors, including the stent design and material, 
the stent’s initial surface roughness, the chemical composition of the electrolyte, the applied voltage 
or current, temperature of the electrolyte, the amount of electrolyte agitation and the polishing time 
(Patil & Dulange, 2014). Stent design, material and surface roughness were taken as provided and 
therefore unalterable.  
A small study was performed to identify a suitable electrolyte and electropolishing solution from the 
body of available literature (See Appendix D), based on experiments. The electrolyte used by Surmann 
and Huser (1998) gave the best surface appearance by visual estimation and was used for stent 
polishing; this electrolyte consisted of 10% Sulphuric Acid, 5% Hydrochloric acid and 85% Glycol by 
volume. Higher temperatures were used to increase polishing rate without sacrificing surface finish, 
as Surmann and Huser (1998) had selected a temperature of 48°C to avoid burning the operator, 
rather than because the best surface finish was obtained at this temperature. A summary of the 
electropolishing parameters is shown in Table 5-1. 
Table 5-1. Electropolishing parameters 
Fixed Inputs Value/Setting
Stent design Variable design slotted 23 mm outer diameter tube, 0.5 mm wall thickness 
Stent material MP35N (ASTM F562) 
Surface roughness (of tubing) Ra ≤ 0.6 µm 
Electrolyte
Electrolyte chemistry 10% H2SO4 (96% concentrated), 5% HCl (37% concentrated), 85% C2H6O2 
Variables
Current 2A 
Temperature 60 ± 5 °C 
Agitation ca. 240 rpm (mild) 
Polishing time Total ca. 6-9 min over two cycles. Stents were polished to desired weight. Stent was 
rotated approximately 120° three times during each cycle. 
Stent-cathode distance ca. 1cm at nearest point 
Removal of stent material during electropolishing is inhibited at the area where electrical contact is 
made with the stent by the anode wire, so the stent was rotated three times during polishing to ensure 
that the stent polished evenly and that the contact point with the stainless steel anode wire was 
moved. Stents were polished to the weight calculated from the CAD software. To ensure correct 
weights were achieved, stents were subjected to approximately 4.5 minutes of electropolishing, 
followed by cleaning, drying and weighing. The weights of the partially polished stents were used to 
calculate polishing rates (the weight of the pickled stents had also been measured), and the times for 
the second polishing cycle were established from these rates. Polishing rate decreased as the 
electrolyte aged, but polishing quality was not noticeably affected. 
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5.1.4 Additional manufacturing steps
As described in subsequent chapters, some stent concepts were equipped with wire arms for 
anchorage. The arms were constructed by plastically deforming 0.44mm MP35N wire (sourced from 
Fort Wayne Metals, Fort Wayne, Indiana in a cold worked condition) and then spot welding the ends 
of the wire to the outside of the commissures of the stent using a Desktop Welding Laser (Rofin-Baasel 
Lasertech, GmbH & Co.KG., Starnberg, Germany). Certain stent concepts were required to have wall 
thickness reduced in regions designed to protrude outwards. In these cases material was removed 
from the inner surface by manually grinding with a rotary multi-tool equipped with a grinding disk. 
5.1.5 Valve Manufacturing
Polymeric valves were manufactured through a proprietary spray coating process to produce flexible 
leaflets of thermoplastic silicone polycarbonate polyurethane (Carbosil, DSM Biomedical B.V., Geleen, 
The Netherlands) with a leaflet thickness of approximately 150µm. After drying overnight, valves were 
removed from the mould and the free edge of the leaflet was cut with miniature scissors or a scalpel. 
A sealing skirt was provided in one of two ways, either by creating a sprayed polyurethane film during 
the final spraying cycle, or using an electrospun fabric manufactured by SATH from the same 
polyurethane and heat bonding to the stent below the level of the leaflet attachment, to seal the valve 
to prevent paravalvular leak.   
Bioprosthetic versions of valves were manufactured and implanted in certain animals. For these 
valves, stent designs were very similar to stents for polymeric valves, but valve attachment sites of 
stents incorporated holes for sutures. Valve leaflets were manufactured by sourcing porcine 
pericardium from a local abattoir. Following thorough cleaning of the pericardium and removal of fat 
layers, pericardium was either cross-linked in 0.7% glutaraldehyde solution or was decellularised 
(Tedder et al., 2009) and subsequently crosslinked. Leaflets were then cut out of the pericardial sheets 
using die cutters to produce leaflets that were approximately 0.25mm thick, with collagen aligned in 
the circumferential direction. Sealing skirts manufactured from either electrospun polyurethane 
(produced by SATH) or from polyester knitted fabric (Bard Peripheral Vascular OEM Products, Tempe, 
Arizona, USA) were stitched to the stents. Leaflets with similar thickness were then manually stitched 
onto the stents. 
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5.2 Materials Testing
Three miniature dogbone samples were laser cut from the 23mm MP35N tubing described above. The 
geometry of the dogbone specimens is shown in Appendix F. Samples were descaled to remove oxide 
and burrs. Cross-sectional area was measured by sectioning a dogbone specimen in half, grinding the 
resulting surface using 4000 grit abrasive paper (also shown in Appendix F) and using a calibrated 
stereo microscope with parallax adjustment to measure the dimensions of the gauge portion (a sector 
of the tube). Simple custom grips were designed and manufactured to hold the specimens. These are 
shown in Figure 5-2. 
Figure 5-2. Tensile grips 
Following a preload of 5N, specimens were subjected to tensile loading to break at a rate of 
12.5mm/min. Three specimens chosen at different locations on the tube circumference were tested 
to determine UTS, 0.2% yield stress and strain to break. Engineering stress and strain were then 
converted to true stress and strain (before necking, where volumetric change during plastic 
deformation is assumed to be negligible) for use in FEA with the following equations: 
   =     (1 +    ) 
   =  ln (1 +   ) 
Equations 5-1 True Stress and Strain 
where    and    are the true stress and strain, respectively, and    and    are the 
engineering stress and strain, respectively. 
After necking, stress-strain data were extrapolated using Hollomon’s power law (Joun, Choi, Eom, & 
Lee, 2007): 
   =     ̅









where    and    ̅ are the effective stress and strain, respectively,    is the reference strength 
coefficient and    is reference strain-hardening exponent, defined as the true strain at the 
necking point.    and    are calculated as follows: 
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Equations 5-3 Hollomon parameters 
where   
  is the nominal strain at the necking point and   
  is the nominal stress at the 
necking point   
5.3 In Vitro Stent Testing
This section describes laboratory testing performed on materials, stents and valves in order to 
characterise performance and compare design outputs to the customer requirements.  
5.3.1 Testing overview
All stent concepts that were manufactured (see Chapter 6) were crimped onto either SATH 
deployment devices or onto used commercial balloon catheters and were deployed using manual 
disposable indeflators equipped with pressure gauges. Physical prototypes were subjectively 
compared to numerical simulations in terms of crimping and deployment behaviour. Two favoured 
concepts were then subjected to rigorous testing as outlined below, including inspection, 
measurement and a variety of mechanical tests of performance. A Control stent was also 
manufactured, inspected and tested in the same manner (see Section 4.2.1). Throughout testing, 
continuous variables were expressed as mean ± standard deviation and comparisons were performed 
using a two-tailed t test, with p ≤ 0.05 considered statistically significant.  
5.3.2 Inspection and Measurement
As described above, stents were drawn at the final desired dimensions, an offset was applied during 
the creation of programmes for laser cutting, and sufficient electropolishing was performed to return 
the stent to its desired weight and therefore dimensions. Kerf width was measured in the longitudinal 
and circumferential directions by cutting several slots in a short section of tubing, in both directions. 
After pickling, the width of the slots was measured near the end of the cut to eliminate the effects of 
initial piercing and to reduce any possible warping due to high cutting temperatures. In order to 
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confirm that stent dimensions matched the designed dimensions and surface quality was acceptable, 
stents were inspected and measured after electropolishing.  
A Nikon stereo microscope was used to inspect the quality of the stent surface at magnifications 
between X13 and X90. A stent manipulation frame was manufactured from acrylic and glass and was 
used to rotate the stent within the field of view, using top ring lighting. Additional high magnification 
inspection of stent surface quality was performed using a LEO S440 Scanning Electron Microscope 
(SEM). Stent dimensions were measured by photographing the stent struts at a magnification of 40X 
using a metallurgical microscope with lighting through the objective and back-lighting provided inside 
the stent using LED strip lighting. Struts were positioned orthogonal to the top light path, and the 
microscope was adjusted until the edges of the strut came into sharp focus, which occurs just below 
the outside surface of the stent and represents the widest dimension of the trapezoidal cross-section 
of struts. 
Three stents of each favoured design and the Control stent were measured. Strut width and hairpin 
width were measured in duplicate at the top and bottom ends of the stents on one of the repeating 
stent “thirds” corresponding to leaflet locations. Strut width was then also measured in the same way 
for each of the other stent thirds (total of 12 strut width measurements per stent). Thickness was 
measured at a single region with direct line-of-sight from the outside. Commissure post width, crown-
shaped member width, arm width, vertical member width, hinge width and link width, where 
appropriate, were measured on a single third on each stent. This led to a total of 20 to 22 
measurements per stent. Measurement locations are further illustrated in Section 7.2.2. 
5.3.3 Stent Mechanical Testing
To determine whether stents satisfy the requirements identified in Section 3.1.2, stents were tested 
for radial strength, recoil, crimping/expansion behaviour, foreshortening, migration resistance and 
manufacturability. 
5.3.3 A)  Radial Crush
The radial force required to crush stents were tested using a stand-alone RX650 segmented head radial 
strength testing machine (Machine Solutions Inc.). Stents were crushed from a diameter of 23 mm or 
30 mm to a diameter of 8 mm. Tests were performed following encoder alignment and diameter and 
force calibration. Test speed was 1 mm/s. The temperature of the segmented head was maintained 
at 37 ± 1.2 °C.  
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The hoop force    was calculated from the transducer force using    = 0.156    . Radial force was 
in turn calculated from  
   = 2      Equation 5-4 Radial force
5.3.3 B)  Crimping, Deployment, Recoil and Foreshortening
Stents were crimped onto balloons using an Edwards Lifesciences disposable crimper following 
calibration of crimper diameter with respect to handle motion, to ensure that stents were crimped to 
a diameter of 6mm. The diameter of the stent was measured at three points along the length, namely 
the top, the bottom and in the annular area of the stent, using Vernier callipers, and total stent length 
was measured. 
Stents were then inflated on balloons to 4 atm and stent diameter was measured at the three locations 
along the length of the stent. Balloons were deflated and the stent diameter was measured at the 
three positions again. The dimensions of any protruding members were also measured. 
The shape of the stent, in particular the shape of the crown structure, was compared to the 
undeformed geometry to estimate the maximum deviation from the original shape; stents were 
photographed before crimping and after expansion. 
Foreshortening was calculated as the percent change in stent length from a crimped to deployed 
condition. Recoil was calculated as the percentage change in stent diameter from its expanded 









Equations 5-5 Foreshortening and recoil
where    is the relaxed stent length after crimping,    is  the relaxed stent length after 
expansion,    is the expanded stent diameter while on the balloon, and    is the relaxed 
diameter following withdrawal of the balloon 
The deformed shape of the stent determined experimentally was also compared to numerical 
predictions of the deformed shape. Stents were also over-expanded by 10% on a 25 mm valvuloplasty 
balloon and then further on a 29 mm balloon to determine failure point.  
5.3.3 C)  Migration Resistance
The ability to anchor in the aortic root was quantified by deploying stents inside a 25 mm Medtronic 
Freestyle xenograft and measuring the force required to dislodge the stents in the direction of the 
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ventricle. A 23mm valve closing under a diastolic pressure of 100 mmHg will experience a downward 
force of 5.4N. Sutures were attached to the bottom row of struts and the sutures were pulled in an 
axial direction using a portable force gauge until the stent was extracted or the Freestyle valve 
appeared to show signs of damage (the test was halted at 22N, which corresponds to four times the 
anticipated force acting to dislodge valves in patients). 
5.3.3 D) Manufacturability
As described above, polymeric valves were manufactured by placing stents onto machined forming 
mandrels. Stents were therefore evaluated for their ability to be expanded to 23mm inside diameter 
and placed over the mould for polymer valve manufacture, without fracture. 
5.4 In Vitro and Ex Vivo Valve Testing
5.4.1 Valve deployment
A polymer valve was crimped onto an SATH deployment device (mechanical expander and annular 
balloon). The valve was then deployed to verify correct interaction between device and valve, and to 
determine whether the valve changed position over the deployment cycle. In this way compensation 
could be made to ensure the valve is deployed in the intended anatomical location. Valve deployment 
was filmed for subsequent still frame extraction to determine valve shape and position in the crimped 
condition, initial expansion using the mechanical expander and final expansion using the annular 
balloon. The displacement of the nadir of the valve from the initial crimped position to the final 
deployment position was measured digitally. 
5.4.2 Explanted heart tester
Valve “simulated use” performance was evaluated by implanting valves into an ex vivo “explanted 
heart” model (using cadaveric pig or sheep hearts) and visualising using endoscopy. Hearts purchased 
from an abattoir were trimmed of excess tissue, and the heart was cannulated in the left ventricle, 
aortic arch and left atrium. A valved access port for device entry was also inserted through the apex 
of the heart, after the placement of purse-string sutures, into the left ventricle. Any leaks were sealed 
using cable ties or surgical clamps.      
The test apparatus, provided by SATH, is shown in Figure 5-3. A lead screw-driven reciprocating pump 
was used to pump water through the apex, into the left ventricle, through the native aortic valve, to 
empty into a reservoir. The reservoir supplied a head of water into the left atrium, which allowed the 
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ventricle to fill during reverse motion of the pump’s piston. Systemic resistance and compliance were 
supplied by a flow restrictor and a Windkessel chamber, respectively. This allowed near-physiological 
cardiac output, aortic and ventricular pressures to be maintained at a heart rate of 60 beats per 
minute. A side port in the pipe entering the left ventricle provided an endovascular ventricular view 
of the aortic (and mitral) valve and a port in the right subclavian artery provided an aortic view of the 
aortic valve. 
Figure 5-3. Photographs of explanted heart rig, showing A) rig placed on table in operating theatre with fluoroscopy and 
endoscopy available, and B) cannulated heart. 
The explanted heart apparatus was placed on an operating table. Valve location and positioning was 
guided by fluoroscopy (using a portable C-arm), although videos were also captured using the 
endoscope by another operator. 
5.4.3 Pulse duplicator
In order to evaluate stent performance as part of a valve, valve hydrodynamics were tested using a 
left heart simulator known as a pulse duplicator (ViVitro Labs Inc., Victoria, Canada), using water as 
the test medium. The pulse duplicator measured aortic flow, aortic and ventricular pressures over the 
heart cycle. Refer to Figure 5-4. From these measurements, the mean transvalvular pressure drop and 
effective orifice area (EOA) during systole, and the total regurgitant fraction during diastole were 
determined.  
EOA was calculated (De Gaetano et al., 2015; ISO-5840-3, 2013) using Equation 5-6 below. 





Equation 5-6 Effective Orifice Area
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where   is the mean pressure difference in mmHg,   is the density of the water in g.cm-3, and 
     is the root mean square of forward flow in mL/s and is given by  






Equation 5-7 Root mean square of flow 
where  ( ) is the instantaneous flow at time  ,    is the time at the start of forward flow and 
   is the time at the end of the forward flow 
Valves were tested at a heart rate of 70 beats per minute, cardiac output of 5 L/min and a mean 
arterial pressure of 100 mmHg. Systole was assumed to make up 35% of the cardiac cycle. Valves were 
filmed from the outflow end using a camera with a frame rate of 400 frames per second in order to 
qualitatively evaluate valve performance. Valve performance was compared to a 23mm surgical 
Hancock 2 tissue valve (Medtronic, Dublin, Ireland). 
5.4.4 Valve Fatigue
Stent fatigue resistance was evaluated using a BDC Labs High Cycle durability tester, shown in Figure 
5-5. Valves were mounted in appropriate silicone holders and tested under pulsatile loading at 15Hz
until valves failed or were replaced. A stroboscope was used to verify that accelerated frequency
leaflet function appeared to be similar to physiological heart rate leaflet function. Stroke length and
resistance for each valve were adjusted individually to maintain a target peak differential pressure of
100 mmHg over the closed valve for over 95% of the test cycles and to maintain the pressure at 100
mmHg or greater for 5% or more of each cycle duration. The stroboscope was used to inspect valve
functionality on week days, and valves were removed from the equipment for inspection for evidence
of stent failure every 100 million cycles, upon visual evidence of leaflet failure, or when valves had to
be removed to accommodate testing of other valves.
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Figure 5-4. ViVitro pulse duplicator 
Figure 5-5. BDC Labs durability tester 
5.5 In Vivo Experimental Methods
Valves were tested in pigs in two study groups. The first study group involved implantation of self-
locating (referred to in later chapters as Design 1) valves in 9 pigs. The second study group, performed 
after the first group, involved the implantation of valves that could self-anchor (referred to in later 
chapters as Design 2) but not self-locate (on second-generation deployment devices that incorporated 
location mechanisms) in 8 pigs. All experiments were performed in the operating theatre at UCT’s 
Cardiovascular Research Unit, shown in Figure 5-6. All experiments were performed with the approval 
of the University of Cape Town Faculty Health Sciences Animal Ethics Committee (FHS AEC), with 
reference numbers 013/021 and 014/015. As for bench testing, continuous variables were expressed 
as mean ± standard deviation and comparisons were performed using a two-tailed t test, with p ≤ 0.05 
considered statistically significant. 
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5.5.1 Study Design
a) Pig Study Group 1
The aim of the first study group was to evaluate the ability to successfully deliver and place a 
replacement self-locating aortic heart valve within the native aortic valve, and to evaluate valve 
performance following implantation.4  
Figure 5-6. Operating theatre 
Twelve animals were included in the group, with a mean weight of 47.7 ± 3.2 kg (range 41.4 to 55.0 
kg). Three animals died prior to any attempt to implant an aortic valve, due to procedural 
complications.5 Valves were therefore implanted into nine animals, in four subgroups: Helical Balloon 
(HB) with Polyurethane (PU) valve (n=3); Mechanical Expander (ME) with Bioprosthetic (BP) valve 
(n=3); HB with BP (n=1); ME with PU (n=2). 
b) Pig Study Group 2
The aim of the second pig study group was to evaluate the ability to deploy self-anchoring 
transcatheter heart valves (see Concept 2D of Section 6.3) using deployment devices that incorporated 
location members (for tactile feedback). These tests were intended to be used to verify the acceptable 
delivery, positioning, deployment and functioning of the stent in vivo without migration or 
4 The same animals were also used to evaluate aortic deployment and mitral repair devices designed by SATH but this will not be described 
in detail here.
5 In two cases the animal could not be resuscitated following arrhythmias caused during port insertion; the third animal died due to 
arrhythmia that occurred in preparation for predilatation of the valve and blood loss that occurred following damage to the port back-up 
seal by the deployment device.
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embolization. Following a pilot study of four animals to evaluate the location performance of 
deployment devices, eight animals were included in the group, with a mean weight of 47.7 ± 3.1 kg 
(range 45.0 to 54.9 kg). 
5.5.2 Procedure
White landrace pigs sourced from a commercial farm were pre-medicated, intubated and restrained 
in a dorsal recumbent position. Animals were then placed on positive pressure ventilation and 
anaesthesia was maintained through inhalation of isoflurane and nitrous oxide.  
The right femoral artery was accessed percutaneously, a 6F sheath was placed and a diagnostic pigtail 
catheter was advanced to the aortic valve cusps for contrast angiography. Injection of contrast 
medium allowed favourable positioning of the C-arm to be established. Lines were placed in the left 
femoral artery for monitoring of arterial blood pressure and in the left femoral vein for infusion of 
fluids and drugs and the measurement of central venous pressure (CVP). In certain animals a cannula 
was inserted into the left atrial appendage for left atrial pressure. Ventricular pressure was measured 
through the apical access port and aortic pressure was measured through the pigtail catheter. 
Transoesophageal echocardiography (TOE) and fluoroscopy were used during all procedures. 
All procedures were performed using a transapical approach. Access to the heart was obtained by 
performing a full sternotomy, after which two concentric pursestring sutures were placed on the left 
ventricular apex with several pledgets. All animals were heparinised and adequate levels of 
heparinisation were maintained by measuring activated clotting time (ACT). The apex was punctured 
with a needle and a guidewire was advanced into the left ventricle, across the aortic valve into the 
ascending aorta. A customised dilator and sheath provided by SATH were then passed over the wire 
into the left ventricle.  
In preparation for implant, valves were crimped onto deployment devices using a disposable valve 
crimper and were partially or completely covered with a thin-walled sleeve. Crimped valves were 
advanced through the sheath, after which the protective sleeve was removed. In the case of self-
locating valves, the valves were advanced through the native aortic valve and withdrawn until correct 
location was established in a tactile manner. Position was then confirmed using fluoroscopy and/or 
echocardiography. In the case of self-anchoring valves, the crimped valve was placed across the native 
aortic valve and positioned using fluoroscopy, echocardiography, tactile feedback incorporated in the 
deployment device, or a combination of these techniques. Once the valve was judged to be in the 
correct position, the valve was deployed using a manual indeflator to inflate the device balloon. 
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Replacement valves were evaluated for their ability to access the aortic root, be positioned correctly, 
be deployed in the correct position and allow the delivery device to be withdrawn out of the valve. 
Delivery success was defined as successful insertion of the crimped valve through the access port and 
positioning of the valve across the aortic annulus. Location success was defined as the positioning of 
all three arms within the native cusps. Deployment success was defined as the ability to inflate the 
replacement valve across the aortic annulus. Withdrawal was judged to be successful when the 
deployment device could be removed from the implanted valve. Valves were judged to be anchored 
if they were in the correct position (if at least two of the valve arms were at or above the level of the 
basal ring and the bottom of the valve was within the annulus) and the valves did not embolise. Valve 
function was judged to be acceptable if replacement leaflets appeared to open and close. Sealing was 
judged to be successful if there was mild or negligible leak or regurgitation. 
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6 Concept development
6.1 Basic Structure – Native Valve Mimicking Shape
During the establishment of the current research project, a simple stent based on repeating zig-zag 
patterns (such as those described in Section 2.5.2) was designed, used to manufacture bioprosthetic 
valves and tested in the explanted heart tester. The same stents were used to manufacture polymeric 
valves. This experience confirmed two significant limitations of these designs. Firstly, the valves rapidly 
embolised into the ventricles of the compliant porcine hearts due to insufficient anchoring within the 
heart (refer to Figure 6-1).  
Figure 6-1. Images from explanted heart tester showing the left ventricular aspect of a first generation zig-zag valve A) 
immediately after deployment and B) following embolization of the valve into the ventricle after several seconds 
Secondly, leaflets were attached to a polymer film formed around the stent during coating, rather 
than to the stent frame itself. This led to the deposition of large amounts of polymer (which caused a 
large crimping profile) and the delamination of polymer film and leaflets from the frame during 
expansion, due to large strains in the polymer “windows” incurred during crimping. Although it is 
possible to sew polymer film leaflets onto a fabric skirt such as Edwards Lifesciences had done during 
their early development of TAVR (Rowe & Bash, 2012), this negates one of the key advantages of a 
polymeric valve, namely low cost manufacture through automation. 
It was therefore decided to use a crown (scallop) shaped stent that allows the leaflets to have a 
continuous contact zone along the metal of the stent, with the optimum shape of the leaflet 
attachment zone determined using FEA. As described in Chapter 2, many different leaflet shapes have 
been proposed, although most of this work was done on surgical valves. For a compressible valve with 
a continuous attachment zone, it was important to select a shape that minimises stresses in the 
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leaflets (to improve longevity) and minimises stresses incurred in the stent structure during crimping 
and deployment (to reduce the risk of acute fracture and fatigue failure). 
The height of the 23 mm Edwards Sapien™ valve was 14.5 mm (Padala et al., 2010), which means that 
the height of the cusps was approximately 12.5 mm. Recognising the need to increase valve height to 
reduce stresses at the commissures of a polymer valve (Vesely, 2003), but also to maintain valve height 
near mean normal coronary artery heights, a leaflet height for this thesis was chosen to be 14mm. 
Bézier curves were used to define different shapes for the crown.6 The explicit formulation of a Bézier 
curve of order   is as follow: 










  are binomial coefficients and    through    are control points defining the 
curve.    and    are the ends of the curve but in general intermediate points do not lie on 
the curve. 
By altering a few parameters an infinite number of curve shapes may be thereby be generated. For a 
third order (cubic) curve, with   = 3, the function may be expressed as follows: 
 ( ) = (1  )   + 3 (1  )
    +  3 
 (1  )   +   
   , 
0 ≤   ≤ 1 
Equation 6-2 Cubic Bézier Curve
Bézier curves for crown construction were drawn on the     plane before wrapping around a 23mm 
diameter cylinder. An example of the cubic curves used for crown construction is shown in Figure 6-2. 
   was selected to be on the origin of the     axis (  = 0,   = 0).    was positioned at a 
commissure, namely at a leaflet height,  , of 14mm and leaflet half-width equal to one-sixth of the 
circumference,    (  =    6⁄ ,   = 14).  
   could then be chosen from a range of values where   =    6⁄ , 0 <   <   and    could be 
chosen from a range of values where    6⁄ <   < 0,   = 0. In this way all crown shapes were 
generated by merely altering   , the   value of   , and   , the   value of   . Eight different curves 
were generated in this manner and are shown below in Figure 6-3. 
6 Bézier curves are parametric curves that may be used to generate smooth curves based on a finite number of parameters. 
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Figure 6-2. Example cubic Bézier function from Scilab used to construct crowns 
Figure 6-3. Diagram showing eight different Bézier curves generated in the x-z plane, and as crown structures 
Curves were generated in Scilab and imported into SolidWorks as multiple points on a plane for 
subsequent joining by a spline, and the creation of a 0.4 mm wide by 0.5 mm thick three-
dimensional crown shape with an outer diameter of 23 mm. For each crown shape a single simplified 
leaflet was drawn with a belly length equal to the valve height and a free edge of arc length 25.96 
mm, as shown in Figure 6-4. A surface was then lofted from the crown-shaped base up to the free 
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Figure 6-4. A) Crown-shape generated from Bézier curves, with simple leaflet attached. B) Simplified Leaflet
Each one-third crown structure was then subjected to simulated stent crimping using five crimping 
plates in a manner similar to that described in Chapter 4 and shown in Figure 6-5, and maximum Von 
Mises stresses were reported. In separate models, each leaflet was then fully constrained along the 
leaflet attachment line and a uniform pressure load of 40 mmHg was applied to the surface of the 
leaflets, firstly on the aortic side and secondly on the ventricular side. At this stage the leaflet was 
assumed to have a thickness of 0.15 mm and to be linearly elastic with a Young’s modulus of 13 
MPa. Maximum Von Mises stress was reported for each leaflet. 
Figure 6-5. Finite element model geometric representation for Bézier analysis 
a 
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Figure 6-6. Bézier Crown Version 1 geometry (left) and FEA Von Mises Stress after crimping (Right)
Figure 6-7. Bézier Crown Version 8 geometry (left) and FEA Von Mises Stress after crimping (Right) 
Figure 6-8. Von Mises Stress for leaflet from Bézier Crown Version 2 under closing pressure (left) and for leaflet from 
Version 1 (right) under opening pressure 
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The two extremes of the crown shapes with the respective Von Mises Stress results are shown in 
Figure 6-6 and Figure 6-7. Example Von Mises stress distributions for two of the leaflet shapes, one in 
each of closed and open configurations, are shown in Figure 6-8. The maximum Von Mises stress 
values for each of the eight geometries investigated are shown in Figure 6-9. Von Mises Stress values 
differed for each crown shape, for stents as well as leaflets. The lowest peak stent stress (674 MPa) 
occurred in Crown 1, which had the narrowest geometry at the nadir, while the highest stent stress 
occurred in Crowns 7 and 8 (1139 MPa and 1084 MPa, respectively), which had the widest geometry 
at the nadir. The location of the peak stress changed from near the nadir to near the commissures as 
the crown widened. Leaflet opening stress had the highest values for extremes of geometry, namely 
Crowns 1 and 8 (6.0 MPa and 6.5 MPa, respectively). Although Crown 1 also had high closing stress 
(4.4 MPa), Crown 8 did not have high closing stress (2.2 MPa).  
Local stress minima occurred for an intermediate crown shape, Crown 4, which had a peak stent stress 
of 695 MPa, a peak opening leaflet stress of 4.7MPa and a peak closing leaflet stress of 2.3 MPa. This 
crown had the second lowest stent stress, the second lowest opening leaflet stress and the third 
lowest closing leaflet stress. This geometry was therefore chosen as the basic structure for further 
stent design.   
Figure 6-9. Graph showing maximum Von Mises stress in crown structure and leaflets for different Bezier functions. 
Stresses for the chosen crown shape, Version 4, are shown in the rectangle. 
6.2 Ideation and Concept Generation
Since anchoring of the stent was identified to be one of the most critical and challenging components 
of the stent design, ideas for many different potential anchoring locations were generated. These 
included anchoring the stent behind the leaflet cusps, anchoring in the basal ring (virtual annulus) and 
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anchoring by making use of the shape of the Sinus of Valsalva. Figure 6-10 shows all potential 
anchoring positions explored. 
Figure 6-10. Potential anatomical positions considered for stent anchoring 
Self-expanding stents, which to the author’s knowledge are all constructed from Nitinol, have the 
advantage that they can be given any of a multitude of different shapes through a process known as 
shape setting. The stent is constrained in some way on a mould and a heat treatment is performed to 
set the desired shape and provide the stent with shape memory and/or super-elastic properties.  
Designers of balloon-expandable valve stents face a number of relatively unique limitations and 
challenges relating to stent structure. Chief among these are 1) the requirement for the stent to be 
formed in such a way that it compresses to the crimped diameter in a predictable manner and remains 
in this crimped condition when the crimper is removed, and 2) the requirement that the deployed 
stent shape has to be achieved through mechanical expansion. 
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6.3 Concept Development
The conceptual design processes described above generated many different concepts for overall stent 
shape, key structural members and in particular mechanisms for stent anchoring and location.  
Table 6-1. Main stent concepts
Anchorage Mechanisms

























CONCEPT 2A CONCEPT 2B CONCEPT 2C CONCEPT 2D 
Concepts were either sketched by hand or on computer and were evaluated qualitatively, taking into 
account anticipated function, simplicity of design, manufacturing feasibility, aesthetics, ability to be 
incorporated into the delivery and deployment methods of the non-occlusive deployment devices 
such as that shown in Figure 1-1. Combinations of various concepts were also considered. A history of 
concept generation, including early conceptualisation, is provided in Appendix G. 
Based on all available ideas, a concept evaluation matrix was constructed by selecting two favoured 
concepts that incorporated the crown shape into the stent design, and four concepts for achieving 
anchorage in the aortic root. This matrix is shown in Table 6-1 and categories are described below. 
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6.3.1 Crown support Concept 1: Support at top and bottom
Concepts were generated that allowed the crown-shaped structure to be substantially isolated from 
the support structure on the inflow and outflow ends. Zig-zag structures were still present at both 
ends to allow the stent to remain firmly on the balloon when crimped and to prevent leaflet prolapse 
when operational. Attachment of support structures occurs only at the nadir of the replacement 
leaflets and near the commissure posts. Additionally, a linkage between the inflow and outflow 
supports is included to prevent longitudinal shortening during loading and to encourage the crown to 
return to its undeformed shape. This stent would have to be positioned with the nadir of the 
replacement valve at the same level as the native valve, as there is no annular support structure above 
this point. 
6.3.2 Crown support Concept 2: Intermediate support
Concepts that incorporated the crown shape of the leaflet attachment zone into the stent structure 
itself were generated. These concepts started from a crown-shaped member, and various traditional 
stent structures, described in the stent design literature review, were incorporated. The result is an 
elegant, relatively short, strong stent. In a favoured concept the valve is intended to be deployed 
slightly sub-annularly. Since struts contact the crown struts at intermediate points, a structure is 
required above the crown to counter the excessive crown deformation that would occur in their 
absence. The radial strength is greatest in the area designed to fit within the annulus.  
6.3.3 Anchorage Concept A: Friction
Concepts designed to anchor by friction have no additional protruding members of anchoring. The 
stent relies on an area of high radial strength over the area of the annulus. In some cases this effect is 
supplemented by the formation of a slightly hourglass shaped stent due to greater strength, and 
therefore greater resistance to expansion, of the waist area, which will resist embolization during 
systole and diastole.  
6.3.4 Anchorage Concept B: “Paper lantern”
The “paper lantern” makes use of the bulbous shape of the Sinus of Valsalva for anchorage. It was 
recognised that the crown shape lengthens considerably during crushing, and has the corollary effect 
that it shortens in height during deployment. This concept uses the shortening that occurs during 
deployment to cause a member to protrude in the area inside the crown. It relies on plastic 
deformation of these central elements so that they do not merely return to the non-deployed shape 
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upon deployment. Instead they take the lowest energy behaviour, which causes protrusion of the 
member in a different plane, i.e. outwards. These were tested on the bench but not tested in animals. 
The protruding members were designed to have thinner wall thickness than the rest of the stent to 
encourage them to bend radially outwards rather than circumferentially. 
6.3.5 Anchorage Concept C: Arms attached to the outside of the stent
The “welded arm” concepts started with a crown-shaped member, then built support structures above 
and below the crown. The stent frame is constructed from annealed Co-Cr to take advantage of the 
low yield strength and extensive work hardening abilities. On the outside of the stent, however, were 
welded arms of the same material, but in a cold-worked wire form. This meant that the wires could 
be manufactured in a shape protruding outwards at the bottom. These arms are held down in the 
crimped condition by a sheath (in some earlier concepts the arms could be held down by portions of 
the stent itself). Upon removal of the sheath, or partial deployment of the stent, the arms protrude 
and allow themselves to be placed behind the native cusps. This concept makes use of balloon-
expanding and self-expanding elements in the same stent.  
6.3.6 Anchorage Concept D: Integrated expanding arms
The “expanding arm” concepts also used the fact that the crown lengthens during crimping and 
shortens again during deployment. This fact is exploited to cause arm members that are attached near 
the commissures to be plastically deformed during crimping, and instead of returning to the pre-
crimped shape in the plane of the original cylinder, the extremities of the arms protrude beyond the 
diameter of the rest of the stent upon deployment. The protruding arms may then push the native 
leaflets into the Sinuses and support the stent on the muscular/fibrous shelf above the virtual annulus. 
6.4 Concept Evaluation
The results of FEA on the concepts are summarised in Table 6-2. The results are discussed further in 
the sections to follow. Although all stents were analysed using FEA, only Concepts 1A, 1B, 1C and 1D 
and Concept 2D were physically prototyped. 
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Table 6-2. Summary of results of different concepts* 
Anchorage Mechanisms















CONCEPT 1A CONCEPT 1B CONCEPT 1C CONCEPT 1D 
Crimped: 1387 MPa 
Deployed: 1422 MPa 
Crimped: 1416 MPa 
Deployed: 1455 MPa 
Crimped: 1402 MPa 
Deployed: 1542 MPa 
Crimped: 1324 MPa 




CONCEPT 2A CONCEPT 2B CONCEPT 2C CONCEPT 2D 
Crimped: 1312 MPa 
Deployed: 1893 MPa 
Crimped: 1360 MPa 
Deployed: 1794 MPa 
Crimped: 1090 MPa 
Deployed: 1631 MPa 
Crimped: 1480 MPa 
Deployed: 1846 MPa 
* Peak Von Mises stresses at the end of crimping and deployment are provided, and the location of the peak deployment
Von Mises stress is shown inside the oval.
6.4.1 Concept 1A
Concept 1A showed that a crown-shaped member supported both at the nadir and at points near the 
commissure posts could be crimped to a low profile. The member designed to facilitate full 
lengthening of the stent during crimping and proper opening of the crown shape during deployment 
was partially successful. Although it did lengthen during crimping, it caused the nadir of the crown to 
push upwards slightly. FEA results are shown in Figure 6-11. A physical prototype (shown in Figure 
6-12) behaved similarly to the FEA results.
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Figure 6-11. Concept 1A FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C)  
Figure 6-12. Concept 1A prototype 
6.4.2 Concept 1B
The crown member of Concept 1B had similar behaviour to that of Concept 1A. In the simple FEA 
model, the double-diamond members that stretch from the top row of struts to the nadir lengthened 
during crimping, and protruded outwards during deployment as intended (see Figure 6-13). When 
physical prototypes were manufactured, however, the double-diamond members were highly 




Figure 6-13. Concept 1B FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C) 
Figure 6-14. Concept 1B prototype after crimping and deployment 
The difference between the FEA model and the physical prototypes was considered to be due to 
difficulty in thinning of the wall through micro-grinding and the symmetry boundary conditions in the 
FEA model, which artificially stabilise the model. In addition, the concept relied on the stent being 
crimped to a diameter of 6mm in order to undergo extensive plastic deformation, but early versions 








The crown member of Concept 1C also had similar behaviour to that of Concept 1A. The welded arms, 
however, form a double layer that causes the stent frame to compress slightly more during crimping. 
The arms protrude following relaxation of the crimping plates, and remain slightly protruding after 
deployment (see Figure 6-15). These stents were prototyped physically, and this is described later. 
Figure 6-15. Concept 1C FEA results following simple modelling, showing deployed stent geometry (A, B and D), crimped 
geometry (C) and relaxed geometry after crimping (E) 
6.4.4 Concept 1D
The crown member of Concept 1D had similar behaviour to other versions of crown support Concept 





6-17. The anchoring arms remained flush with the stent in the crimped condition, and protruded much
further that the welded arms of Concept 1C at the end of deployment, but the arms were weak and
could be deflected easily.
Figure 6-16. Concept 1D FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C) 
Figure 6-17. Concept 1D prototype before crimping (left), and after crimping and deployment (right) 
6.4.5 Concept 2A
Concept 2A features the crown shaped member integrated into the stent support structure. Although 
some struts became slightly bent during crimping, upon deployment the stent returns to a shape very 
close to the original undeformed geometry, as shown in Figure 6-18. This design was not physically 




Figure 6-18. Concept 2A FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C) 
6.4.6 Concept 2B
The crimped version of Concept 2B had a very similar appearance to Concept 2A, since they differ only 
in the structure of the area immediately above the nadir of the crown. The members above the nadir 
protruded as designed, as shown in Figure 6-19, although they did not protrude as far as the 
protrusions in Concept 1B. This design was not physically prototyped. The reduction of wall thickness 
in the protruding areas of the stent using micro-grinding while maintaining wall thickness in other 




Figure 6-19. Concept 2B FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C) 
6.4.7 Concept 2C
The crown member of Concept 2C also had similar behaviour to that of Concept 2A. The protruding 
arms behaved in the same way as they did for Concept 1C, protruding sufficiently following relaxation 
after crimping, and remaining slightly protruded after deployment (see Figure 6-20). These stents 





Figure 6-20. Concept 2C FEA results following simple modelling, showing deployed stent geometry (A, B and D), crimped 
geometry (C) and relaxed geometry after crimping (E) 
6.4.8 Concept 2D
The crown member of Concept 2D had similar behaviour to Concept 2A despite the fact that the 
expanding arm members were not attached the crown member. The arm member prevented the two 
halves of the crown member from protruding towards each other too much during the crimp, as 
shown in Figure 6-21. Although the attachment points of the expanding arms with the crown member 
prevent full restoration of the crown to its original shape, the effect is relatively minor and 






Figure 6-21. Concept 2D FEA results following simple modelling, showing deployed stent geometry (A, B and D) and 
crimped geometry (C) 
6.5 Concept Selection
A concept selection matrix was constructed to help determine which concepts to proceed with for 
more complex analysis and experimentation. All concepts incorporated the required design attributes 
described in Chapter 3, including having a tri-leaflet design, a continuous attachment site, a balloon-
expandable construction, the ability to be manufactured at deployed dimensions, and the ability to 
scale to other diameters. Therefore stents were evaluated based on the design criteria listed in Table 
6-3. Each criterion was weighted based on judged importance, and each design was scored from 0-5,
using an arbitrary score of 2 to correspond to the perceived score of the reference stent, the Edwards
Sapien 3™. Values above and below 2 reflect better or worse performance than the reference,
respectively.
In general Crown Support Concepts 1 and 2 were considered to be novel because both employed 
methods of incorporating a crown shaped member into balloon-expandable stent construction. The 
use of an annealed stent frame and cold-worked wires in stents with welded arms, thereby utilising 
balloon-expandable and self-expanding functions from the same material, also contributed towards 
novelty. Designs that utilised plastic deformation to cause elements to protrude were considered to 




Table 6-3. Concept selection matrix for comparing design concepts (score 0-5) 
Design Criteria Weight 1A 1B 1C 1D 2A 2B 2C 2D Sapien 3
Novelty 3 3 5 4 5 3 5 4 5 2 
Anchorage 3 1 3 5 3 2 3 5 4 2 
Manufacturability 3 2 1 1 2 3 1 1 3 2 
Correct shape 2 1 1 1 1 2 2 2 2 2 
Foreshortening 2 3 3 3 3 2 2 2 2 2 
Integrity/durability 2 1 1 1 1 2 2 2 2 2 
Crimpability 1 3 2 2 2 2 2 1 2 2 
Low leaflet damage 1 3 2 3 3 2 2 2 2 2 
Push leaflets 1 1 2 2 1 2 2 2 2 2 
Weighted total 35 43 47 46 42 45 47 54 36 
Stents designed to anchor using friction offered the least secure anchoring. Crown support concept 1 
relies on a narrow “landing zone”, but Crown support concept 2 anchorage was considered to be 
comparable to the Sapien 3 because greater radial strength is achieved in the waist area and a slight 
hourglass shape is formed at deployment, which may resist migration. The greatest anchoring security 
was offered by having members behind the native cusps, but members designed to push leaflets aside 
and to utilise the shape of the SoV still offered promising anchoring.    
Manufacturability was evaluated based on the ease with which stents could be manufactured as well 
as the ease with which polymer leaflets could be sprayed onto the stents. In this regard, designs that 
required grinding techniques were ranked lower, as were designs that were challenging to place on 
spray coating mandrels or interfered with the ability to spray the mould directly.  
The ability to return to the correct functional shape following crimping and deployment was better 
for designs using Crown Support Concept 2 than Crown Support Concept 1. Foreshortening was lower 
for concepts 1A to 1D than for Concepts 2A to 2D, which was comparable to the Sapien 3. Stents of 
Crown Support Concept 2 generally crimped and deployed more regularly, and Crown Support 
Concept 1 had high stresses at the hinge members near the nadir, so Crown Support Concept 2 stents 
were scored higher for integrity and durability. 
The ability to be crimped to a low profile was influenced by the density of struts and strut width around 
the circumference, and whether the concept had another wire arm layer. In this respect, the lowest 
crimp profile would be achievable by Concept 1A while the largest profile would be Concept 2C. Most 
designs were able to push the native leaflets away, but Concept 1A did not have a mechanism to 
achieve this, and Concept 1D was considered too weak to perform this function reliably. No stents 
were considered to be a significant risk for leaflet damage, but the more open designs of Concepts 1A, 
C and D were considered less likely to cause damage. 
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The concept selection matrix was used as a guideline, recognising the fact that each design could be 
tweaked to improve score. The highest scoring stents were Concepts 2D, 1C and 2C. It was decided to 
proceed with two design concepts, namely Concept 1C and Concept 2D. This allowed stents with two 
different anchorage mechanisms and two different support concepts to be tested more thoroughly, 
including implantation in animals. Concept 1C had the ability to self-locate, which allowed fully 
functional valves to be tested in animals relatively early in the development phase for the deployment 
devices. Concept 2D had the ability to anchor, but not locate during delivery, and could be used with 
deployment devices that incorporated location mechanisms (or using guidance from medical imaging). 
Concept 2D stents were therefore manufactured and tested in animals chronologically after Concept 
1C, as described in Section 5.5. 
In the sections to follow, these two favoured stent concepts (1C and 2D) are referred to as the Design 
1 stent (or self-locating stent) and Design 2 stent (or expanding arm stent), respectively. Stent height 
was 22.87 mm for Design 1 and 19.28 mm for Design 2, and Control stent height was 17.9 mm. Stent 
outside surface areas were 170 mm2, 168 mm2 and 189 mm2, respectively.  
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7 Results
This chapter presents the results of complex FEA modelling, verification of manufacturing quality and 
dimensions, and the results of in vitro, ex vivo and in vivo testing performed on the two favoured 
design concepts. 
7.1 Modelling Results
7.1.1 Balloon Modelling Results
The comparison between experimental and predicted diameters is shown in Table 7-1 and Figure 7-1. 
Predicted balloon diameter differed by a maximum of 0.1 mm at 2 atm and 4 atm. No balloon inflations 
beyond 4 atm were simulated. The stages of balloon inflation, starting with a four-pleat wrapped 
structure, through to a clover-leafed structure, to a fully unwrapped circular cross-section and finally 
a “stretched” circular cross-section at 4 atm are shown in Figure 7-2. When fully inflated to 4 atm, the 
median Von Mises stress in the balloon material was 95.1 MPa and the range of predicted stresses in 
the material was over the narrow range of 93.7 MPa to 96.5 MPa, as shown in Figure 7-3.  
Table 7-1. Comparison between experimental and model results of balloon diameter 
Pressure Experimental (mm) Model (mm)
0 atm 21.1 21.1 
2 atm 21.6 21.7 
4 atm 22.8 22.7 
Figure 7-1. Comparison between experimental and predicted balloon diameters 
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Figure 7-2. Balloon deployment simulation showing initial unfolding, and subsequent stretching, from 0 atm to 4 atm. 
Figure 7-3. Von Mises Stress distribution in the balloon at 4 atm. 
7.1.2 Model structural validation – Radial crush
Radial crush force predicted using FEA correlated well with the force measured experimentally, as 
shown in Figure 7-4. FEA under-predicted radial force for the Control stent, Design 1 and Design 2 
stents by 6.2%, 7.0% and 9.6%, respectively at 15% diameter reduction, and only 1.3%, 3.1% and 8.3%, 
respectively at 50% diameter reduction. 
Figure 7-4. Comparison between radial crush force predicted from FEA and determined experimentally 
2 atm 4 atm 
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7.1.3 Crimping and Deployment
A summary of FEA results for complex modelling on the Control stent, Design 1 and Design 2 is 
provided in Table 7-3, and more frames through the modelling stages are provided in Appendix H. 
7.1.3a Control Stent
The Control stent was meshed using 99,200 hexahedral elements. The maximum Von Mises and 
Maximum Principal stresses in the stent at the end of each modelling step are shown in Table 7-2, as 
calculated at element integration points. Von Mises Stress reached 1650 MPa at the end of 
deployment. 








Crimp 1223 1213 48% 
Relax 778 607 48% 
Deploy 1650 2591 95% 
Recoil 754 853 96% 
The Von Mises stress distributions at the end of crimping and deployment steps are shown in Figure 
7-5. Crimped and deployed stents showed regular structured geometry, with the highest stresses
concentrated near stent hairpin junctions and the lowest stresses near the strut midpoints. The
deployed stent is slightly hourglass shaped, with a waist positioned just below the midline.
As shown in the stent shape progression in Table 7-3, the stent only reached full deployment at 4 atm. 
The greatest value of Von Mises Stress occurred at the inside radius of a hairpin junction, as shown in 
Figure 7-6. The greatest value of Maximum Principle Stress after recoil also occurred at the inside 
radius of a hairpin junction, on the bottom row of struts.  
A stress history of the element with the greatest stress after recoil is plotted in Figure 7-7, showing 
that the stress at the inside radius is compressive during the crimp, reaches a tensile residual stress 
during relaxation, rises to peak at the end of deployment and drops to a final tensile residual stress of 
853 MPa. A small amount of dynamic oscillation can be seen at the beginning of recoil but this resolves 
rapidly. 
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Figure 7-5. Von Mises stress distribution for Control stent in crimped (A&B) and deployed (C&D) conditions. Stents are 
shown with and without balloons. 




Table 7-3. Summary of results of complex modelling 


































Figure 7-7. Maximum Principal Stress of Control stent at integration point of element 53426, which is the element with the 
highest maximum principal stress at the end of relaxation after deployment.
7.1.3b Self-locating Stent (Design 1)
The self-locating stent (Design 1) was meshed using 153,756 hexahedral elements for the stent and 
30,993 tetrahedral elements for the wire arms. The mesh is shown in Figure 7-8. Although the greatest 
stresses in the model occurred at the extremities of the wire arms (peak Maximal Stress values were 
2929 MPa during crimping and 2741 MPa during deployment), the focus of development in this project 
was the stent frame, so stresses in the welded arms are ignored in the analyses below. The maximum 
Von Mises and Maximum Principal stresses in the stent at the end of each modelling step are shown 
in Table 7-4 as calculated at element integration points. Von Mises Stress reached 1604 MPa at the 
end of recoil. 
Figure 7-8. Mesh used for Design 1 
Crimp Relax Deploy Recoil 
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The Von Mises stress distributions at the end of crimping and deployment steps are shown in Figure 
7-9. As shown in the stent shape progression in Table 7-3, the stent achieved fully deployed shape at
approximately 2 atm, although diameter continued to expand until 4 atm.








Crimp 1418 1683 48% 
Relax 1427 1651 49% 
Deploy 1437 2175 82% 
Recoil 1604 1626 82% 
The greatest values of Von Mises Stress occurred at the hinge points on either side of the crown nadirs, 
as shown in Figure 7-10A. The greatest value of Maximum Principle Stress after recoil occurred at the 
hinge of the branch elements attached to the crown shape near the commissure posts, although high 
residual stress values were present at the hinges on either side of the crown nadir. This final residual 
Maximum Principle Stress exceeded the true stress value of UTS (1315 MPa) in several areas near such 
hinge points. 
Figure 7-9. Von Mises stress distribution for Design 1 stent in crimped (A&B) and deployed (C&D) conditions. Stents are 




During crimping, stent struts did not all compress evenly (see Figure 7-9). Struts closest to the 
commissure posts tilted towards each other. As the stent compressed further, a more regular stent 
structure was obtained, as may be seen in the figure of the crimped stent. During deployment, there 
was tendency for the top row of diamonds to bend slightly up or down. There was also a tendency for 
the bottom row of struts to open to a greater extent at the longest strut, in the area beneath the 
commissure posts. The stents also showed distortion of crown geometry near the nadir, particularly 
in the hinge portions. At one of the hinge points, a single hairpin junction became trapped at the hinge, 
preventing proper expansion of the stent in this area and resulting in the development of high stresses. 
These stent irregularities are shown in Figure 7-10. 
Figure 7-10. Deformed geometry and Von Mises stress distribution associated with Design 1 stent irregularities. A) 
Distorted crown, showing area of greatest Von Mises stress in the model, B) Preferential stretching of long elements (*), C) 
Raised top row of diamonds elements (arrow), D) Trapped hairpin junction (++) 
7.1.3c Expanding Arm Stent (Design 2)
The expanding arm stent (Design 2) was meshed using 113164 hexahedral elements. The mesh is 
shown in Figure 7-11. The maximum Von Mises and Maximum Principal stresses in the stent at the 
end of each modelling step are shown in Table 7-5, as calculated at element integration points. Von 






Figure 7-11. Mesh used for Design 2 








Crimp 1434 1914 54% 
Relax 1311 927 54% 
Deploy 1633 3019 86% 
Recoil 1155 962 86% 
The Von Mises stress distributions at the end of crimping and deployment steps are shown in Figure 
7-12. Crimped and deployed stents showed mildly irregular strut deformation but crimped geometry
was compressed in a single layer and arms extended outward during deployment. As shown in the
stent shape progression in Table 7-3, the stent reached fully deployed shape at approximately 75% of
the deployment step (or 90% of the pressure).
The greatest values of Von Mises Stress occurred during deployment at the inside radii of hairpin 
junctions in the top row of the expanding arm, as shown in Figure 7-13. The greatest value of 
Maximum Principle Stress after deployment (3019 MPa) and after subsequent recoil (962 MPa) also 
occurred in the top row of struts but at the junction between the top row and the support structure 
of the arm, at an area with a very small radius (with only one element across the width of the radius), 
therefore representing a stress concentration. When this row of elements was removed from results, 
the peak Maximum Principle Stresses were 2613 MPa and 949 MPa, respectively, and occurred at the 
inside radii of hairpins in the bottom row of the stent. As with other stents, lowest stresses occurred 
near strut midpoints. A distortion of the crown shape occurred near the commissure post, as shown 
in Figure 7-13B. 
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Figure 7-12. Von Mises stress distribution for Design 2 stent in crimped (A&B) and deployed (C&D) conditions. Stents are 
shown with (B&D) and without (A&C) balloons 
Figure 7-13. Deformed geometry and Von Mises stress distribution associated with Design 2 stent irregularities. A) Area of 






7.1.4 Foreshortening and recoil
Average deployed outer diameters for the Control stent, Design 1 stent and Design 2 stent, as 
determined through FEA modelling (and based on orthogonal measurements at three points along the 
stent length), were 22.3 mm, 23.3 mm and 23.0 mm, respectively. The average predicted percentage 
recoil values for the stents were 1.9%, 3.4% and 1.9% respectively, as shown in Table 7-6. The 
measurements did not include arm protrusion.  
Table 7-6. Summary of recoil values from FEA and physical measurements 
Design Position


















Top 22.62 22.22 1.8 22.96 22.55 1.8 
Middle 21.23 20.72 2.4 21.17 20.66 2.4 
Bottom 23.08 22.71 1.6 23.01 22.69 1.4 
Design 1 
Top 23.50 22.71 3.4 23.38 22.67 3.0 
Middle 23.15 22.14 4.4 23.48 22.50 4.2 
Bottom 23.30 22.76 2.3 23.54 22.85 2.9 
Design 2 
Top 23.25 22.75 2.2 23.39 22.86 2.3 
Middle 22.16 21.74 1.9 22.36 21.92 2.0 
Bottom 23.72 23.32 1.7 24.12 23.74 1.6 
Table 7-7. Summary of foreshortening values from FEA and physical measurements 
Design













Control 24.32 19.53 19.7 24.19 19.45 19.6 
Design 1 29.44 24.77 15.9 29.32 24.97 14.8 
Design 2 25.51 20.92 18.0 25.39 20.73 18.4 
Foreshortening was predicted to be the greatest for the Control stent (19.7%), followed by the Design 
2 stent (18.0%) and finally the Design 1 stent (15.9%), as summarised in Table 7-7.  
7.1.5 Radial strength and fatigue analysis
Modelling demonstrated that radial strength (radial force at 15% diameter reduction) was much lower 
for Design 2 stents than Control stents (116 N vs 347 N). The radial force as a function of stent diameter 
is shown in Figure 7-14.  
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Figure 7-14. Radial strength 
Fatigue diagrams (charts of the mean and alternating stresses at each element) are plotted in Figure 
7-15 and in Figure 7-17 for the Control stent and Design 2 stent, respectively. Fatigue analysis was not
performed for Design 1 due to the fact that mean stresses exceeded the true UTS of the material and
therefore necessarily exceed Goodman criteria.
The minimum fatigue safety factor for the Control stent was 2.08, and the location of the element 
with the worst-case fatigue scenario is shown in Figure 7-16.  The mean and alternating stresses at 
this element were 621 ± 5 MPa, meaning that fatigue risk at this point is mainly influenced by mean 
stress. An example of an element experiencing greater alternating stresses is shown in Figure 7-16, 
where mean and alternating stresses were 439 ± 10 MPa, resulting in a fatigue safety factor of 2.7. 
The minimum fatigue safety factor for the Design 2 stent was 1.00, which narrowly predicts fatigue 
safety. The location of the two elements with the worst-case fatigue scenarios are shown in Figure 
7-18. The highest risk of fatigue occurred in the top row of struts at a small fillet radius, where the
mean and alternating stresses were 839 ± 122 MPa. The second highest risk of fatigue occurred at the
junction between the crown member and a connecting strut near the nadir, where the mean and
alternating stresses were 408 ± 214 MPa.
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Figure 7-15. Fatigue diagram of inverse fatigue safety factors for Control stent 
Figure 7-16. Contour plots of nodal inverse fatigue safety factors for Control stent 





Figure 7-18. Contour plots of inverse fatigue safety factors for Design 2 
7.2 In Vitro and Ex Vivo Results
7.2.1 Material properties
Tubing material properties were similar for all three MP35N samples. Stress-strain curves are shown 
in Figure 7-19. UTS of the MP35N tubing was determined to be 877 ± 5 MPa, strain to break was 53 ± 
0.2 % and the 0.2% proof stress was 424 ± 5 MPa. Plasticity data from Sample 1 were used for FEA 
(refer to Table 7-8). 
Table 7-8 Material Properties for MP35N
Young’s Modulus 236 GPa 
Poisson’s Ratio 0.4 
Yield Strength 426 MPa 
True stress at start of necking 1315 MPa 
True plastic strain at start of necking 41% 
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Figure 7-19. Stress-strain curves from uniaxial tensile testing of MP35N dogbones: A) Engineering stress-strain for three 
samples; B) True stress-strain and extracted plastic stress-strain data for FEA for Sample 1 
7.2.2 Stent inspection and measurement
All stent designs could be laser cut, descaled and electropolished as intended. Laser kerf width was 
measured to be 57 ± 3 µm for slots in the longitudinal direction and 59 ± 2 µm for slots in the 
circumferential direction. See Appendix D. Approximately one in four cut stents were rejected for 
obvious cutting errors before three of each design were processed further. These rejects were caused 
by stent waste material (diamond “windows”) protruding outwards slightly during cutting, causing the 
stent to briefly bump into the laser cutter nozzle, which rotated the stent tubing in the clamping jaws. 
The result of these errors is the appearance of very wide struts and very narrow struts in the same 
stent, which were easily detected by brief stereo microscope inspection. Acid descaling and 
mechanical scrubbing with a miniature nylon brush were able to remove surface oxides and waste 




Occasional small oxide particles were considered acceptable, and did not subsequently affect the 
polished surface. 
Figure 7-20. Macro photographs of stents. A) Design 1, B) Design 2 
Figure 7-21. Micro photographs of stents. A) Design 1, B) Design 2 
Figure 7-22. SEM images of stents. A) Design 1, B) Design 2 
Electropolished stent surfaces were smooth. The outside and inside surfaces were very smooth, while 
the side (cutting) surfaces were smooth on a micro level but still had a slightly textured topography 
on a macro level. Macro photographs, microscope images and SEM images of electropolished Design 









images of the cut and pickled stents of both designs are shown in Appendix I. Cut, pickled and polished 
images of the Control stents are also provided in Appendix I.  
Figure 7-23. Measurement locations for Design 1 
Stent measurement locations for Design 1 are shown in Figure 7-23. Mean stent dimensions for Design 
1 were all within 4% of target dimensions (Table 7-9). Individual measurements are provided in 
Appendix E. The greatest deviation from target values occurred for a strut width, which was 29 µm 
below target for one of the stents. In general strut widths were slightly below target, while hairpin 
widths were slightly above target. Mean strut widths of the three sectors of the stent were within 1 
µm of the stent mean strut width. 
Table 7-9. Stent dimensions for Design 1 
Region Specification Value (µm) Diff* (µm) % Diff
Strut 
250 µm 
247 ± 12 3 1.2 
Top strut (2,3) 247 ± 8 3 1.3 
Bottom strut (7,8) 247 ± 15 3 1.2 
Strut first sector 246 ± 12 4 1.7 
Strut second sector 247 ± 11 3 1.0 
Strut third sector 248 ± 14 2 1.0 
Hairpin 
327 µm 
330 ± 5 -3 -0.8
Top hairpin (10,11) 330 ± 6 -3 -1.1
Bottom hairpin (12,13) 329 ± 5 -2 -0.6
Commissure post (1) 560 µm 550 ± 5 10 1.7 
Crown member (4) 250 µm 252 ± 9 -2 -0.9
Vertical member (6) 260 µm 268 ± 2 -8 -3.0
Branch member (9) 200 µm 207 ± 10 -7 -3.6
Crown hinge (5) 100 µm 101 ± 3 -1 -1.4
Wall thickness 470 µm 466 ± 7 4 0.9 
* Diff = specification minus mean
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Figure 7-24. Measurement locations for Design 2 
Stent measurement locations for Design 2 are shown in Figure 7-24. Mean stent strut dimensions for 
Design 2 were within 5% of target dimensions (Table 7-9). Individual measurements are provided in 
Appendix E. The greatest deviation from target values occurred for wall thickness, which was 27 µm 
below target for one of the stents. In general strut widths were below target, while hairpin widths 
were slightly above target. Top struts were slightly narrower than bottom struts. Mean strut widths 
of the three sectors of the stent were within 3 µm of the stent mean strut width. 
Table 7-10. Stent dimensions for Design 2 
Region Specification Value (µm) Diff (µm) % Diff
Strut 
290 µm 
281 ± 9 9 3.1 
Top strut (2,3) 278 ± 5 12 4.3 
Bottom strut (5,6) 284 ± 11 6 1.9 
Strut first sector 279 ± 9 11 3.6 
Strut second sector 284 ± 10 10 3.3 
Strut third sector 280 ± 9 7 2.3 
Hairpin 
290 µm 
294 ± 6 -4 -1.5
Top hairpin (7,8) 292 ± 6 -2 -0.7
Bottom hairpin (9,10) 297 ± 4 -7 -2.3
Commissure post (1) 600 µm 590 ± 9 -10 -3.4
Crown member (4) 290 µm 300 ± 3 10 2.4 
Arm (11) 440 µm 430 ± 4 10 1.7 
Wall thickness 470 µm 452 ± 8 18 3.9 
Representative photographs and measurements of the Control stent are shown in Appendix E. 
Individual stent measurements are also provided in Appendix E.  
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7.2.3 Stent mechanical performance
7.2.3 A) Crimping, deployment, recoil and foreshortening
All stent designs could be crimped to 6mm diameter on a commercial valvuloplasty balloon without 
fracture and without damaging the balloon. Images of the Control stent and the two favoured designs 
are shown crimped on a commercial balloon in Figure 7-25. The regular zig-zag pattern of the Control 
stent allows for a neat crimped stent pattern. This is also largely true for Design 1 at the top and 
bottom rows of diamonds. Some warping of the scallop hinges near the nadir occur, however, as 
predicted in FEA. Design 2 shows bending of struts in the bottom row attaching to the nadir, and in 
struts near the middle of the expanding arm, but the structure is neat and symmetrical as predicted 
in FEA. 
Following crimping to a diameter of 6 mm, stents relaxed to average diameters along the stent length 
(excluding protruding arms in the case of Design 1) of 6.62 mm, 6.29 mm and 6.34 mm, for the Control, 
Design 1 and Design 2 stents, respectively; the largest crimped diameters were 6.71 mm, 6.50 mm and 
6.49 mm, respectively, which occurred in the centre for the Control stent, but at the ends for the two 
new designs, as shown in Appendix J. Crimped stent lengths after removal from the crimper were 
24.19mm, 29.32 mm and 25.39 mm, respectively. All stent designs could also be deployed on a 23 mm 
commercial valvuloplasty balloon without fracture or balloon damage. Images of stents deployed on 
balloons are shown in Figure 7-26. In all cases the proximal end of the balloon filled with water first, 
followed by filling at the distal end, during which small stent rotations occurred. Obvious stent 
expansion occurred after this. Control stents deployed at higher pressures than Design 1 and Design 
2 stents, requiring almost 4atm to deploy fully. It displayed a clear hourglass shape throughout 
deployment, and was even slightly hourglass-shaped at 4 atm.  





Figure 7-26. Deployed stents on commercial balloon. A) Control stent, B) Design 1, C) Design 2 
The Design 1 stent expanded rapidly, opening first at the bottom (proximal) end, followed by the top 
(distal) end. No true hourglass shape formed. Fully deployed shape occurred at approximately 1 atm, 
but diameter continued to grow up to 4 atm. The rate of deployment for Design 2 was between the 
Control and Design 1 stents. The bottom (proximal) end flared initially, follow by relatively even 
deployment of the rest of the stent, during which time the arms started to protrude. Fully deployed 
shape occurred at approximately 2 atm, with diameter increasing up to 4 atm. Arms protrusion also 
increased with increased balloon diameter.  
Photographs of undeformed stents and stents after deployment are shown in Figure 7-27, along with 
deformed and undeformed stents from the FEA modelling. Deformed stent shapes corresponded 
closely with shapes determined computationally. Average stent diameters (excluding protruding 
arms) were 22.38 mm, 23.47 mm and 23.29 mm for the Control stent, Design 1 and Design 2, 
respectively, recoiling to 21.97 mm, 22.67 mm and 22.84 mm, respectively. The experimentally 
determined average recoil values were therefore 1.9%, 3.4% and 2.0%, for the Control stent, Design 1 
stent and Design 2 stent, respectively. The arms protruded to a virtual diameter of 27.26 mm and 





Figure 7-27. Undeformed and deformed stents. A) Control Stent, B) Design 1, C) Design 2. Clockwise from top left for each 
cluster: photograph of as-manufactured stent, FEA model of original geometry, FEA model of deformed geometry after 






The stent lengths following deflation of the balloon (recoil phase), were 19.45 mm, 24.97 mm and 
20.73 mm for the Control stent, Design 1 stent and Design 2 stent, respectively; therefore physical 
measurements of foreshortening were 19.6%, 14.8% and 18.4% respectively. Recoil and 
foreshortening values are provided in Table 7-6 and Table 7-7, respectively, along with FEA predictions 
of the same values. All stent designs could be inflated to 25.3 mm (10% over-inflation) without 
fracture. Control and Design 2 stents could be deployed on a 29mm balloon without fracture, but 
Design 1 fractured at one of the branch members at the attachment to the crown member. 
7.2.3 B) Migration resistance
Polymeric valves of Design 1 and Design 2 were deployed under direct sight into a 25 mm Medtronic 
Freestyle Full Root valve and tested for migration resistance. The inner diameter at the annulus was 
approximately 21.5 mm, which is within the target native valve size range for a 23mm replacement 
valve. A stentless replacement valve such as the Freestyle valve offered the advantage that a force 
could be applied directly to the stent in an axial direction. Images of a Design 2 valve positioned in the 
xenograft, and tested for migration resistance, are provided in Figure 7-28. Design 1 and Design 2 
resisted embolisation up to a force of 22N. At this point it was felt that greater forces would risk 
damaging the xenograft and the test was stopped. 
Figure 7-28. Migration test. A) Design 2 valve deployed into Freestyle xenograft. B) Test setup for migration test, including 
a force gauge and sutures connecting the base of the stent to the gauge. 
7.2.4 Valve performance
7.2.4 A) Valve manufacturability
Stents of both designs were expanded to an inner diameter of 23mm using tapered PTFE rods and 
positioned over stainless steel spray-coating moulds. In the case of stent Design 2 the arms had to be 
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lifted slightly upwards to prevent the sprayed polyurethane from forming a web or film between the 
arm and the crown member, and were easily returned to their starting positions.  
In the case of Design 1, special care was required during placement on the mould to prevent 
longitudinal stent compression; the vertical members beneath the commissures could be forced 
upwards, bending the “branch” elements in the wrong direction. Examples of polymeric valves 
constructed from Design 1 and Design 2 stents are shown in Figure 7-29. Design 1 valves had 
polyurethane film sealing skirts while Design 2 valves had electrospun sealing skirts.  
Figure 7-29. Polymeric valve constructed from Design 1 stent (left) and Design 2 (right). Design 1 incorporates a 
polyurethane film skirt and shows marker lines used to indicate free edge of leaflet for cutting. Design 2 incorporates an 
electrospun polyurethane skirt 
7.2.4 B) Valve Deployment behaviour
A polymeric valve constructed from Design 2 was manufactured and crimped onto an SATH 
mechanical expander and annular balloon and deployed by first expanding the mechanical arms to 
dilate the valve to approximately 18mm and subsequently to inflate the annular balloon to dilate the 
valve to 23 mm.  
The valve could be crimped onto the deployment device without damage to the valve or device and 
could be covered by the device protector. Leaflets remained undamaged and the electrospun sealing 
skirt remained attached to the stent frame. 
Although the stent foreshortened as expected, the absolute position of the nadir of the valve moved 
towards the handle by only approximately 1 mm, as shown in Figure 7-30. The valve deployed fully 
and the expanding arms protruded as per design. 
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Figure 7-30. Free deployment of Design 2 valve on SATH Mechanical expander and annular balloon. The long black line 
indicates the location of the nadir of the crown shape in the crimp condition and the short line indicates the location of the 
nadir in the deployed condition 
7.2.4 C)  Haemodynamic Behaviour
Ten polymer valves of each stent design were tested for haemodynamic performance. Values for 
pressure drop, EOA and regurgitation are provided in Table 7-12.  
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Table 7-11. Frames from high speed photography at different parts of the cardiac cycle 









Both designs passed the requirements of the relevant ISO standard (ISO-5840-3, 2013). Both stent 
designs also had lower pressure drop and larger EOA than the Hancock 2 valve, while regurgitation 
was lowest in the Hancock 2 valve.  
Frames from high-speed videos of one of each valve are shown at several moments within the cardiac 
cycle, from the initial movement of the leaflets at the start of systole to full leaflet closure. The frames 
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show that the polymeric valves open and close slower than the bioprosthetic Hancock 2 valve. The 
images also illustrate the greater geometric opening area achieved by percutaneous valves, since the 
outer diameter of each valve is approximately 23mm. Both TAVR stent designs allowed for good 
hydrodynamic function. EOA was significantly greater for valves constructed from Design 2 compared 
to Design 1 (2.03 ± 0.12 vs. 2.38 ± 0.19, p<0.001). 
Table 7-12. Haemodynamic results 
Design Pressure Drop (mmHg) Effective Orifice Area (cm2) Regurgitation (%)
Design 1 8.56 ± 1.31 2.03 ± 0.12 5.22 ± 1.43 
Design 2 6.12 ± 0.93 2.38 ± 0.19 5.14 ± 1.17 
Hancock 2 13.50 1.68 3.52 
7.2.4 D) Durability
Seven valves constructed using stents of Design 1 (specifically Concept 1A) were subjected to fatigue 
testing, while 29 valves constructed using stents of Design 2 (Concept 2D) were subjected to fatigue 
testing. Fatigue testing was performed on valves and not on stents alone, as a stent fatigue tester was 
not available. 
Table 7-13. Durability test results 
Numbering of stents without fatigue fracture at
various time points (percentage pass)
Design 1
0 – 20 million cycles 6 (100%) 
21 – 100 million cycles 1 (100%) 
Design 2
0 – 20 million cycles 24 (100%) 
21 – 100 million cycles 14 (93%)* 
101 – 400 million cycles 2 (100%) 
> 400 million cycles 1 (100%) 
* A stent failed due to a manufacturing defect from laser cutting
Fatigue fracture was found in only one stent, a stent of Design 2 that had been subjected to 40 million 
cycles. Stent inspection showed that the stent had a manufacturing defect that had not been identified 
following laser cutting. In all other cases, valves were removed from the durability testers either to 
provide space for newer polymer leaflet designs or following failure of the polymer leaflets 
themselves. As a result, stents were subjected to a wide range of total fatigue cycles. The number of 
stents surviving valve durability testing free of fatigue fracture is shown in Table 7-13. 
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The maximum number of cycles tested for Design 1 was 22 million cycles. Seventeen stents of Design 
2 survived more than 20 million cycles. This includes a stent that survived more than 400 million cycles, 
and at the time of writing was still being tested successfully.  
7.2.4 E) Ex Vivo Explanted Heart
Valves constructed using stents of both designs were delivered and implanted into cadaveric pig 
hearts in an explanted heart tester. Valves were successfully crimped and could be covered with an 
introducer sheath, which was used to advance the valves through the port without damage until they 
were positioned in the left ventricle (in the case of Design 1 the introducer sheath also kept the welded 
arms down). Valves were delivered and placed under fluoroscopic guidance (and tactile feedback for 
Design 1), and videos of the implant were captured using endoscopy.  
Several attempts were made to locate Design 1 valves within the native valve. Initially the valve passed 
through the open leaflets during withdrawal without capturing the leaflets, but when stent placement 
was timed to occur exactly during diastole, the arms of the stent could be placed behind the leaflets, 
and the correct positioning within the aortic root could be confirmed using fluoroscopy (see Figure 
7-32). It was noted from endoscopy that the stent arms had captured the leaflets and prevented the
native leaflets from opening fully. During valve deployment the arms remained in position behind the
cusps (Figure 7-31). The valve was fully expanded, but it was clear that it was nevertheless undersized
for the heart used in the explanted heart tester (the animals available from the abattoir were older
than subsequently used for in vivo studies). Despite this undersizing, the valve functioned correctly
and did not embolise. It is anticipated that some leakage occurred between the replacement valve
and the native valve (such leakage may occur at the asterisk shown in Figure 7-31), but the apparatus
had no means of determining leaks.
Design 2 valves were crimped onto deployment devices that incorporated location mechanisms. 
Initially location was performed using these devices, but adjustments were made to valve position 
based on fluoroscopy alone (see Figure 7-34).  
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Figure 7-31. Endoscopic images of location and deployment of Design 1 valves, from the aortic view. Asterisk shows area of 
potential leakage.
Figure 7-32. Fluoroscopic images of location and deployment of Design 1 valves, deployed using SATH non-occlusive 
balloon catheter
It was possible to position the valve axially by aligning the nadir of the stent crown-shaped member 
with a position just above the virtual annulus, and to position the valve circumferentially by aligning 
the expanding arms with the SoV prior to deployment. When the valve was deployed, two of the arms 
were positioned as intended, pushing the leaflets into the SoV and resting on the muscular shelf at 
the VAJ. The third arm, position at the non-coronary cusp was positioned slightly below the virtual 
annulus. As a result the valve was tilted slightly, and the non-coronary leaflet curved over the top row 
of struts at the free edge, although this did not interfere with polymer leaflet function. Ventricular and 
aortic views of the valve are shown in Figure 7-33. The heart used for Design 2 evaluation was also 
oversized relative to the stent, as had been the case in the evaluation of Design 1. Despite this tilt and 
relative size difference, Design 2 did not embolise. The replacement leaflets opened and closed over 
the heart cycle, but a tear was present in one of the leaflets near the commissure post. It was not clear 
whether this had occurred during crimping or deployment. 
*
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Figure 7-33. Endoscopic images of deployed Design 2 valves, from the ventricular (left) and aortic (right) views
Figure 7-34. Fluoroscopic images of location and deployment of Design 2 valves, deployed using SATH mechanical 
expander and annular balloon 
7.3 In Vivo Results
Stents of two different designs were tested in 17 pigs with a mean weight of 47.3 ± 2.8 kg. The mean 
diameter of the aortic annulus, as determined through (primarily transoesophageal) 
echocardiography, was 20.6 ± 2.0 mm during systole and 19.7 ± 2.1 mm during diastole (range 17-23 
mm for both). Annulus diameter could not be measured reliably in four animals due to difficulties 
obtaining acceptable TOE images. Animal data, details of devices used and pre-implant comments may 
be found in Table 7-14. 
Implantation of self-locating valves was attempted in the first nine pigs, and implantation of valves 
with expanding arms was attempted in the last eight pigs. Mean weights of the animals were not 
statistically different (46.9 ± 2.5 kg and 47.7 ± 3.1 kg, respectively, p=0.5).  
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Figure 7-35. Exemplary crimped valves used in the preclinical evaluation of Design 1. A) Bioprosthetic valve on SATH 
mechanical expander; B) Polymeric valve on SATH self-sustaining balloon catheter 
Figure 7-36. Exemplary crimped valves used in the preclinical evaluation of Design 2. A) Bioprosthetic valve on SATH 
mechanical expander; B) Polymeric valve on SATH self-sustaining balloon catheter 
Prior to aortic valve implant, the first nine pigs were also used for the evaluation of mitral valve repair 
strategies by other investigators; these procedures did not directly appear to influence the ability to 
deliver and deploy the aortic valve. The mean diameter of the aortic annulus during systole was 
greater for the first nine animals than for the last eight animals (22.5 ± 0.5 mm versus 19.1 ± 1.2 mm, 
p<0.001), and similarly during diastole (21.7 ± 1.2 versus 18.0 ± 0.8 mm, p<0.001). The performance 
















1-3 49.0 22/21 D1: Self-locating SSB Poly Mechanical commissurotomy 
1-4 48.2 22/20 D1: Self-locating ME/AB Bio Annular balloon predilatation 
1-5 47.8 22/21 D1: Self-locating SSB Poly Annular balloon predilatation 
1-6 44.7 CNM D1: Self-locating ME/AB Bio Annular balloon predilatation 
1-7 45.8 CNM D1: Self-locating SSB Poly N/A 
1-8 41.4 CNM D1: Self-locating ME/AB Poly N/A 
1-9 49.2 23/23 D1: Self-locating ME/AB Poly N/A 
1-10 48.2 23/23 D1: Self-locating SSB Bio Mini-thoracotomy attempt 
1-11 47.5 23/22 D1: Self-locating ME/AB Bio N/A 
2-5 45.0 17/17 D2: Expanding arms SSB Poly N/A 
2-6 47.0 19/18 D2: Expanding arms SSB Poly N/A 
2-7 54.9 20/CNM D2: Expanding arms ME/AB Poly Helical balloon predilation 
2-8 49.0 19/17 D2: Expanding arms ME/AB Poly Helical balloon predilation 
2-9 46.6 19/18 D2: Expanding arms SSB Poly N/A 
2-10 45.9 21/19 D2: Expanding arms ME/AB Bio N/A 
2-11 46.0 20/19 D2: Expanding arms ME/AB Bio N/A 
2-12 47.5 18/18 D2: Expanding arms SSB Bio N/A 
CNM – Could not measure. SSB – Self-sustaining balloon. ME/AB – Mechanical expander with annular balloon. Poly – polymeric. Bio – 
bioprosthetic.  
7.3.1 Design 1: Self-locating valve
The self-locating valve was successfully delivered to the aortic root in all nine pigs in which implant 
could be attempted. Procedural results are summarised in Table 7-15. Typical images of Design 1 
valves crimped onto SATH deployment devices in preparation for implant are shown in Figure 7-35. 
Successful valve location using locating arms was achieved in eight of the nine cases. In the case of 
unsuccessful location (Pig 1-3), tactile, echo and fluoroscopic feedback indicated correct placement 
but with subsequent manipulation one of the arms tore through the native leaflet. 
Valves could be successfully deployed without rapid pacing in eight of nine animals (Figure 7-37). 
Unfortunately prior to attempted deployment, Pig 1-8 experienced fibrillation from which it could not 
be resuscitated. Valve position was correct (aligned with natural leaflets and positioned within the 
annulus) in 7 of the 8 valves that were deployed (including Pig 1-3, which had pierced a leaflet cusp). 
The valve that was deployed in the incorrect position (Pig 1-5) was implanted slightly supra-annularly 
(thought to be due to slow expansion of the balloon). In one of the cases with correctly deployed 
valves (Pig 1-6), the pigtail catheter was not pulled back far enough before deployment, causing the 
stent to crush the pigtail against the wall of the aortic root. The valve nevertheless continued to 
function. 
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Table 7-15. Device performance and complications for Design 1 (self-locating) valve 
Pig # 












































Device/Procedural complications Stent/Valve complications
1-3 
     
Catheter leak prevented full inflation, so valve was 
under-deployed at waist. Balloon caught on stent.  
Animal experienced cardiac arrest soon after 
deployment. 
Initial tactile feedback obtained 
but subsequently lost. Valve 
under-deployed. 
Post-mortem findings: Balloon reinforcing fibres got hooked on stent. One stent arm pierced through native leaflet. Other two arms in correct 
position. 
1-4 
      
Deployment device inadvertently clamped pigtail 
catheter. Protective sleeve from balloon appeared to 
be have been removed after catching on stent. 
Port complications led to blood loss, reduced cardiac 
output and subsequent sacrifice. Animal experienced 
cardiac arrest soon after deployment. 
None. 
Post-mortem findings: Valve position was optimal. Stent deployment was cylindrical. 
1-5 
      
Pre-implant air embolization into coronaries; took 90 
minutes to stabilise. During inflation balloon not 
cylindrical. Animal sacrificed after slowly declining 
physiological conditions.  
Valve under-deployed. 
Post-mortem findings: Valve slightly high; thought to be due to slight champagne-cork effect from slow inflation. Polymer skirt separated from 
bottom row of stent. 
1-6 
      
Extensive pre-implant blood loss due to port leakage; 
animal stabilised. Pigtail catheter trapped during 
deployment. 
None. 
Post-mortem findings: Stent perfectly positioned with arms in cusps, with full deployment in annulus and at top row. Flushing with syringe on 
top of leaflets seals without leakage. 
1-7 
      
Throat trauma made TOE difficult. Ventricle cut during 
sternotomy. Deployment not complete due to balloon 
leak, despite efforts to maintain 15atm. 
Valve under-deployed. 
Post-mortem findings: Valve position correct; all three arms in native cusps. Native leaflets rest on replacement leaflets. Coronaries 
unobstructed. 
1-8       
Air introduced during mitral repair procedures caused 
rapid blood pressure drop to 60/40 and fibrillation. 
This required port removal and subsequent port re-
entry. When the crimped valve was positioned across 
the native valve and the sheath was fully retracted, the 
heart started fibrillating. The heart was defibrillated 
three times before the procedure was abandoned. 
None 
Post-mortem findings: N/A 
1-9 
      
Sheath interfered with the ventricular pressure 
readings. Animal was sacrificed after gradual drop in 
aortic pressure. 
None 
Post-mortem findings: Stent deployed very well, to correct size. Stent position perfect, with arms in all three cusps. Skirt does not cover 
bottom row of diamonds fully. 
1-10 
      
Extensive blood loss caused by failure of balloon 
catheter shaft.  
Valve leaflets inadequately 
cleaned of fatty tissue, causing 
thickening in vivo. 
Post-mortem findings: Valve in correct place, but leaflets clearly thickened. Outer stent diameters at top and bottom were 23.2mm and 
22.5mm. Subsequently tested on pulse duplicator and found to have pressure drop of 8mmHg, EOA of 2.7cm2 at 5l/min CO. 
1-11 
      
Deployment device leak caused blood to leak through 
inflation line.  
Valve appeared to cause trivial 
mitral regurgitation to become 
mild. 
Post-mortem findings: Valve position and size good. Natural leaflets pulled taut. Valve slightly hourglass shaped. Top and bottom outer 
diameters of stent were 23.0mm and 23.0mm. Deployed length was 25.4mm. 
Successful acute valve function occurred in eight pigs (pigs 1-3, 1-4, 1-5, 1-6, 1-7, 1-9, 1-10, 1-11), with 
five valves functioning for more than ten minutes (1-5, 1-7, 1-9, 1-10, 1-11), including at least one each 
of bioprosthetic valve on helical balloon, bioprosthetic valve on mechanical expander, polymer valve 
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on helical balloon and polymer valve on mechanical expander (Figure 7-37). Central leakage and 
paravalvular leak were absent or insignificant in seven of eight valves; leakage was present in Pig 1-3, 
as a result of the pierced cusp and under-deployed valve. All valves deployed in the correct position 
maintained their location, confirmed by echocardiography, fluoroscopy and subsequent autopsy 
(Figure 7-38). 
Two of the deployments resulted in cardiac arrest shortly after deployment (1 to 3 minutes), namely 
Pigs 1-3 and 1-4. In general, valves deployed using the mechanical expander and annular balloon were 
fully expanded, while most valves deployed using the self-supporting balloon were under-expanded. 
All stents were considered sufficiently radiopaque to position the valve in the correct position under 
fluoroscopy. 
Figure 7-37. Typical fluoroscopic image of an implanted Design 1 valve, from Pig 1-10; the valve is circled 
Figure 7-38. Post-mortem images of Design 1 valve in position in a porcine aortic root. A) Typical valve shown with most of 
the SoV excised; note location of arm behind cusps and proximity of native leaflets to replacement leaflets. B) Ventricular 
view of valve from Pig 1-3 showing arm pierced through leaflet. 
A B
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7.3.2 Design 2: Expanding arm valve
Procedural results for Design 2 are summarised in Table 7-16. Typical images of Design 2 valves 
crimped onto SATH deployment devices in preparation for implant are shown in Figure 7-36. Valves 
were successfully delivered to the aortic root in seven of the eight pigs in which implant could be 
attempted. In the case of unsuccessful delivery (Pig 2-10), the valve embolised before deployment 
could be performed.  
Table 7-16. Device performance and complications for Design 2 (expanding arm) valve 
Pig # 
















































A     
Balloon leak prevented full inflation. Valve deployed 
approximately 5mm too low. 
Valve under-deployed. Valve 
embolised during device 
withdrawal. 
Post-mortem findings: The valve could not be properly inspected post-mortem because the stent, which had embolised into the left ventricle, 
was flattened during explant of the heart. A review of echocardiography showed that the stent was positioned approximately halfway across 




A      
Some bleeding from port while placing guidewire 
across aortic valve.  
Moderate regurgitation at one 
leaflet. 
Post-mortem findings: The valve was also orientated correctly, with the replacement valve aligning closely with the native valve. One of the 
stent arms appeared to be below the native leaflet base. Another appeared to be in the correct position. The third arm was positioned behind 
one of the native leaflets. One of the replacement valve leaflets was in an open position, which appeared to be due to being positioned 
against a native leaflet and pressed against the upper wall of the sinotubular junction. The valve was oval at the inflow side, although this may 




A      
Some bleeding from port while placing guidewire 
across aortic valve.  
N/A. Valve initially pulled back 
with deployment device and 
advanced across the valve again. 
Mild regurgitation. 




A      
Port came out several times. ST Elevation during 
predilation but resolved. ST changes occurred during 
valve inflation as well. Balloon leaked. 
Valve under-deployed. Initial 
moderate regurgitation that 
resolved. 
Post-mortem findings: The valve was in the correct position but all three leaflets were behind the native leaflets, and the valve was very 




A      
Inadvertent cut on left ventricle from sternotomy 
caused ventricular fibrillation, requiring defibrillation. 
Port insertion difficult. ST segment elevation after 20 
second inflation. Device moved distally during 
deployment. 
Stent deployed high initially but 
shifted into correct position. Mild 
eccentric leakage. 
Post-mortem findings: At valve explant, valve in correct position in annulus and in correct orientation. Diameter 19.5mm ID. Two location arms 





A      
Animal had to be sacrificed when blood flow to the 
extremities was obstructed by the embolised valve.  
Valve shifted on device and 
embolised firstly into left 
ventricle and then into the aorta 




A      
ST elevation developed during deployment and animal 
never recovered. Blood pressure dropped further. 
Echocardiography showed anterior mitral leaflet 
impeded. 
Valve deployed too low. Leakage.  




A      
Blood pressure low after device removal. Valve appeared to be regurgitant 
based on fluoroscopy. 
Post-mortem findings: Valve damaged during CPR. 
118
The stent had shifted distally on the balloon during attempts to locate within the valve. An attempt to 
remove the deployment device and crimped stent (in order to re-crimp) caused the stent to embolise 
completely firstly into the ventricle and subsequently into the descending aorta. A commercial 
valvuloplasty balloon was introduced to deploy the stent within the descending arch, but the valve 
had tilted over, causing it to occlude blood flow to the extremities, and the animal had to be 
euthanized. 
All valves that were successfully delivered to the aortic valve could be deployed. Figure 7-39 presents 
a fluoroscopic image of a Design 2 valve in position. One of the valves embolised during withdrawal of 
the deployment device (Pig 2-5). The valve was deployed approximately 5mm too low. This was 
verified retrospectively from fluoroscopy and echocardiography. The valve had been positioned using 
a measurement scale on the deployment device, and in all subsequent cases valve position was 
checked against fluoroscopy and echocardiographic images during the procedure and position was 
adjusted where necessary. Removal of the balloon before full deflation (slow balloon deflation due to 
the use of 100% contrast medium) was considered to have contributed to stent embolization. 
Valves remained anchored in the remaining six of the eight attempted implants. In four of these valves 
(Pigs 2-6, 2-7, 2-8 and 2-9), at least one expanding arm was located behind the native leaflet. During 
removal of the deployment device from the valve implanted in Pig 2-7, part of the deployment device 
that had failed to deflate fully caught on the valve, causing it to be pulled backwards. The valve was 
immediately advanced distally into position, and remained in position following withdrawal of the 
deployment device, and continued to function. At explant, all three arms were found behind the native 
leaflets. In Pig 2-6, one arm was behind the native leaflet, another was on the luminal side of the 
leaflet on the muscle shelf and the third was below the level of the annulus. Both of these cases are 
shown in Figure 7-40. Mild regurgitation was present but the location could not be discerned. In Pig 
2-9, fluoroscopy showed that the device had moved substantially distally before deployment
(undetected at the time), and that the stent moved under diastolic flow to a secure position at the
annulus.
Moderate regurgitation occurred in at least two of the animals. In one of the animals (Pig 2-6), where 
leakage could be detected on echocardiography and was evidenced through a large pulse pressure, 
explant showed that one of the leaflets was immobilised due to the fact that it was pressed against 
the sinotubular junction. In another animal (Pig 2-8), the moderate central regurgitation resolved 
entirely in the first few minutes. Another two animals also showed signs of regurgitation based on 
contrast injection (Pigs 2-11 and 2-12), although blood pressure had reduced before and during 
deployment and animals did not survive long enough to measure flow or regurgitation on 
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echocardiography before euthanasia. In the case of Pig 2-11, ST elevation occurred during 
deployment, the valve was deployed too low and the anterior mitral valve leaflet motion appeared to 
be impeded. The location of the regurgitation could not be ascertained for Pig 2-12. Haemodynamics 
could only be reliably measured in two animals, Pig 2-8 and Pig 2-9, where EOA was measured to be 
2.50 cm2 at a cardiac output of 3.7 L/min and 1.43 cm2 at 2.8 L/min, respectively.  
Figure 7-39. Typical fluoroscopic image of an implanted Design 2 valve, from Pig 2-7; the valve is encircled. 
Figure 7-40. Post-mortem images of Design 2 valve in position in a porcine aortic root. A) Valve from Pig 2-7 shown with 
ascending aorta excised; arms are located behind cusps. B) Ventricular aspect of valve from Pig 2-6 showing arm below the 
basal plane (arrow); the arm behind the leaflet indicated by the asterisk is on the muscle shelf, while the third arm (not 





TAVR has revolutionised the treatment of aortic valve disease. Much current debate centres on the 
application of this technology to younger patients, who have much lower surgical risk and for whom 
valve durability will be a more important consideration. Adoption of the technology has been fastest 
in Europe and the USA due to the advanced facilities required to perform the procedures and the high 
cost of the devices. Sufferers of rheumatic heart disease have limited access to both traditional 
surgical valve replacement and TAVR due to the limited resources available in the developing countries 
affected by the disease. 
A report on the design and evaluation of novel balloon-expandable transcatheter valve stents that 
incorporate a continuous attachment site for polymeric leaflets and mechanisms for anchoring the 
valves in the absence of calcification is presented. To the best of our knowledge, these are the first 
balloon-expandable TAVR stents designed to be suitable for implantation in compliant non-calcific 
aortic roots. 
8.1 Stent Design
It was demonstrated that balloon-expandable stents could be constructed with crown-shaped 
structural members, and still be crimped to 6 mm and deployed to the target diameter of 23 mm. 
These designs differ appreciably from all other marketed balloon-expandable stents, which have 
repeating zig-zag, diamond or chevron patterns (Nietlispach, Wijesinghe, Wood, Carere, & Webb, 
2010; Ribeiro, Urena, Allende, Amat-Santos, & Rodes-Cabau, 2014). 
Two crown support member concepts (either supported at the ends or integrated into the stent 
structure) combined with four different anchoring mechanisms (relying on friction, bulbous 
protrusions, welded arms and integrated protruding arms) to produce eight concepts that were 
subjected to simplified FEA for comparison; some were also prototyped, crimped and deployed. 
Although FEA suggested all eight concepts were feasible for the construction of polymeric heart 
valves, they differed substantially in their novelty, ability to anchor effectively, ease of manufacture, 
ability to return to the correct crown shape and other factors. The two favoured different stent designs 
reported here as Design 1 and Design 2 were selected from the available concepts for further analysis 
and testing because they offered two good alternative means of achieving the primary goals of 
supporting continuous attachment of polymer leaflets and anchoring in a complaint native aortic root. 
Both stents had axial symmetry to receive a tri-leaflet valve. The two preferred designs also allowed 
two different support structures and two different anchoring methods to be evaluated further. In 
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addition, Design 1 stents (welded arm anchorage) permitted the stent to be used for locating position 
within the anatomy during delivery, at a time when such a mechanism had not yet been incorporated 
into the SATH deployment devices. 
Design 1 stents consisted of a triple crown-shaped structure supported by a double row of zig-zags at 
either end of the stent, a mechanism to join the two ends of the stent to each other between the 
crowns while allowing the stent to lengthen during crimping, and elastic wire arms welded to the 
outside of the stent at the commissures. The stent frame was constructed from cobalt chromium in 
an annealed condition so that it can plastically deform during crimping and expansion, and limit stent 
recoil. The arms were constructed from the same material as the stent but in a cold-worked form to 
maximise elasticity so that the arms released following crimping to allow them to be used to locate 
the native cusps. Since the same material is used for both frame and arms, galvanic corrosion is not a 
concern (Stoeckel, Pelton, & Duerig, 2004). A few nitinol valves have been manufactured with locating 
arms, typically formed from the stent tube itself such as in the JenaValveTM (Kempfert et al., 2011) or 
as an additional layer, such as for the Medtronic Engager valve (Falk et al., 2011) and the JC Medical 
J-Valve (Zhu, Hu, Meng, & Guo, 2015). No investigators have reported the use of locating arms on a
primarily balloon-expandable valve, or indeed a stent that incorporates balloon-expandable and self-
expanding elements on the same stent, using either different or identical materials.
Design 2 stents integrated the crown shape into the stent structure, so struts connected to the crown 
member at the top (commissure), bottom (nadir) and at two regions along the crown with 
approximately equal spacing around the circumference. The design offered the potential to anchor 
without the addition of arms on the outside of the stent. Integration of a crown shape within the stent 
structure has been implemented in some stents constructed from nitinol wire (Cai et al., 2013; 
Rahmani et al., 2016; Wu et al., 2016) and, in the case of the JenaValveTM, included a nearly crown-
shaped member in a laser-cut nitinol stent (Rudolph & Baldus, 2013). To our knowledge, no reports 
on the integration of a crown member into a balloon-expandable stent have been presented. The use 
of elements that protrude as a result of stent expansion has been reported by M. Young et al. (2012) 
for a mitral valve stent. Stents were produced at a diameter intermediate between the compressed 
and expanded diameters, and a “wing anchoring fixation system” was able to remain flush with the 
stent during crimping, but (due to geometric configuration and indentations) expanded more during 
deployment. Although the authors report the use of cobalt chromium for the stents, the expansion is 
caused by a particular geometric shape and would therefore undergo the same shape change even if 
the stent were constructed from nitinol. In the case of Design 2, however, the expansion of the arms 
is intended to occur because plastic deformation occurs in the arm. The plastic deformation and work 
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hardening ensure that the arm has higher strength, which means that it requires less energy for the 
arms to protrude outwards than for the arms to return to their pre-crimped state. The stent can be 
also be constructed at the functional diameter, which overcomes the deformation that occurs if the 
stent needs to be expanded from an intermediate geometry first (Kemp et al., 2013). Design 1 arms 
require a sheath to constrain the arms until ready for release, but Design 2 may be used without a 
sheath.  
The material chosen for both stents was MP35N, for which the properties of high Young’s Modulus, 
high UTS and elongation to failure, and relatively low yield strength make it very suitable for balloon-
expandable valve construction. The stent could also have been constructed from L605, which is more 
frequently used in the construction of coronary stents (Suttorp et al., 2015). These Co-Cr alloys are 
durable and have history as haemocompatible materials. Valve heights (22.9 mm and 19.3 mm for 
Design 1 and Design 2, respectively) were slightly higher than an Edwards Sapien 3™ stent (17.9 mm), 
in part to accommodate higher leaflets and in part to provide sufficient crown support at the inflow 
and outflow ends of the stent. The heights of the new stents were much shorter than the height of 
the Medtronic Corevalve Evolut valve (45 mm) (Zavalloni, De Benedictis, Pagnotta, Scrocca, & 
Presbitero, 2014). Metal-to-artery ratios were 10.3 % and 12.1% for Design 1 and Design 2, 
respectively, which were lower than the 14.6 % for the Control stent. Although high metal-to-tissue 
ratios have generally been viewed as harmful due to increased foreign body response (R. Hoffmann & 
Mintz, 2000), a certain amount of scaffolding support is required to prevent tissue prolapse and 
therefore reduce cross-sectional lumen area. The surface area ratios for the novel stent designs were 
below 25% and therefore considered acceptable.  
The ideal position for the new valves is with the nadir of the replacement valve at the level of the basal 
ring or slightly above. Under the former conditions, Design 1 extends 15.7 mm above and 7.2 mm 
below the basal plane and Design 2 extends 14.1 mm above and 5.2 mm below the basal plane. These 
dimensions ensure that the stent does not contact the interventricular septum at the level of the LBB, 
which is approximately 12mm below the basal plane, thereby reducing the risk of conduction 
disturbances (Atkinson et al., 2016). Valve dimensions also ensure that the outflow end of the 
replacement valve is at the same level or slightly below the level of the native valve commissures in 
AS and normal anatomy and therefore will not be contact the wall of the ascending aorta above the 
SoV. (Akhtar et al., 2009; Calleja et al., 2013). The valves will therefore be unlikely to jail the coronary 
ostia in most patients and will permit blood flow into the SoV. Calleja et al. (2013) showed that in 
patients with a mean annulus size of 24.2/24.5 mm (normals/AS), the combined mean free edge 
lengths were 94.4 mm and 86.2 mm for normals and AS, respectively, corresponding to 30.0 mm and 
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27.4 mm diameters, respectively. The new replacement valve designs are therefore not expected to 
stretch the native leaflets taut unless the valves are over-sized in diameter by approximately 24% or 
12%, respectively. This may however not hold true for valves affected by RHD as leaflet retraction is a 
notable feature of this disease (Wallby et al., 2013), but no suitable measurement data is yet available 
for such valves. 
The crown geometry forms a continuous attachment site for leaflets. Crown shapes for valve leaflet 
attachment are usually defined by conic or cylindrical sections (Bezuidenhout et al., 2015). We chose 
to define the crown shape using Bézier functions in order to select a shape that provides a compromise 
between peak stent stress and peak leaflet opening and closing stresses. This approach allows the 
selection of optimum geometry, rather than using a preselected fixed mathematical relationship. The 
stent analysis was based on a crown shaped stent member only (without reinforcement), and the 
leaflet analysis was based on simplified lofted leaflet geometry. It is therefore possible that different 
leaflet and stent definitions would have led to the selection of different optimum crown-shaped 
geometry.  
Although design was focused on the development of a 23 mm valve (one of the most frequently 
implanted balloon-expandable valve sizes), the size of the valve may be scaled up or down as 
appropriate by maintaining the ratio of valve height to diameter and repeating the crown optimisation 
study (the 23 mm stent accommodates a 14 mm valve). Strut width would have to increase to maintain 
radial strength at greater diameters if similar wall thickness were used. Since the diameter of the 
native aortic valve increases by approximately 8 mm from the second to the tenth decade of life, a 
balloon-expandable valve would however not accommodate this change in diameter and would need 
subsequent intervention (Kitzman et al., 1988)).  
Design 1 and Design 2 stents allow the valve to be positioned for antegrade or retrograde delivery. 
Both designs satisfy the attribute requirements described in Chapter 3. 
8.2 Stent and Valve Manufacture
Stents were produced using techniques that have become standard in the stent industry, but for which 
the detailed methods are typically protected by companies. A reject rate of approximately 25% at laser 
cutting (due to material protruding outwards during cutting) suggests that optimisation of cutting 
parameters, including laser power, process gas pressure, distance of the nozzle from the part, pulse 
width etc. could result in a more reliable process. All stents that passed inspection after laser cutting 
were successfully descaled and electropolished, suggesting good reliability of these processes.  
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Mean stent dimensions after electropolishing differed by less than 4% from specifications for all 
members, including strut and hairpin widths, and standard deviations were ≤ 15 µm. This was achieved 
through a two-step electropolishing process whereby the first cycle was used to estimate polishing 
rate and the time for the second cycle was adjusted accordingly to achieve the weight predicted from 
the CAD drawings. In general mean strut widths were 3 µm and 9 µm below specification for Design 1 
and Design 2, respectively, while mean hairpin widths were 3 µm and 4 µm above specification, 
respectively. In the absence of cut stent measurements, it is unclear whether these differences were 
due to cut stent geometry or to differences in electropolishing rate at different stent features, but is 
thought to be primarily due to electropolishing, since kerf width was very similar in the longitudinal 
and circumferential directions. It is likely that a small increase in cut strut width and a small decrease 
in cut hairpin width will therefore allow actual mean dimensions to be closer to specifications.  Design 
1 stents appeared to have no dimensional variation across the length or around the circumference of 
the stent. Design 2 showed a slight trend towards thinner struts and hairpins in the top row than in 
the bottom row; more samples will be required to determine whether these differences are 
significant.  
Stent surface quality for outside and inside surfaces compared favourably with stent surface quality 
reported in the literature for cobalt chromium coronary stents (Sojitra et al., 2009). The side surfaces 
created by the cutting path of the laser beam had a waviness that was visible at lower magnifications 
but showed smooth surface under higher magnifications. It is anticipated that this could be improved 
through changes in cutting parameters, but more effectively through increased polishing times. Cut 
stents were intended to have members 30 µm larger than final polished dimensions to allow 15 µm 
to be removed from either side during electropolishing. A higher than anticipated kerf width however 
(average 58 µm compared to predicted 50 µm) resulted in cut dimensions that would be expected to 
be only 22 µm larger than final target dimensions, with only 11 µm removed from each surface. 
Greater cut stent dimensions should allow greater material removal during polishing and therefore 
better side surface quality. Although the manufacturing methods developed in this report were 
sufficient to produce stents of good quality by visual inspection, surface roughness, XPS analysis, 
corrosion and biocompatibility tests may be required to verify acceptable biocompatibility and 
enhance the reaction between the cobalt chromium and the tissue (Aihara, 2009). 
Both stent designs could be used to manufacture polymeric and bioprosthetic valves. The stents could 
be expanded to an inner diameter of 23 mm for placing on spray coating mandrels, although some 
care needed to be taken to avoid longitudinal crushing in Design 1 stents. A slight mismatch between 
the leaflet attachment line on the mould and the crown shape on the stent sometimes occurred, but 
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this was not sufficient to interfere with leaflet function. Both designs permitted the attachment of a 
sealing skirt to the outside surface of the stent crown member and to the bottom rows of struts. Early 
polymer film skirts separated from the bottom of the stent during crimping, but this did not occur for 
the highly flexible electrospun skirts. Both designs had open structures and allowed for leaflets to be 
produced using spray coating, although the arms of Design 2 had to be manually separated by a small 
distance from the crown member to ensure that polymer webs did not form between these members. 
Both stent designs satisfy the manufacturing criteria listed in Chapter 3. 
8.3 Experimental Testing
Both stent designs passed crimping, deployment, recoil and foreshortening requirements. Crimped 
stent lengths were shorter than the maximum 35 mm length specification (to allow the valve to be 
crimped on SATH deployment devices) and stents could be deployed to nominal diameter (23 mm) 
and could be over-expanded by 10% without fracture. Indeed both stents could be dramatically over-
expanded without fracture. Stent over-expansion may be considered by clinicians if paravalvular leak 
is severe or if native valve size is in the zone between to replacement valve sizes (Shivaraju et al., 
2015). It is probable that over-expansion limits will be determined by resulting leaflet function changes 
caused by alterations in crown member geometry and reduced leaflet coaptation rather than due to 
the risk of stent fracture. All stents could be crimped down to 6 mm diameter on commercial balloons, 
but such low diameters were not yet possible on SATH devices. Although stent recoil was greater for 
the two designs than for the Control stent (2.0 to 3.4 % versus 1.9 %), the recoil was lower than the 
maximum specification of 5%. Recoil is of particular clinical importance because high values of recoil 
could result in stents being under-deployed (risking paravalvular leak and stent movement), or could 
necessitate native valve over-expansion, with potential complications such as annular rupture, in 
order to reduce leakage. This inevitable recoil means that sizing for the current replacement valves 
should be done based on systolic measurements, as recommended for Edwards valves, rather than 
diastolic measurements, in order to reduce the risk of migration and leakage. 
In order to compare stent performance to a “standard” design, a Control stent was created based on 
an Edwards Sapien 3TM stent. Stent foreshortening was lower for the new stents than for the Control 
stent. Although foreshortening was over 14% for both designs, the change in length would not affect 
stent location within the anatomy: Design 1 is correctly located by the location arms; Design 2 stent 
deployment demonstrated that the nadir of the replacement valve, which is the most critical 
landmark, did not move relative to the deployment device handle by more than 1 mm during 
deployment. Sapien 3TM valves are deployed in the correct positon by positioning the central balloon 
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marker at the level of the basal plane, despite greater foreshortening of the inflow end of the valve 
(Schymik et al., 2015). In a similar manner, Design 2 would be deployed in the correct position if the 
nadir of the replacement valve is positioned at the basal plane. The areas of commissure attachment 
were constructed from straight members that cannot foreshorten during deployment. Foreshortening 
is therefore considered to be acceptable. 
The Control stent crimped length of 24.2 mm was close to the 24.5 mm length reported for the Sapien 
3TM valve (Wendt et al., 2015). The deployed (recoiled) length of the Control stent was 19.5 mm 
(foreshortening 20%), compared to 18 mm expanded length reported for the Sapien 3TM. The 
difference in deployed stent lengths between the measured Control stent length and the Sapien 3TM 
expanded length may be partially accounted for by the fact that the mean diameter of the Control 
stent after deployment and recoil was 22.4 mm. The original 23 mm diameter corresponds to the 
starting height of 18 mm. Since the valve has five rows of struts, a diameter increase of 0.6 mm results 
in a length reduction of 0.54 mm (because of a change in strut angle). The remaining difference in 
height may be accounted for by the presence of leaflets and skirt material that may provide an extra 
1 mm to the valve diameter and a resultant additional length reduction of 0.98 mm. The shape of the 
Control stent after deployment appeared similar to the shape of the Sapien 3TM stent, with slight 
bottom end flaring and subtle hourglass shape (Schymik et al., 2015). 
For correct valve function, it is important that the crown-shape of the valve returns to its intended 
shape. The deformed shapes of Design 1 and Design 2 were compared to the manufactured shapes 
and were considered to be acceptable for leaflet function (see Figure 7-27), although Design 2 more 
closely approximated the starting shape. Design 1 showed distortion of the crown shape near the 
nadir caused by insufficient ability for struts to extend sufficiently during crimping, which could 
probably be repaired through tweaks in stent design. Both designs showed the ability to resist 
migration when positioned correctly in the aortic valve, resisting axial forces four times higher than 
would be exerted through 100 mmHg diastolic pressure on a 23 mm valve. All stents could be crimped 
with standard crimping devices to 6 mm diameter. In terms of stent crimpability, Designs 1 and 2 
differed appreciably. Design 2 had a wall thickness of 0.47mm, had only one layer of metal in the 
crimped condition and did not have any protruding elements to snag on the native aortic root. Design 
1, on the other hand, had two metal layers, namely a 0.47mm tube-like structure and an additional 
0.44mm wire structure that protruded intentionally in the crimped condition. The protruding struts 
could easily be held down with a removable sheath for delivery.  
Valves produced from both stent designs performed well in a left heart simulator, with mean total 
regurgitant fraction below 6% and mean EOA above 2.0 cm2; these values are well in excess of the ISO 
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minimum performance requirements of 20% and 1.25 cm2, respectively (ISO-5840-3, 2013). Mean 
pressure drop was below 9 mmHg for both valves. This data compares favourably to commercial and 
experimental valves; using the same commercial pulse duplicator system and identical system 
parameters (70 beats per minute, 100 mmHg mean pressure and 5 L/min cardac output), the EOA and 
pressure drop of the Sapien XT valve were 1.7 cm2 and 18 mmHg, respectively (Rahmani et al., 2017). 
A possible reason for apparent improved performance for the current valves is that the investigators 
tested the valves in mock 21 mm aortic roots that included simulated native leaflets, while the current 
valves were tested in a 23mm mock annulus inside a glass aortic root. EOA was significantly greater 
for valves constructed from Design 2 compared to Design 1 (2.03 ± 0.12 vs. 2.38 ± 0.19, p<0.001), but 
the differences may be explained by improvements in leaflet design. Design 1 valves were constructed 
first, using earlier generation leaflet designs while more sophisticated leaflets had been created by 
the time Design 2 was tested in the pulse duplicator and subsequently in animals. Both stents are 
considered to be acceptable for producing valves with good haemodynamic function. Stents were 
demonstrated to be able to function in a high cycle fatigue tester for over 400 million cycles, the target 
based on ISO 5840 requirements. This is the first reported case of a balloon-expandable polymeric 
valve having achieved this milestone. With the exception of a stent with a manufacturing defect that 
had not been detected at spray coating, no stents showed evidence of fatigue fracture. Since durability 
testing was performed on valves and not directly on stents under appropriate physiological loads, 
radial loading on the stent was under-estimated. In addition, since valves were routinely removed 
upon leaflet failure, few valves were subjected to long-term loading. The fatigue testing is 
encouraging, but can only be viewed as anecdotal until thorough stent fatigue testing can be 
performed. Although functional valve performance was not evaluated in the pulse duplicator after 
400 million cycles, valve performance appeared to be satisfactory based on stroboscopic visualisation 
of the valve in the high cycle durability tester. Simulated use testing in artificially pressurised cadaveric 
animal hearts demonstrated proof of concept for both valve designs using intended implant 
techniques. The ability to deliver and deploy the valves was confirmed using fluoroscopy and 
endoscopy.    
Self-locating stents (Design 1) proved to be an effective method of locating and anchoring valves in 
the native aortic root of pigs, as demonstrated through successful leaflet capture in all nine animals in 
which the valves were delivered. The inadvertent piercing of a native leaflet by a location arm in the 
first animal was ascribed to the “learning curve” associated with tactile location of valve position, and 
this case provided the only evidence of valve leakage for this group of animals. The protruding arms 
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allowed clear visibility of valve position under fluoroscopy. Although an animal died before 
deployment could be attempted, the valve was deployed successfully in the remaining eight animals.  
Despite the successes in this group, several challenges were experienced. Firstly, aortic valve 
procedures were typically preceded by experiments with mitral valve intervention by another 
research group in order to maximise the amount of useful data that could be obtained from live 
animals. Secondly, the valve was developed alongside early developments in implant technique, apical 
access ports and balloon catheter technology. The relatively low availability of functional data for the 
self-locating valves was mostly due to physiological changes in the animals over long procedures, or 
procedural complications, particularly related to difficulties with the access port such as blood leakage 
and the introduction of air. Catheter leakage led to valve under-deployment in three animals. Design 
1 was constructed with an open crown-shape structure. In ex vivo and in vivo tests it became apparent 
that the native leaflets sometimes interacted with the replacement leaflets. Although the healthy 
leaflets of pigs did not appear to interfere with polymer or bioprosthetic leaflet behaviour, it is possible 
that the thickened and stiffened leaflets associated with diseased valves would interfere with proper 
replacement leaflet function. 
Expanding arm stents (Design 2) were located within the native valve of pigs using gradations on the 
deployment devices or using fluoroscopic and/or echocardiographic guidance. Since six of the eight 
valves in which implant was attempted were able to anchor within the native aorta of the pigs, it 
appears that self-anchoring using a balloon-expandable stent is feasible. Procedural difficulties meant 
that the valves were not always deployed in the correct position; two valves were deployed too low, 
while another was deployed too high. The stents were visible under fluoroscopy, but a prominent 
radiopaque would be beneficial to indicate more clearly the location of the leaflet nadir. The first of 
the low deployments embolised but the other remained anchored. Echocardiography showed that the 
latter interfered with the anterior leaflet of the mitral valve, although no mitral leaflet damage was 
seen at autopsy. This animal developed ST elevation during deployment that never resolved, and 
paravalvular leakage also occurred. Two additional animals experienced ST segment changes 
indicative of myocardial ischaemia that did resolve. In one of these animals the ST elevation occurred 
during predilatation and during valve deployment. This suggests that the device temporarily occludes 
coronary blood flow when inflated. The valve that had been deployed high shifted into a secure 
position with the valve arms behind the leaflets. Interestingly, some valves that were deployed in the 
correct position also had one or more arms that were positioned behind the native leaflets. This 
suggests that the flexible leaflets are able to slip under the expanding arms during diastole. Although 
this leads to secure anchoring, it has the disadvantage that the native leaflets may interfere with the 
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replacement leaflet motion. A design that encourages such leaflet capture while holding the native 
leaflets away may anchor particularly well.  
The single case of stent embolisation during handling (before deployment) is indicative of insufficient 
stent security. Although stent security is a function of several factors, including the coefficient of 
friction between the balloon and the valve leaflets, the crimping pressure and the handling of the 
valve and delivery system, radial strength of the stent directly impacts on this force. Although valves 
were crimped conservatively with low force to reduce the risk of balloon damage, higher stent radial 
strength will nevertheless improve security. Regurgitation greater than mild occurred in another three 
of the valves. In two of these animals the regurgitation was central. In the first of these cases the cause 
was shown to be due to the entrapment of a leaflet against the roof of the sinus, and this was 
suspected in the second case because the regurgitation resolved after a few minutes. Although a case 
of “frozen leaflet” has been reported clinically (Agostoni, Buijsrogge, & Stella, 2012), the occurrence 
in the current work is associated with the animal model, since the aortic root is shorter in pigs than in 
humans (Reid, 1970). Some difficulties with the interaction between the valve and the deployment 
device were also experienced in this group, notably valve under-deployment, catheter leakage, and 
difficulty in deploying the valve in the correct position. Greater length of the stent below the level of 
the crown nadir will increase the device “landing zone”, hopefully improving positioning.    
The age and weight of pigs in the animal study were chosen to ensure that the native aortic valve 
diameter was 18 to 21 mm, appropriate for a 23 mm replacement valve. Although TOE measurements 
placed the animals substantially within these requirements, measurements based on two-dimensional 
echocardiography are known to under-estimate aortic valve diameter (Tsuneyoshi et al., 2016). Aortic 
annulus diameters were significantly different between the two groups of pigs. This is assumed to be 
due to inter-operator measurement variability, as pigs were sourced from the same supplier and 
weights were similar. In the absence of three-dimensional TOE or CT imaging, fluoroscopy 
measurements prior to implant could help ensure appropriate valve sizing. The selection of slightly 
smaller animals may also be prudent for the evaluation of future stent generations, since pig aortic 
valves are much more compliant than human valves (Li, Wang, Pham, & Sun, 2014). 
8.4 Finite Element Modelling
In order to most efficiently model stent behaviour in this report, two different levels of complexity 
were used in model construction. Simple models based on the use of one-sixth symmetry and an 
expanding cylinder for stent deployment allowed the comparison of eight design alternatives in 
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approximately 10 hours per simulation on an 8 core AMD Opteron computer. Complex models based 
on full 360° geometry and balloon simulation for stent deployment ran for up to 14 days. The complex 
modelling process was demonstrated to be accurate, and therefore a validated model, through 
comparison of predicted and physical geometry (see Figure 8-1), predicted and measured radial 
crushing force (less than 10% difference for all stents), and predicted and measured recoil and 
foreshortening. Absolute predicted recoil percentage differed by ≤ 0.1% and absolute predicted 
foreshortening differed by ≤ 1.1% from experimental values, with the greatest difference occurring 
for the relatively less stable Design 1.  
A nonlinear Ogden material model was used to describe the balloon material for complex modelling, 
based on uniaxial tensile test data. Since rubberlike materials exposed to biaxial stress (such as 
experienced in a thin-walled pressure vessel such as the balloon) often have behaviour that cannot be 
modelled accurately using uniaxial data alone, biaxial test data may have produced a more accurate 
model of balloon behaviour. The close correlation between the experimental and predicted balloon 
diameters, however, suggests that errors introduced through the use of uniaxial data are negligible in 
the present investigation. 
A Hollomon necking model was used to predict stresses beyond the UTS (i.e. during necking), and is a 
method frequently used in metal forming simulation such as for drop-forming (Joun et al., 2007). This 
model provides a more conservative estimate of stent stresses than when perfect plasticity is assumed 
to occur after the UTS. This is the first reported use of a power law in stent FEA. As shown in Appendix 
K, the Hollomon model predicts higher Von Mises and Maximum Principle Stresses while reaction 
forces are unaffected by the model. No validation of necking stress predictions against experimental 
calculations were however attempted in the current work. Unfortunately this model cannot currently 
be used to predict the onset of acute fracture. It would be beneficial to model the stent over-
expansion described above in order to calculate the predicted true fracture strains and stresses. 
Maximum Von Mises stresses predicted from the simple model were similar to the complex model for 
Design 1 (≤ 3.0% difference), while the simple model over-predicted maximum stresses by 13.0% at 
deployment for Design 2, and the location of peak stresses differed between the two models as well. 
The discrepancies are considered to be as a result of differences in deformation behaviour between 
stents deployed using a balloon and using an expanding cylinder. Stents deployed using the balloon 
simulation had a notably more hour-glassed shape than stents deployed using a rigid cylinder, and 
transient behaviour was very different. Balloon configuration has also been found to affect stent 
stresses and the impact on the anatomy (Martin & Boyle, 2013).  
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Although the complex model provided more accurate stent performance predictions (including stress, 
fatigue and deformation), the long run times make it unsuitable for rapid evaluation of design 
alternatives, for which the simple model is well suited. The simple model is limited in its ability to 
predict such behaviour as stent extremity flaring, or buckling across the symmetry planes. Since it was 
typically possible to produce physical prototypes and test crimping and deployment behaviour within 
in a few days, certain design behaviours may be better tested through agile rapid prototype 
manufacture. 
Figure 8-1. Comparison between In Vitro test geometry and FEA geometry for Control (A,B), Design 1 (C,D) and Design 2 
(E,F). The images on the left (A,C,E) show FEA original geometry superimposed over photograph of as-manufactured stent. 





Leaflets are sometimes modelled in TAVR simulations, either indirectly through the application of 
forces on the stent frame (Esterhuyse et al., 2012), or directly through the inclusion of leaflets in the 
original geometry (J. Bailey et al., 2015) or applied after stent deployment (Auricchio, Conti, Morganti, 
et al., 2014). In the latter study the leaflet attachment edge was altered to map onto the stent surface 
prior to the application of pressure loads. The inclusion of leaflets after stent deployment were 
successfully modelled in the current study by attaching the leaflet to the deformed stent geometry 
using tie constraints and appropriate position tolerances. 
The radial strength predicted for Design 2 under free loading conditions (116 N) was higher than the 
radial strength predicted for the SapienTM stent (88 N) by Tzamtzis et al. (2013), but it was lower than 
the radial strength predicted for the Control stent (347 N). No comparative radial strength 
measurements or predictions could be found for the Sapien 3TM. A Stress/Life method of fatigue 
analysis suggested that Design 2 stents were safe from fatigue failure, although no safety factor could 
be applied. A safety factor of 2 on the control stent suggests that Design 2 is twice as likely to fail in 
fatigue as the Control stent under the same loading conditions. This is due in part to the high residual 
stresses in the stent following recoil and to the lower radial strength of Design 2 compared to the 
Control stent, which would reduce the alternating stresses. An increase in radial strength is proposed 
for the stent, together with fatigue-focused geometric optimisation. Design 1 was particularly 
vulnerable to fatigue failure because mean stresses exceeded the true UTS of the material and 
therefore necessarily exceeded Goodman criteria, although no formal analysis was done on Design 2 
due to time constraints. 
In this report stent designs were evaluated through free crimping and deployment, without simulation 
of the aortic root. This was done in order to effectively compare the performance of competing 
designs. Patient-specific models of a preferred stent will be required to more accurately predict the 
behaviour of stents in relevant anatomy (Bosi et al., 2015; Morganti et al., 2015; Ovcharenko et al., 
2016; Schultz et al., 2016). An early version of Design 1 (specifically Concept 1A) has been subjected 
to patient-specific modelling (Shirzadi, 2016), where the susceptibility to stent migration was 
demonstrated, but for which fatigue analysis was not performed. 
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9 Conclusions and Recommendations
Novel compressible stents were developed for the manufacture of a polymeric balloon-expandable 
polymeric TAVR, capable of anchoring in an aortic root in the absence of calcification.  Designs 
successfully incorporated a crown shape into the balloon-expandable frame to allow for continuous 
attachment of polymeric leaflets. Two different novel mechanisms were developed, and proof of 
concept obtained, for anchoring the valve into a compliant aortic root. The first of these involved the 
use of annealed cobalt chromium stent frame to which a cold-worked wire member of the same 
material was welded. This combination allowed a stent to be constructed from a single material but 
nevertheless incorporated balloon-expandable and self-expanding elements. It further provided a 
location mechanism to ensure correct positioning within the anatomy. The second concept involved 
the use of elements in the stent frame that deform plastically during crimping, to cause an outward 
protrusion of anchoring arms during stent expansion, in order to secure the stent above the base of 
the native leaflets.  
It was shown that the stents could be manufactured through laser cutting, descaling and 
electropolishing and had good surface quality and dimensions were within specifications. The stents 
also facilitated manufacture of polymeric valves through spray coating. 
Satisfaction of engineering requirements was demonstrated through in vitro, ex vivo and in vivo 
testing. Stent mechanical properties such as recoil, foreshortening and the ability to crimp and deploy 
as required were shown to be acceptable, and valves manufactured from the stents exceeded the 
haemodynamic requirements of international standards. Stents were shown to be able to anchor 
securely in explanted aortic root xenografts and in explanted hearts through simulated use testing. 
Implantation of valves in an acute termination porcine model demonstrated proof of concept for both 
stent designs.  
FEA proved to be a powerful technique to aid in concept selection, characterise deformed geometry 
and quantify stresses. Simulations matched experimental results closely, and provided a tool to 
estimate fatigue resistance. Despite the demonstration that stent requirements were satisfied in 
general, physical testing and numerical simulation highlighted aspects of stent design that could be 
further improved.  
While self-locating stents performed well in experiments, further valve development will align with 
the goal to deliver and deploy valves on deployment devices that employ location members. 
Expanding arm (self-anchoring) stents promise to provide the basis for this strategy. Further animal 
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studies will need to be performed once design changes have been made to demonstrate consistently 
reliable device performance. 
9.1 Limitations
The lack of sufficiently powered numbers of animals in preclinical studies is a significant limitation in 
terms of device safety and efficacy. For this project, however, the goal of initial preclinical trials was 
to demonstrate proof of concept, which has been done. Furthermore, the valves described in this 
paper were being developed simultaneously with the development of the delivery system, meaning 
that failures in the delivery system and difficulties deploying the valves in the correct position 
interfered with the ability to judge valve performance. No dedicated stent fatigue testing was 
performed. Such testing needs to be performed in a compliant tube to adequately simulate 
physiological loading. Several aspects of stent and valve performance were tested on one or only a 
few samples. True verification of stent performance will require greater numbers of samples. 
Simulation results should be interpreted within the context of possible limitations of the modelling in 
this thesis. Concepts were compared to each other during free deployment of the stents. This means 
that the effects of aortic root geometry and physiology, including the effects of fibrous thickening and 
calcification, are not considered. It is possible that such conditions may have favoured one of the 
concepts over another or led to specific design changes.  
A sensitivity study was used to select a stent crown shape that would minimise stent and leaflet 
stresses. This study was however performed using simple stent crown and leaflet geometry. Results 
may differ for more complex stent geometries and the complex interaction between the leaflet and 
the stent. An extensive stent and leaflet combination study may yield different optimum geometry 
but will require considerable computing resources and are anticipated to yield similar geometry. 
9.2 Recommendations
Based on the experimental and numerical results in this report, the following design improvements 
are recommended for Design 2: 
 An additional row of struts below the nadir is recommended to provide a larger “landing zone”.
In vivo animal testing demonstrated that the area below the nadir of the stent was too short to
provide reliable coverage.
 The stent should be also be provided with a radiopaque marker at the crown. Tantalum wire was
purchased for this purpose. While animal studies showed that the stent crown was basically
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visible, orientation of the valve was time-consuming and valves were occasionally deployed in 
the wrong position.  
 Stent struts should be made wider to increase radial strength. Higher radial strength is expected
to reduce the susceptibility of stents to slip off balloons, and is expected to improve fatigue
resistance. The crown should also be made wider to more reliably align the polymer valve
manufacturing mandrels with the crown of the stent. It is also anticipated that this would allow
the crown to more closely form the correct shape upon deployment.
 Linkage elements that attach near the bottom of the crown should be curved slightly and should
attach to the crown at a shallower angle to reduce the extensive deformation that occurs during
crimping and expansion and hence high stresses. Larger radii are also recommended to reduce
stress concentrations.
 A mechanism to increase the distance by which the stent arms protrude is also recommended.
This may be achieved by moving the point at which the attachment arms attach to the stent
from the crown member itself to the centre of the first strut connected to the commissure post.
It is also proposed that more than one set of arms should be included above the crowns, to
allow the uppermost arms to latch over the native leaflet free edge while the bottommost arm
rests on the VAJ.
For stent manufacturing, it is recommended that that cut stent geometry be made larger such that 
more material may be removed during electropolishing and a better surface quality on the side of 
stent struts may be achieved. To ensure all stent elements are as close as possible to their intended 
dimensions, material should preferentially be added to the cut stent in the straight portion of struts.   
Several procedural and species-specific challenges were faced during animal trials. Porcine aortic roots 
are far more compliant than aged human aortic roots (Li et al., 2014), so it is recommended to over-
inflate substantially more than has been done in animal studies by using younger animals. 
Echocardiographic measurements of aortic annulus size should be supplemented using fluoroscopic 
measurements to ensure correct valve sizing. While deployment device performance is being refined, 
it may be prudent to consider using commercial valvuloplasty balloons in animal trials to ensure full 
deployment of replacement valves.  
Once design refinements have been made and analysed using the simple and complex approaches 
developed in this thesis, it is recommended that valve deployment should be simulated in various 
patient-specific models that include detailed fatigue analysis. 
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The following patent applications have been submitted based on the work presented in this thesis: 
 WO 2014/170870 
US 2016/0067038 
“A Prosthetic Heart Valve” 
 GB 2513195 A “A Stent for a Prosthetic Heart Valve” 
 GB 2513194 A “A Valve” 
9.3.2 Congresses and Presentations
Park, K., Appa, H., Scherman, J., Conradie, D., Coetzee, J., de Villiers, J., Geldenhuys, G., Williams, D., 
Zilla, P., Bezuidenhout, D. (2014). Transcatheter aortic heart valves for rheumatic heart valve disease. 
Surgical Research Day, University of Cape Town, Cape Town, 28 November 2014. 
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 Comprehensive list of transcatheter valves
Appendix Table A-1. Balloon Expandable Valves 
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Appendix Table A-2. Self-expanding bioprosthetic valves without orientation
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Appendix Table A-4. Alternative valve technologies 
Appendix Table A-5. Adjunct Devices 
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Appendix Table A-7. Nitinol valves for minimally invasive surgery 
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Characterisation of stents
Appendix Figure B-1. Categorisation of stents based on form, material, geometry and method of fabrication 




The accuracy of a finite element solution is linked to the size of the mesh used. As the element size 
approaches zero, the accuracy of the solution to the finite element equations approaches the exact 
solution. Finer meshes require additional computational cost, so a mesh refinement study is required 
to establish the trade-off between the accuracy of the approximation and the computational 
resources. Mesh refinement studies were therefore performed to determine the level of refinement 
required to accurately represent stress, strains and displacements in a typical valve stent at reasonable 
computational cost. Studies were performed on a portion of a Control stent.  
Methods
Two struts were used to model a representative portion of the Control stent. Although axial and 
longitudinal symmetry were used to simplify the model, two struts were included to ensure there 
were no erroneous edge effects associated with the symmetry assumptions. An image of the struts is 
provided in Appendix Figure C-1, which illustrates where symmetry boundary conditions were applied, 
defines major parts of the stent, and shows where the geometry was typically partitioned. Semi-rigid 
cylinders, shown in Appendix Figure C-2, were used to crimp and expand the stent. The expansion 
cylinder was meshed using 63 linear quadrilateral (S4R) shell elements, while the crimping cylinder 
was compressed using 364 elements.  
Appendix Figure C-1. Control stent struts used for mesh refinement study 
Symmetry boundary conditions 





Appendix Figure C-2. Crimping and expansion cylinders 
Stents were subjected to crimping, relaxation, expansion, relaxation and pressurisation steps similar 
to those described in Chapter 4; similarly contact definitions and material definitions have been 
described and are not repeated here.  Stent geometry was partitioned to demarcate distinct parts of 
the stent, defined here as the strut, which is the straight or near-straight portion of the stent, the 
hairpin, which arch-shaped end of the struts, the transition curve, which is the curved area joining the 
strut to the hairpin, and the link, which joins two rings of struts to each other. Thickness corresponds 
to tubing wall thickness, while width and length refer to measurements on the outer surface of the 
stent. 
Four different levels of mesh refinement were modelled, labelled Coarse, Medium, Fine and Superfine. 
Stents were meshed using 8-noded linear brick elements with reduced integration and hourglass 
control (C3D8R). Each level of refinement used different numbers of elements along the strut 
thickness, strut width, strut length, transition curve length, hairpin inside radius length, hairpin outside 
radius length, hairpin depth and link width. These are illustrated in Appendix Table C-1. For all 
parameters elements were evenly distributed, except for strut length, which was given a double bias 
of 4 to ensure areas with most bending had a more refined mesh. Strut width typically had more 
elements than strut thickness since bending in a circumferential direction dominates. 






ElementsMesh Thick Width Length* Inside Outside Depth
Coarse 2 2 6 2 4 2 4 1 184 
Medium 4 5 12 4 8 7 8 2 1888 
Fine 8 10 24 8 16 14 16 4 15160 
Superfine 16 20 48 16 32 28 32 8 118784 
* Elements along strut length were given a double bias of 4 so that mesh was finer at each end.























Appendix Figure C-3. Four levels of mesh refinement 
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Results
The critical Von Mises Stress at the end of the expansion step, the critical Maximum Principle Stress 
at the end of the expansion step and at the end of the relaxation step, and the maximum magnitude 
of displacement and the end of expansion are shown in Appendix Figure C-4, normalised with respect 
to the values of the Superfine model for each parameter. The computational cost is reflected in the 
total number of variables for each model, shown in Appendix Figure C-5. 
Appendix Figure C-4. Critical nodal Von Mises Stress, Critical Maximum Principle Stress and Displacement Magnitude for 
each level of mesh refinement, normalised by the Superfine value 
Appendix Figure C-5. Total number of variables for each level of mesh refinement 
The Von Mises Stress in the stent, as determined with a Medium mesh and a Superfine mesh are 
compared in the contour plot in Appendix Figure C-6. The magnitude of Von Mises Stress are higher 
in the Superfine mesh model, but stress distribution is similar for both levels of meshing. 
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Appendix Figure C-6. Contour plots of Von Mises stress for Superfine (top) and Medium (bottom) meshes 
Discussion
Stresses and displacements are under-estimated for coarse, medium and fine meshes. 
A coarse mesh predicts maximum displacement to within 89% of the value for the Superfine mesh, 
but stresses are less than 60% of the Superfine values. 
A medium mesh offered an acceptable compromise. The maximum displacement was 93% of the 
accurate displacement, which is an error of only 43 µm. Although the crucial Von Mises and Maximum 
Principle Stresses at the end of expansion were 83% and 84% of the accurate values, respectively, the 
residual Maximum Principle Stress after relaxation was 93% of the accurate value. This is considered 
more important because of the implications for fatigue analysis. 
C-6
A fine mesh offered a small improvement in accuracy for Von Mises and Maximum Principle Stresses 
at the end of expansion, but offered no significant advantage for residual (relaxed) Maximum Principle 
Stress or peak displacement, despite a five-fold increase in the number of variables compared to the 
Medium mesh (and ten-fold compared to the coarse mesh). For the superfine mesh the cost is 
extremely high, with 63 times the number of variables compared to the coarse mesh. Incompatible 
mode elements are frequently used for FEA modelling of stents. An attempt was made to include 
incompatible mode elements (C3D8I) in the mesh refinement study, but numerical instabilities were 
seen consistently across all levels of refinement. This is illustrated in Appendix Figure C-7, which shows 
a singularity in the Maximum Principle Stress at the end of the crimping step. The instability is also 
evident (see Appendix Figure C-8) when plotting the stress at the node in the bottom right corner of 
Appendix Figure C-7. This is discussed further in the body of this report.  
Appendix Figure C-7. Contour plot (sectioned) of Maximum Principle Stress at the end of the crimping step, showing 
singularities with stress up to 11450 MPa for incompatible mode elements 





Stent tube rotation eccentricity was reduced by measuring using a dial gauge, as shown in Appendix 
Figure D-1) and adjusting tube position accordingly. 
Appendix Figure D-1.  Method of measuring eccentricity in tube rotation 
Kerf width was measured by making axial and circumferential cuts in the tubing (Appendix Figure D-2), 
photographing under a calibrated metallurgical microscope and measuring digitally (kerf width 
measurements are shown in Appendix Table D-1). 
Appendix Figure D-2.  Kerf width measurement – example images 




1 2 3 4 5
Longitudinal 60.0 60.6 56.9 54.7 53.8 57 ± 3 
Circumferential 56.4 58.5 60.6 59 ± 2 
Acid Descaling
Acid descaling of stainless steels, nickel-cobalt or cobalt-chromium alloys is frequently performed 
using mixtures of nitric (5-25%) and hydrofluoric (1-3%) acids (Sojitra et al., 2009). Hydrofluoric acid 
D-2
(HF) is a strong reducing agent that reduces the oxide scale present, but also reduces the protective 
oxide layer on the base material of the stent. Nitric acid on the other hand is an oxidising agent and 
serves to preserve the protective oxide layer and therefore effectively inhibits the attack by the 
hydrofluoric acid on the base metal (AISI, 1988). An ideal pickling process removes oxide scale while 
preserving the base metal. 
Stents were observed to have light oxide scale on the outside surfaces, heavy oxide scale on the laser-
cut surfaces, and a build-up of oxide-rich scale and dross on the inside surface, even after removing 
burrs mechanically. Initial attempts to perform pickling using different concentrations of hydrofluoric 
acid (0.5% to 3%) and nitric acid (5% to 20%) were not considered optimal. High concentrations of 
hydrofluoric acid (up to 3%) tended to attack the base material aggressively, while lower 
concentrations tended to be ineffective at removing oxides even after several hours of pickling. Two 
changes were made to the HF/Nitric acid mixtures to improve pickling. Firstly the HF was replaced by 
an aqueous ammonium bifluoride solution (a common alternative to HF in pickling solutions) in order 
to allow safer storage and mixing of chemicals. Secondly, since sulphuric acid has been shown to be 
an effective first step in multi-step pickling processes (Homjabok, Permpoon, & Lothongkum, 2010), 
sulphuric acid was also added to the solution. 
A mixture of sulphuric acid, nitric acid, ammonium bifluoride and deionised water was therefore used 
for pickling, in the mass ratio 22:7:15:55. This solution proved to be effective at removing oxides 
without aggressive base metal attack. 
Polishing
Several different electrolytes were identified from academic and commercial literature for cobalt 
chromium and chromium-rich alloys; these are shown in Appendix Table D-2. Informal exploratory 
tests were conducted on short diamond-mesh rings7 (to simulate a stent) using the electrolytes and 
parameters described in the table, except for electrolytes consisting of perchloric acid (due to safety 
concerns) or those requiring active cooling (to simplify the process). Although all electrolytes polished 
the rings to some degree, the electrolyte used by Surmann and Huser (1998) gave the best surface 
appearance by visual estimation and was therefore used for stent polishing; this electrolyte consisted 
of 10% Sulphuric Acid, 5% Hydrochloric acid and 85% Glycol by volume. 
7 Initial electropolishing experiments were not exhaustive as electrolyte comparison was not a goal of this thesis project; they were merely 
used to select an effective electrolyte to produce stents with good surface quality. Unless specifically stated otherwise in the references 
provided, temperatures of 70°C and currents of 3A were used.
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Appendix Table D-2. Electrolytes used by other investigators 
Investigators Material Electrolyte Temperature,
parameters 
Aihara (2009) L605 Phosphoric acid (85%, 50% or 15%) 0°C to 45°C 
Surmann and Huser 
(1998) 





25% perchloric acid and 75% acetic acid 30°C, 25V 
Piesslinger-Schweiger 
and Bohme (2011) 
Cobalt and 
Cobalt Alloys 
55% methanesulfonic acid and 45% glycolic acid 40°C to 70°C 
Ishmaku and Han (2004) MP35N discs 19% sulphuric acid, 76% methanol and 5% phosphoric 
acid 
3°C to 5°C, 28-
32mA 
Shih, Shih, Chou, Lin, and 
Su (2006) 
MP35N wire 80% phosphoric acid and 20% glycerine 65°C, 10Acm-2, 30s 
Lee and Li (2003) 316L Sulphuric acid, phosphoric acid, glycerine and 
deionised water.  
60°C 
Kosmac (2010) Stainless 
steels 
50% sulphuric acid and 50% orthophosphoric acid 40°C to 75°C, 
5Adm-2 to 5Adm-2 
Kang and Lee [17] 316L 34% phosphoric acid, 47% glycerol and 19% water (by 
weight) 
3 min. at 1 Acm-2 
Haïdopoulos, Turgeon, 
Sarra-Bournet, Laroche, 
and Mantovani (2006) 
316 35% phosphoric acid, 50% glycerol, and 15% water 
(v/v) 
0.75 A.cm 1, 20°C 
to 90°C 
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Stent measurements – additional information
Measurement of Control Stent
Stent measurement locations for the Control stent are provided in Appendix Figure E-1, and mean (± 
standard deviations) of measurements for this stent are provided in Appendix Table E-1. 
Appendix Figure E-1. Control stent measurement points 
Appendix Table E-1. Mean Control stent measurements 
Region Specification Value (µm) Diff (µm) % Diff
Strut 
350 µm 
350 ± 10 0 0.0 
Top strut (1,2) 349 ± 9 1 0.2 
Bottom strut (5,6) 351 ± 11 -1 -0.2
Strut first sector 352 ± 11 -2 -0.7
Strut second sector 349 ± 12 1 0.3 
Strut third sector 348 ± 7 2 0.5 
Hairpin 
450 µm 
462 ± 11 -12 -2.6
Top hairpin (3,4) 459 ± 13 -9 -2.0
Bottom hairpin (7,8) 465 ± 9 -15 -3.3
Vertical long member (9) 300 µm 298 ± 6 2 0.7 
Vertical short member (10) 300 µm 304 ± 4 -4 -1.3
Wall thickness 470 µm 465 ± 5 5 1.0 
Individual Stent Measurements for All Designs
Individual measurements performed on three of each design, including the Control stent, are shown 























refers to the second sector and the strut numbered “1” within the sector. Location of these member 
numbers may be found in Figure 7-23, Figure 7-24 and Appendix Table E-1. 
Appendix Table E-2. Individual stent measurements (in µm)
Control Design 1 Design 2
Stent 1 2 3 Stent 1 2 3 Stent 1 2 3
#1-1 354 358 351 #1-1 555 547 549 #1-1 580 597 593 
#1-2 332 365 340 #1-2 232 244 250 #1-2 280 272 275 
#1-3 464 467 457 #1-3 247 243 260 #1-3 283 266 276 
#1-4 434 471 461 #1-4 252 244 261 #1-4 302 297 301 
#1-5 361 363 344 #1-5 100 100 105 #1-5 272 296 281 
#1-6 352 366 344 #1-6 268 266 269 #1-6 287 274 293 
#1-7 467 467 452 #1-7 267 251 255 #1-7 284 293 285 
#1-8 467 477 458 #1-8 227 240 233 #1-8 296 294 300 
#1-9 292 304 298 #1-9 215 195 212 #1-9 300 289 298 
#1-10 307 299 305 #1-10 323 323 334 #1-10 300 294 299 
#2-1 352 358 359 #1-11 334 330 339 #1-11 430 425 434 
#2-2 333 360 343 #1-12 328 324 333 #2-2 275 277 284 
#2-5 336 359 346 #1-13 329 323 336 #2-3 276 274 275 
#2-6 349 364 328 #2-2 244 247 254 #2-5 276 269 280 
#3-1 339 348 352 #2-3 236 252 244 #2-6 294 287 298 
#3-2 352 348 342 #2-7 263 263 262 #3-2 282 - 283 
#3-5 361 348 343 #2-8 231 239 236 #3-3 284 279 281 
#3-6 354 353 339 #3-2 252 235 250 #3-5 273 266 288 
Thick 466 460 470 #3-3 259 242 249 #3-6 300 289 298 
#3-7 266 256 265 Thick 454 458 443 
#3-8 221 233 241 
Thick 469 457 471 
Measurement Definitions
Appendix Figure E-2. Measurement Definitions 
E-3
Measurement definitions are shown in Appendix Figure E-2. Typical microscopy images used for the 
measurement of stent members is shown in Appendix Figure E-3. 
Appendix Figure E-3. Typical images used for measurements of stent members 
Graticule Commissure Post Strut
Hairpin Hinge Branch 
Arm Crown Vertical Member
F-1
Dogbone for materials testing
To determine the material properties of MP35N, tensile dogbone (dumbbell) specimens were laser 
cut from the stent tubing with the following dimensions. 
Appendix Figure F-1. Dogbone drawing 
Multiple dogbones were cut (cutting geometry shown below) and three random samples were taken 
for tensile testing. 
Appendix Figure F-2. Dogbone laser cutting geometry 
One of the dogbones was sectioned for cross-sectional area measurement, as shown below. The 
cross-sectional strut area was 0.277 mm2. 
Appendix Figure F-3. Images used to measure dogbone cross-sectional area
Area = 0.277 mm2 
G-1
Stent origins, concepts and structures: the fuzzy front end
Stent concepts evolved from simple cylindrical designs to the more complex designs summarised in 
this thesis. In order to make rapid design changes as part of an agile design process, several 
manufacturing methods were used during early stent concept development. This appendix presents 
some of the original concepts and some concepts that did not progress to the prototyping stage. These 
early prototypes were handled, used to make valves, shown to surgeons and the sponsor and served 
as a base for the development described in the body of this report. 
Sheet metal stent 
The first stent prototypes were constructed from laser-cut 316 stainless steel and had 
very simple diamond mesh designs. Stents were laser cut by a nearby sheet metal 
company and cost approximately US$5 for 20 stents. The stents were curved into a 
cylindrical shape and the ends were brazed together. These prototypes only helped 
determine some of the parameters important for polymer valve manufacture. 
First additive manufacturing stent 
The next stent prototypes were constructed from titanium by selective laser melting 
(“lasercusing”). These stents were more reliable and accurate than sheet metal stents 
but still could not be used to construct a stent that could be crimped from 23mm to 
6mm without breaking, even after annealing. Surface roughness was also a problem 
when attaching polymer leaflets. 
First laser cut full-size stents 
The first prototype stents to be laser cut and electropolished were constructed with 
a structure similar to traditional balloon-expandable stents. Radial strength was 
designed to be similar to the Edwards Sapien XT valve. Valve height was 16.5mm to 
accommodate a 14mm polymeric valve of 14mm height and allow space below the 
leaflets for a skirt. Three posts also allowed the stent to be used for early 
bioprosthetic valve manufacture. For these prototypes the laser cutting and 
electropolishing was outsourced to MeKo (Sarstedt, Germany) as a laser cutting 
machine had not yet been procured and electropolishing methods had not yet been 
developed. 
Miniature prototypes 
The limitations of diamond mesh “chicken fence” designs became clear during early 
valve manufacture and testing, so various concepts were generated based on the 
incorporation of a crown shape. A local coronary stent manufacturer, DISA Vascular 
(Pty) Ltd., kindly manufactured miniature versions of stent crown support members 
out of 1.8mm outer diameter L605 tubing. 
Crown-shaped stents - Lasercusing 
The first crown-based stents of appropriate size were created for testing. These 
designs, including those shown here, were prototyped using additive manufacturing 
techniques. A) The first design consisted of a crown shape with zig-zag struts at inflow 
and outflow ends. B) Various shapes of the crown were developed to improve 
crimping and expansion behaviour, including changes in crown width. C) Crown 
shapes with different angles at the commissure posts were developed in an attempt 
to lower leaflet stresses at this point. Crown-shaped stents without structures 
connecting the top row to the bottom row were susceptible to longitudinal 
shortening during valve loading, so designs such as D) were created to provide 
longitudinal support. E) Instability in a single row of zig-zags was solved by 
incorporating a double row at the outflow end. D) was also laser cut by MeKo and 
used to evaluate the ability to spray coat polymeric valves.   
Alternative Connector Mechanisms 
Several alternatives to connect the top row of struts to the bottom row were 
attempted.  
G-2
Different starting diameter 
An attempt was made to produce 23mm valves from 20mm tubing. Although this 




 FEA results of stent crimping and deployment
The figures below show the Control stent, Design 1 and Design 2 at various stages of simulation. 
Appendix Figure H-1.  Stent shape changes over the analysis for Control stent. A) Crimped (original & deformed), B) 
Relaxed, C) 25% deployed, corresponding to approx. 0.4 atm, D) 50% deployed, E) 75% deployed, corresponding to approx. 








Appendix Figure H-2.  Stent shape changes over the analysis for Design 1 stent. A) Crimped (original & deformed), B) 
Relaxed, C) 25% deployed, corresponding to approx. 0.4 atm, D) 50% deployed, E) 75% deployed, corresponding to approx. 








Appendix Figure H-3.  Stent shape changes over the analysis for Design 2 stent. A) Crimped (original & deformed), B) 
Relaxed, C) 25% deployed, corresponding to approx. 0.4 atm, D) 50% deployed, E) 75% deployed, corresponding to approx. 










Microscopic, microscopic and SEM images of cut, descaled and electropolished stents for Control, 
Design 1 and Design 2 stents are shown in the figures below. 
Appendix Figure I-1.  Macro photographs of Design 1 after a) laser cutting, b) descaling and c) electropolishing 
Appendix Figure I-2.  Microscopic images of Design 1 after a) laser cutting, b) descaling and c) electropolishing 
Appendix Figure I-3.  SEM images of Design 1 after a) laser cutting, b) descaling and c) electropolishing 
I-2
Appendix Figure I-4.  Macro photographs of Design 2 after a) laser cutting, b) descaling and c) electropolishing 
Appendix Figure I-5.  Microscopic images of Design 2 after a) laser cutting, b) descaling and c) electropolishing 
Appendix Figure I-6.  SEM images of Design 2 after a) laser cutting, b) descaling and c) electropolishing 
I-3
Appendix Figure I-7.  Macro photographs of Control stent after a) descaling and b) electropolishing 
Appendix Figure I-8.  Microscopic images of Control after a) laser cutting, b) descaling and c) electropolishing 
Appendix Figure I-9.  SEM images of Control after a) laser cutting, b) descaling and c) electropolishing 
J-4
 Detailed predictions and measurements of stent recoil and
foreshortening
Recoil
Detailed stent diameter and recoil predictions from FEA are shown in Appendix Table J-1. Detailed 
experimental measurements of diameter and recoil are shown in Appendix Table J-2. 















Top 6.00 6.65 10.8 22.62 22.22 1.8 
Middle 6.00 6.66 11.0 21.23 20.72 2.4 
Bottom 6.00 6.65 10.8 23.08 22.71 1.6 
Design 1 
Top 6.00 6.77 12.8 23.50 22.71 3.4 
Middle 6.00 6.28 4.7 23.15 22.14 4.4 
Bottom 6.00 6.65 10.8 23.30 22.76 2.3 
Design 2 
Top 5.75 6.13 6.2 23.25 22.75 2.2 
Middle 6.00 6.41 6.8 22.16 21.74 1.9 
Bottom 5.87 6.33 7.8 23.72 23.32 1.7 















Top Could 6.55 Could 22.96 22.55 1.8 
Middle not 6.71 not 21.17 20.66 2.4 
Bottom measure 6.59 calculate 23.01 22.69 1.4 
Design 1 
Top Could 6.50 Could 23.38 22.67 3.0 
Middle not 5.87 not 23.48 22.50 4.2 
Bottom measure 6.50 calculate 23.54 22.85 2.9 
Design 2 
Top Could 6.19 Could 23.39 22.86 2.3 
Middle not 6.49 not 22.36 21.92 2.0 
Bottom measure 6.35 calculate 24.12 23.74 1.6 
The amount of arm protrusion following deployment as also measured physically for each arm as the 
distance from the arm extremity to the opposite outside wall of the stent. These arm protrusions were 
measured to be 24.63 mm, 25.02 mm and 24.99 mm for Design 1, and 25.00 mm, 24.73 mm and 24.72 
mm for Design 2. 
Foreshortening
Detailed stent length and foreshortening predictions from FEA are shown in Appendix Table J-3. 
Detailed experimental measurements of length and foreshortening are shown in Appendix Table J-4. 
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Control 24.36 24.32 19.24 19.53 19.7 
Design 1 29.43 29.44 24.18 24.77 15.9 
Design 2 25.54 25.51 20.58 20.92 18.0 









Control 24.19 19.16 19.45 19.6 
Design 1 29.32 24.28 24.97 14.8 
Design 2 25.39 20.46 20.73 18.4 
K-1
Hollomon material model
A Hollomon power law was used to model stress-strain behaviour beyond the point of necking. In 
order to determine whether stent stress and radial strength were affected by the use of this model, a 
Design 2 stent was subjected to modelling using the simple FEA described in Section 4.2, followed by 
crushing described in Section 4.3.  
Two material models were used. The first material model used stress-strain behaviour up to 1330 
MPa, near the true stress value of UTS. In this model the stress is assumed to stay constant after 
necking. The second material model used stress-strain behaviour extrapolated to 200% strain (2508 
MPa stress) using the power law. 
The Hollomon material model predicted higher stresses than the UTS model, for Von Mises Stress and 
Maximum Principal Stress (see Appendix Table K-1). Radial strength did not differ between the two 
material models, as shown in Appendix Figure K-1.  
Appendix Table K-1. Stress stresses for different material models 
Material model
Highest Stress (MPa)
Von Mises Max Principal
UTS 1330 1936 
Hollomon 1954 2527 
Appendix Figure K-1. Radial strength of Design 2 stents as predicted using simple FEA modelling, for two material models, 
firstly using stress-strain behaviour up to true UTS, 1330 MPa (“UTS”) and secondly using stress-strain behaviour projected 
to 2508 MPa based on the Hollomon power law (“Hollomon”) 
